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ABSTRACT 
 
Amanda Marie Eudy: Gestational Weight Gain and Pre-Conceptional Cardiovascular Health in Pregnant 
Women with Systemic Lupus Erythematosus 
(Under the direction of Anna Maria Siega-Riz) 
 
 Systemic lupus erythematosus (SLE) is an autoimmune disease largely affecting women of 
childbearing age. Compared to the general population, SLE patients have a higher risk of poor pregnancy 
outcomes. We investigated three aspects of pregnancy in SLE patients in the Hopkins Lupus Pregnancy 
Cohort: a) weight gain during pregnancy, b) preconceptional cardiovascular health as a risk factor for 
pregnancy outcomes, and c) the effect of pregnancy on disease activity. 
  For the analysis of gestational weight gain (GWG), of the 211 pregnancies with available data, 
34%, 24%, and 42% had inadequate, adequate, and excessive GWG, respectively, based on pre-
pregnancy BMI, according to Institute of Medicine (IOM) guidelines. In exploratory analyses, differences 
in IOM adherence were observed by pre-pregnancy BMI, race, elevated creatinine, and pre-pregnancy 
blood pressure. Odds of inadequate and excessive GWG increased 12% with each 1 kg/m2 increase in 
pre-pregnancy BMI. Lower maternal education was associated with increased odds of inadequate and 
excessive GWG. 
 Next, we analyzed 308 births with available preconceptional cardiovascular data, of which 56% 
had ideal BMI (<25 kg/m2), 86% ideal total cholesterol (<200 mg/dL untreated), and 51% ideal blood 
pressure (<120/<80 mm Hg untreated). In adjusted models, overweight was associated with decreased 
odds of small for gestational age (OR: 0.26; 95% CI: 0.11, 0.63) compared to ideal weight, 
intermediate/poor total cholesterol was associated with increased odds of preterm birth (OR: 1.91; 95% 
CI: 0.96, 3.79), and intermediate/poor blood pressure was associated with decreased gestational age at 
birth (β: -0.96; 95% CI: -1.62, -0.29).  
 Finally, due to adverse effects of flares on pregnancy outcomes, we estimated rates of flares 
during pregnancy and a 1-year postpartum period compared to unexposed periods. We observed an 
increased rate of flares during pregnancy in stratified Cox models for PGA flare (HR: 1.59; 95% CI: 1.27, 
iv 
1.96) and SELENA SLEDAI flare (HR: 1.57; 95% CI: 1.25, 1.92). The HR of flares during pregnancy 
compared to unexposed periods was modified by hydroxychloroquine use. 
 Our results demonstrated the need for interventions to improve GWG guideline adherence and 
pre-conceptional cardiovascular health, and the importance of continuing to monitor SLE patients for 
flares during pregnancy. 
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CHAPTER 1: INTRODUCTION 
 
 Systemic lupus erythematosus (SLE) is an autoimmune disease which largely affects women, 
with disease onset typically occurring between the childbearing ages of 15 and 44 (1). In the United 
States, the most recent analyses of population-based registries in Georgia and Michigan estimate the 
overall age-adjusted prevalence to be 73 per 100,000 persons (~128 per 100,000 women) (2, 3). 
 Pregnancy remains contraindicated in SLE patients with severe end-organ manifestations of SLE 
(e.g., kidney, heart, brain) or in patients who have experienced a severe disease flare within the previous 
six months (4). Complications during pregnancy in women with SLE are quite common, with up to 76% of 
women experiencing complications, including disease flares, worsening or new onset of kidney failure, 
hypertension, preeclampsia, or pulmonary embolism (5).  
 Compared to women in the general population, women with SLE have a higher risk of poor 
pregnancy outcomes, including four times the risk of preterm deliveries and three times the risk of fetal 
loss (6, 7). In SLE patients, the presence of thyroid disease, kidney disease, and certain autoantibodies 
are associated with an increased risk of poor pregnancy outcomes. There are, however, a number of risk 
factors associated with poor pregnancy outcomes that have not been examined in the population of 
women with SLE.  
 Gestational weight gain (GWG) has been shown to be associated with preterm birth, small for 
gestational age (SGA) and large for gestational age (LGA) in the general population, with pre-pregnancy 
weight being an important modifier (8). Previous research has found that among women who are 
underweight, less than ideal GWG is associated with preterm birth, while exceeding the IOM guidelines is 
associated with preterm birth in women of all pre-pregnancy BMI categories (9, 10). The vast majority of 
women in the general population do not meet the IOM guidelines for weight gain, with one study finding 
that 17% of mothers had inadequate, 31% had adequate, and 53% had excessive weight gain (11). It is 
currently unknown how many women with SLE meet the Institute of Medicine (IOM) recommendations for 
GWG and the effect of insufficient GWG on pregnancy outcomes in this population.  
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 This dissertation investigated three interrelated aspects related to pregnancy in women with SLE 
not previously examined: a) weight gain during pregnancy, b) pre-conceptional cardiovascular health as a 
risk factor for pregnancy outcomes, and c) the effect of pregnancy on disease activity. The knowledge 
obtained from this research will provide a basis for understanding the effects of SLE on pregnancy, as 
well as the effect of pregnancy on SLE. We used data from the Hopkins Lupus Pregnancy Cohort of 515 
pregnancies that occurred over a period of almost 30 years. 
 
Specifically, we investigated the following aims: 
Specific Aim 1: To estimate the proportion of pregnant women with systemic lupus erythematosus 
(SLE) who meet the Institute of Medicine (IOM) guidelines for gestational weight gain (GWG) and 
to determine factors associated with adherence to IOM guidelines for GWG. 
 Sub-Aim 1a: To estimate gestational weight gain trajectories for women with SLE. 
 
Specific Aim 2: To estimate the effect of preconceptional cardiovascular health, as measured by 
blood pressure, total cholesterol and body mass index, on preterm birth and fetal growth (birth 
weight for gestational age z-score) in women with SLE. 
 
Specific Aim 3: To estimate the effect of pregnancy on disease activity (i.e., disease flares) in SLE 
using a Cox proportional hazards model. 
Sub-Aim 3a: To compare traditional methods for estimating the incidence of disease flares to the 
estimates from counting process and stratified Cox proportional hazards models. 
Sub-Aim 3b: To perform a sensitivity analysis excluding women without a pregnancy from the 
study population. 
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CHAPTER 2: LITERATURE REVIEW 
 
Systemic Lupus Erythematosus 
 Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease that affects a wide 
range of organ systems, including the skin, kidney, heart, lungs, central nervous system and 
musculoskeletal system. SLE is diagnosed according to the American College of Rheumatology (ACR) 
criteria (Appendix 1), a list of 11 measures, of which a patient must meet at least four of the criteria in 
order to be diagnosed with SLE (12, 13).  
 In the United States, the annual incidence of SLE is approximately 5 cases per 1,000 persons (2, 
3). Women have a higher prevalence of SLE than men and are typically diagnosed at a younger age than 
men, most often during the childbearing years (ages 15 – 44 years) (14, 15). A racial/ethnic discrepancy 
is apparent in SLE, with African Americans, Asians, and Hispanics having a higher prevalence and 
incidence of SLE compared to Caucasians (16-35).  
 SLE is typically treated with a multi-drug combination of corticosteroids, anti-malarials, 
immunosuppressants, and non-steroidal anti-inflammatory drugs (NDAIDs) (36). During pregnancy, some 
of these medications that are toxic to the fetus need to be stopped or have the dose reduced in order to 
protect the fetus. Due to concerns surrounding the treatment effects on the fetus, a challenge of treating 
SLE during pregnancy is that changes in medications may lead to an increase in SLE disease activity, 
which could also lead to a poor pregnancy outcome (37).  
 Hydroxychloroquine (HCQ), an anti-malarial, is recommended for continued use during 
pregnancy (38). HCQ use during pregnancy appears to be beneficial to the mother, with a study of SLE 
patients reporting higher disease activity and flares in women who stopped taking HCQ compared to 
women who continued to take HCQ throughout pregnancy, thus providing evidence that HCQ use should 
not be discontinued during pregnancy (39).  
 Corticosteroid use during pregnancy should be limited to the lowest dose possible to control 
disease activity. Use of corticosteroids has been found to increase the risk of preterm birth and possibly 
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restrict fetal growth (40-43). Azathioprine, an immunosuppressant, can be used during pregnancy if 
limited to a maximum daily dose of 2 mg/kg/day. Higher doses during pregnancy can increase the risk of 
fetal blood cell reduction (cytopenia; e.g. anemia, thrombocytopenia, leucopenia, and pancytopenia), and 
immune suppression, which will increase the susceptibility to infections (37, 38). Other 
immunosuppressants, such as cyclophosphamide, methotrexate, and mycophenolate, should be avoided 
during pregnancy, as first trimester exposure can lead to birth defects (36, 37).   
  
Pregnancy Outcomes in SLE & Risk Factors for Poor Pregnancy Outcomes 
 It was previously recommended that women with SLE avoid pregnancy, as the risk for poor fetal 
and maternal outcomes was high. Over the past several decades as the treatment and management of 
SLE has improved, so have fetal and maternal outcomes in pregnancies to women with SLE (44). It is 
currently advised that women with SLE consult with their rheumatologist prior to becoming pregnant for 
preconception counseling to determine factors that could increase the risk of pregnancy complications, 
such as severe organ system damage, high disease activity, antiphospholipid syndrome, anti-Ro or anti-
La antibodies, or medications that may harm the fetus (4).  
 Standard obstetrical care dictates close monitoring of women throughout pregnancy for changes 
in disease activity and kidney function, with regular monitoring of blood to assess cell counts, 
inflammatory changes and renal function, urine for protein and cells that would signify lupus nephritis, and 
frequent measurements of blood pressure to detect preeclampsia or imminent kidney flares (45). For 
women who are anti-Ro or anti-La antibody positive, which are found in up to 40% of women with SLE, 
repeated ultrasounds of the fetus’s heart between 18 and 28 weeks of gestation should be conducted to 
detect congenital heart block (4). 
 
Fetal Loss  
 Fetal loss is defined by the Centers for Disease Control and Prevention (CDC) as the 
“spontaneous intrauterine death of a fetus at any time during pregnancy” and can be divided into 
spontaneous miscarriages and stillbirths (46). Spontaneous miscarriages, also known as miscarriages or 
spontaneous abortions, are intrauterine fetal deaths at a gestational age when the fetus would not be able 
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to survive outside of the uterus, whereas stillbirths are intrauterine fetal deaths at a gestational age when 
a fetus would be able to survive outside of the uterus (47). The gestational age cut-point used to 
distinguish between spontaneous miscarriages and stillbirths varies by state, country and study, ranging 
from 20 to 28 weeks of gestation (46, 47).  
 Presently, the majority of SLE pregnancies, 66 to 95% depending on the study population, result 
in a live birth (6, 7, 39, 48-54); however, previous research has shown that women with SLE have poorer 
pregnancy outcomes compared to women in the general population. In women with SLE, the frequency of 
spontaneous miscarriage (loss of pregnancy prior to 20 weeks gestation) ranges from 6 to 22%, and the 
frequency of stillbirth (loss of pregnancy after 20 weeks gestation) ranges from 0 to 12% (Table 1) (7, 39, 
48-57). Comparatively, the CDC estimates that 17% of pregnancies to women of all ages in the US end in 
a fetal loss (spontaneous miscarriage or stillbirth) (58). The majority of the data for SLE pregnancies 
comes from prospective cohorts, which can under-count early pregnancy loss if a woman suffers the loss 
before she visits her physician to be enrolled in the study. 
 
Table 1. Frequency of spontaneous abortions, stillbirths and fetal loss in SLE pregnancy 
Reference,  
Year 
Country 
# of 
Pregnancies 
Spontaneous 
Abortion 
Definition 
Spontaneous 
Abortions 
Stillbirths 
Fetal 
Loss 
Ambrosio 
2010 (48) 
Portugal 136 <20 weeks 5.9% 0.0% 5.9% 
Andrade 
2008 (55) 
US, Puerto 
Rico 
102 <20 weeks 20.5% 4.9% 25.5% 
Cavallasca 
2008 (51) 
Argentina 72 
<20 weeks with 
fetal weight 
<500 g 
6.9% 8.3% 15.3% 
Clowse 2006 
(39) 
US 257 <20 weeks 6.6% 7.4% 14.0% 
Cortes-
Hernandez 
2002 (53) 
Spain 103 <20 weeks 14.6% 11.7% 26.2% 
Georgiou 
2000 (54) 
Greece 59 <21 weeks 15.3% 1.7% 16.9% 
Gladman 
2010 (57) 
Canada 193 <20 weeks 21.8% 3.1% 24.9% 
 
 General risk factors for spontaneous miscarriage, in women with or without SLE, include 
increased maternal age and co-morbidities such as hypothyroidism or uncontrolled diabetes. Risk factors 
for stillbirths include increased maternal age, obesity, smoking and diabetes (47). In SLE, increased 
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disease activity and co-morbidities such as kidney disease, hypertension, antiphospholipid syndrome, 
heart failure, and pulmonary disease are associated with an increased risk for fetal loss (4, 7, 53, 55, 59).  
 
Preterm Birth 
 Preterm birth is defined as delivery prior to 37 completed weeks of gestation. In the general 
population, approximately 12% of births in the United States are preterm (60). The rate of preterm births 
in the US increased by more than 20% from 1990 to 2006, although more recent reports indicate that the 
rate is slowly declining after its peak in 2006 (61). A racial disparity is apparent in the rate of preterm birth, 
with 17.5% of births to non-Hispanic black mothers in 2008 being preterm, compared to 11.1% and 12.1% 
in non-Hispanic white and Hispanic mothers, respectively (61). Although the majority of preterm infants 
survive, the risks of mortality and morbidity (such as neurological, respiratory, gastrointestinal, and kidney 
systems development) are higher in preterm infants compared to infants born at term (62).  
 Within the overarching outcome of preterm birth, there are subtypes: spontaneous preterm labor, 
premature rupture of membranes, and medically indicated preterm birth. In the general population, the 
largest proportion of preterm births is due to spontaneous labor (45%), and the pathways that lead to 
each type of preterm delivery vary (62), though some overlap. Medically indicated preterm births occur 
when a baby is intentionally delivered before 37 weeks due to medical complications in the mother or the 
fetus. In addition to the high burden of morbidity due to preterm birth, the costs associated with a preterm 
delivery increase substantially for each week prior to term that an infant is delivered (63). Once study 
reported that for medical costs during the first 5 years of life, infants born at <28 weeks gestation accrued 
almost $23,000 more in hospital utilization costs compared to term infants, and infants born at 28 to 31 
weeks gestation had costs almost $19,000 greater than term infants (63).  
 In the general population, risk factors for preterm birth include prior preterm births, low education, 
sociodemographic characteristics, maternal age, low BMI, multiple gestations, and infections (62). The 
literature reports that 8 to 53% of infants born to women with SLE are delivered preterm (Table 2) (6, 7, 
39, 48-54, 64). Compared to women in the general population, the odds of preterm delivery among 
women with SLE was 6 times that of women in the general population (OR=6.17; 95% CI: 3.28-11.58), 
adjusting for instrumentation to assist in the delivery and caesarean section (65). In SLE, risk factors for 
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preterm birth include hypertension, increased disease activity during pregnancy, the presence of anti-
cardiolipin (aCL) antibodies, and prednisone use either prior to or during pregnancy (6, 7, 51-54). 
Although data are limited, one study reported that 75% of preterm births in women with SLE were 
medically indicated (50). Reasons for a medically indicated preterm delivery in SLE, either by a 
caesarean section or induction of labor, include maternal high blood pressure, pre-eclampsia, proteinuria, 
decreased amniotic fluid volume, intrauterine growth restriction, and HELLP syndrome (hemolysis, 
elevated liver enzymes, and low platelets), a complication of eclampsia (6). 
 
Table 2. Frequency of preterm birth in SLE pregnancy. 
Reference Country 
# of 
Pregnancies 
Live Birth 
Preterm 
Birth*,† 
Ambrosio 2010 (48) Portugal 136 94.9% 24.0% 
Brucato 2002 (49) Italy 149 84.6% 19.8% 
Carvalheiras 2010 (50) Portugal 51 90.0% 17.4% 
Cavallasca 2008 (51) Argentina 72 86.1% 46% 
Chakravarty 2005 (52) US 63 87.3% 52.7% 
Clark 2003 (6) Canada 88 83.0% 38.4% 
Clowse 2005 (7) US 267 85.8% 38.0% 
Cortes-Hernandez 2002 (53) Spain 103 66.0% 27.9% 
Georgiou 2000 (54) Greece 59 66.1% 7.7% 
Mecacci 2009 (64) Italy 62 82.3% 29.4% 
*Defined as <37 weeks of gestation 
†Frequency among live birth infants 
 
Low Birth Weight for Gestational Age 
 Low birth weight is defined as a birth weight of <2500 g, and the CDC estimates that 8% of births 
in the US general population in 2012 were low birth weight (66). Low birth weight infants are at increased 
risk for infant mortality (death within 1-year after birth) than heavier infants (53.05 deaths per 1,000 births 
vs. 2.21 deaths per 1,000 births, respectively) (67) and are at increased risk for complications such as 
respiratory distress syndrome, intraventricular hemorrhage, and necrotizing enterocolitis (68). It has been 
estimated that 5 to 39% of infants born to mothers with SLE are classified as low birth weight (48, 51, 53, 
54). Hypertension and aCL antibodies are risk factors for delivering a low birth weight infant in SLE (53). 
 A methodological issue of low birth weight is that it is largely dependent on the duration of 
gestation, as approximately half of infants who are classified as low birth weight are born preterm (47). An 
alternative measure of fetal growth that takes gestational age into consideration is classifying infants as 
small for gestational age (SGA), defined as infants who weigh less than the 10th percentile for weight 
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based on their gestational age and sex. Among infants born to mothers with SLE, 16 to 23% are SGA 
(39, 57). Women with SLE have an increased risk of delivering a SGA infant, with one study finding the 
odds of delivering a SGA infant to be 2.5 times that of women in the general population (OR=2.54; 95% 
CI: 1.42, 4.55), when adjusted for instrumentation to assist in the delivery and caesarean section (65). 
The prevalence of SGA is higher among women with active kidney disease during pregnancy (defined as 
the presence of hematuria, pyuria, casts, and proteinuria), compared to women without active kidney 
disease (57). 
 
Gestational Weight Gain 
 Gestational weight gain (GWG) is the amount of weight a mother gains throughout her pregnancy 
and is composed of maternal and fetal factors. For fetal factors, the average weight gained is 4.8 
kilograms, with the fetus itself comprising an average of 3.3 kilograms (kg) of the weight gained. The 
remaining fetal weight gained is from the placenta (~0.7 kg) and amniotic fluid (~0.8 kg). For maternal 
factors, the average weight gained is 7 kilograms, largely due to increase in fat (~4.0 kg), blood volume 
(~1.2 kg) and extracellular fluid (~1.2 kg) (69).  
 The greatest increase in weight in nonfat tissues is due to water, with an increase of 6 to 7 liters 
of water (70). Fat is used to meet a mother’s metabolic requirements and as an energy source throughout 
pregnancy in times of deprivation as well as for lactation postpartum. The largest amount of maternal fat 
is accrued during the second trimester, but fat begins to be deposited early in pregnancy (69). The 
increase in body fat during pregnancy has been found to vary with pre-pregnancy BMI, with one study 
noting that women classified as overweight and obese had a minimal increase in total body fat during 
pregnancy. The study also found that women who met the 1990 IOM guidelines for gestational weight 
gain did not amass excessive amounts of fat (71). 
 The pattern of weight gain during pregnancy varies greatly between women, and is most variable 
for obese women. One study found that the average weekly weight gain for the second and third 
trimesters was higher for underweight and normal weight women, compared to overweight and obese 
women. Additionally, all women except obese women had higher weekly rates of weight gain in the 
second trimester than in the third trimester (72). 
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 In 1990, the Institute of Medicine (IOM) published guidelines on the ideal weight gain during 
pregnancy based on pre-pregnancy BMI, and these guidelines were updated in 2009 due to the concern 
of rising obesity rates in the population (Table 3) (8).  
 
Table 3. 2009 IOM Recommendations for Gestational Weight Gain in the General Population (8) 
Pre-Pregnancy BMI (kg/m2) 
Total Weight 
Gain (kg) 
2nd and 3rd Trimester Rates of Weight 
Gain, mean kg/wk (range) 
Underweight (<18.5)  12.5-18 0.51 (0.44-0.58) 
Normal weight (18.5-24.9)  11.5-16 0.42 (0.35-0.50) 
Overweight (25.0-29.9)  7-11.5 0.28 (0.23-0.33) 
Obese (≥30.0)  5-9 0.22 (0.17-0.27) 
 
 The vast majority of women do not meet these guidelines for weight gain, with one study finding 
53% of mothers gain more than the recommended weight, 17% gain less than the recommended weight, 
and only 31% gain the ideal amount of weight (11). In this analysis, women who were classified as 
overweight or obese were at increased risk of gaining more than the recommended amount of weight 
during pregnancy, compared to women with normal BMI. The proportion of women who are not meeting 
the guidelines for GWG is increasing. In 1997, 39.6% of women who had a pre-pregnancy BMI in the 
normal range exceeded the IOM’s recommendations for GWG, which increased to 46.3% in 2007. The 
increase in the proportion of women exceeding the IOM weight gain recommendations has also been 
seen in women classified as being overweight or obese prior to pregnancy (8). 
 The appropriate amount of weight gained during pregnancy has great implications for the fetus: 
gaining too much weight during pregnancy has been shown to be associated with delivering large for 
gestational age or macrosomic (>4000 g) infants (73-89), while insufficient weight gain is associated with 
the delivery of a small for gestational age infant (74, 75, 78-84, 90). Gestational weight gain also has 
implications for preterm birth. There appears to be a U-shaped association of GWG with preterm birth, 
with modification by pre-pregnancy BMI (10, 91-94). Among women who are underweight according to 
their pre-pregnancy BMI, less than ideal GWG is associated with preterm birth, while more than ideal 
GWG may be associated with preterm birth in women of all pre-pregnancy BMI categories (9, 10). 
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Cardiovascular Health and Pregnancy 
 The American Heart Association (AHA)’s 2020 Impact Goals included the development of the 
concept of “ideal cardiovascular health,” which focuses on primordial prevention and is composed of 
seven modifiable cardiovascular metrics: health factors (glucose, cholesterol, and blood pressure) and 
health behaviors (body mass index, physical activity, diet, and cigarette smoking; Table 4) (95). Meeting 
these metrics for ideal cardiovascular health is associated with a lower risk of cardiovascular disease, 
lower cardiovascular mortality rates, and lower all-cause mortality.  
 
Table 4. American Health Association Definitions of Poor, Intermediate, and Ideal Cardiovascular 
Health (95) 
Goal/Metric Poor Health Intermediate Health Ideal Health 
Current smoking Yes Former ≤12 months Never or quit >12 
months 
Body mass index ≥30 kg/m2 25-29.9 kg/m2 <25 kg/m2 
Physical activity None 1–149 minutes/week moderate 
intensity  
or 1–74 minutes/week vigorous 
intensity  
or 1–149 minutes/week 
moderate + vigorous  
≥150 min/week 
moderate 
intensity or ≥75 
minutes/week 
vigorous 
intensity or≥150 
minutes /week 
Healthy diet score 0–1 Components 2–3 Components 4-5 Components 
Total cholesterol ≥240 mg/dL 200–239 mg/dL or treated to 
goal 
<200 mg/dL 
Blood pressure Systolic ≥140 
Or 
Diastolic ≥90 mm 
Hg 
Systolic 120–139 or Diastolic 
80–89 mm Hg or treated to goal 
<120/<80 mm Hg 
Fasting plasma 
glucose 
≥126 mg/dL 100–125 mg/dL or treated to 
goal 
<100 mg/dL 
 
 The guidelines for ideal total cholesterol, blood pressure, and fasting glucose are in agreement 
with the definitions used by  the Third Adult Treatment Panel of the National Cholesterol Education 
Program (96), the Seventh Joint National Committee of the National Blood Pressure Education Program 
(97), and the American Diabetes Association (98), respectively.   
 Longitudinal cohort studies have reported that hypertension, dyslipidemia, and obesity are 
common co-morbidities in SLE, afflicting 30-60% of patients (99-101).  Maternal cardiovascular health at 
conception and during the beginning of pregnancy has implications for the in utero environment. Obesity 
at time of conception can lead to alterations in metabolic adjustments during gestation, which can affect 
placental, embryonic and fetal growth. Increased body fat is associated with increased levels of 
11 
proinflammatory proteins, and obese women are more likely to enter pregnancy in a state of subclinical 
inflammation than non-obese women (102-104). Maternal obesity increases the risk of delivering an infant 
who is macrosomic (>4000 g) or large for gestational age (105-107). 
 Studies have shown that hypertension is a risk factor for preterm birth (108, 109), even in studies 
where pregnancies affected by preeclampsia were removed from the study population, with one study 
noting the risk of preterm birth increased 29% for each 10 mm Hg increase in diastolic blood pressure 
(110). Additionally, chronic hypertension is associated with fetal growth restriction and low birth weight 
(108, 109, 111), with the risk of preterm small for gestational age births being 5.5 times greater than in 
woman without hypertension and the risk of term small for gestational age births being 1.5-1.7 times 
greater than in women without hypertension (109).  
 Previous research, although limited, has demonstrated that increased total cholesterol during the 
first trimester is associated with preterm birth, and it has also been suggested that the association of 
cholesterol and preterm birth may be modified by maternal inflammation (110, 112, 113). One study 
reported the risk of preterm birth at <34 weeks to be 2.8 times greater among women with 
hypercholesterolemia than women with normal cholesterol (112), and another study estimated a 24% 
increase in the risk of preterm birth for each 40 mg/dL increase in cholesterol (110). 
 It has been theorized that maternal risk factors for cardiovascular disease may also be risk 
factors for fetal growth restriction and fetal programming (114). As SLE is a chronic inflammatory disease, 
it will be important to study the way these cardiovascular health factors affect preterm birth and fetal 
growth during SLE pregnancies. Additionally, understanding how SLE specific components of the 
disease, such as disease activity and autoantibodies, may modify the association is important in 
improving the outcomes of infants born to mothers with SLE. 
 
SLE Disease Activity during Pregnancy 
 SLE is characterized by fluctuations of disease activity, with periods of high disease activity (i.e., 
flares) followed by periods of low disease activity. Disease indices have been designed and validated to 
describe the severity of a patient’s disease activity, including the SELENA revision of the Systemic Lupus 
Erythematosus Disease Activity Index (SLEDAI) (115-118), British Isles Lupus Assessment Group 
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(BILAG) index (119, 120), Systemic Lupus Activity Measure (SLAM) Index (121, 122) and European 
Consensus Lupus Activity Measurement (ECLAM) index (123-125).  
 The effect of pregnancy on disease activity and flares in SLE has long been debated. Previous 
research has found that between 19 and 68% of women with SLE experience a flare during pregnancy (7, 
39, 50-53, 57, 126-129). Risk factors for flare during pregnancy include active disease at conception, 
prednisone use, kidney disease and previous flares (52, 53, 57). 
 When compared to SLE patients who are not pregnant, there are conflicting results about the 
effect pregnancy has on disease activity (Table 6). Some studies report an increased rate of flares during 
pregnancy, while others report no difference in disease activity during pregnancy or post-partum. The rate 
of flares per person-months in pregnancy ranges from 0.06 – 0.14, compared to 0.04 – 0.05 in non-
pregnant SLE patients (126, 127, 130, 131). A study by Lockshin et al. (132) analyzed flare 
characteristics of pregnant and non-pregnant SLE patients, including laboratory values (urine protein, 
anti-dsDNA, complement, hemoglobin, etc.) and symptoms (rash, fever, serositis, arthritis, neurologic 
events, etc.), and did not find a difference between women who were pregnant and women who were not 
(Table 5). 
 
Table 5. Incidence of flares in SLE pregnancy per person-month 
Reference Country Pregnancies (n) Rate of Flares per Person-Month 
Garsenstein 1962 (130) US 33 32 weeks pre-pregnancy: 0.04  
0-20 weeks of pregnancy: 0.13  
21-40 weeks of pregnancy: 0.07  
0-8 weeks postpartum: 0.27  
9-40 weeks postpartum: 0.04  
Mintz 1986 (130) Mexico 102 Pregnant patients: 0.06  
Non-pregnant patients: 0.04  
Petri 1991 (126) US 40 During pregnancy: 0.14  
Post-partum: 0.05  
Non-pregnant patients: 0.05  
Ruiz-Irastorza 1996 (127) UK 78 Pregnant patients (any time): 0.08  
1st trimester: 0.008 
2nd trimester: 0.15 
3rd trimester: 0.07 
1-year postpartum: 0.15 
Non-pregnant patients: 0.04  
Wong 1991 (131) China 29 Pregnant patients: 0.08  
Non-pregnant patients: 0.04  
 
 A limitation of the current literature is the inconsistency in which flares are defined. A different 
scale or set of parameters are used for each study, making it difficult to make comparisons across 
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studies. Many previous studies were also limited by a small sample size, which reduced power to 
determine differences in the rate of flares between pregnant and non-pregnant patients. Additionally, it 
can be challenging to differentiate between pregnancy related changes and changes that are related to 
SLE flares. Lateef et al. (37) constructed a comparison of pregnancy-related changes and flare 
characteristics to assist in distinguishing between the signs and symptoms of these two conditions (Table 
6). 
 
Table 6. Differentiating pregnancy-related changes from SLE flares during pregnancy (37). 
Characteristic Pregnancy-related changes SLE flare 
Mucocutaneous Facial flush 
Palmar erythema 
Postpartum hair loss 
Photosensitive rash 
Oral or nasal ulcers 
Musculoskeletal Arthralgias 
Myalgias 
Inflammatory arthritis 
Hematologic Mild anemia 
Mild thrombocytopenia 
Leucopenia, lymphopenia 
Immune hemolytic anemia 
Thrombocytopenia 
Kidney Physiologic proteinuria <300 
mg/day 
Active urinary sediment 
Proteinuria >300 mg/day 
Immunologic Higher complement levels Falling complement levels 
Rising anti DNA levels 
Others Fatigue 
Mild edema 
Mild resting dyspnea 
Fever 
Lymphadenopathy 
Pleuritis 
From Lateef A, Petri M. Managing lupus patients during pregnancy. Best Practice & Research Clinical 
Rheumatology 2013;27(3):435-47 (37). 
 
 
Research Gaps 
 Although pregnancy outcomes to women with SLE have improved in recent years, the prevalence 
of preterm birth and infants born small for gestational age remain two- to six-times greater in women with 
SLE, as compared to women in the general population (65). Many well-researched aspects of pregnancy 
in the general, “healthy” population remain unstudied in the population of women with SLE, and there are 
gaps in the literature relating to risk factors for poor pregnancy outcomes in SLE and the effect on 
pregnancy on the SLE disease course. 
 One aspect of pregnancy that has yet to be studied in a population of women with SLE is 
gestational weight gain (GWG). In 2009, the Institute of Medicine (IOM) formed a committee to update the 
recommendations for GWG. Guidelines were updated to reflect the recognized need for weight gain 
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recommendations to be specific to a woman’s pre-pregnancy body mass index (BMI) and co-morbidities. 
Although the 2009 committee was not intended to develop GWG guidelines for specific diseases or 
conditions, a noticeable gap in the literature was the availability of data on the weight gain patterns in 
patients with autoimmune diseases, namely SLE. It is not presently known if women with SLE are gaining 
the appropriate amount of weight and what factors may affect weight gain in these women. Additionally, it 
has yet to be determined if the IOM guidelines for weight gain in the general population are appropriate 
for women with SLE.  
 The impact preconceptional cardiovascular health has on the occurrence of poor pregnancy 
outcomes in women with SLE is presently unknown. The American Heart Association (AHA)’s 2020 
Impact Goals included the development of the concept of “ideal cardiovascular health,” which focuses on 
primordial prevention and is composed of seven modifiable cardiovascular metrics: health factors 
(glucose, cholesterol, and blood pressure) and health behaviors (body mass index, physical activity, diet, 
and cigarette smoking) (95). Longitudinal cohort studies have reported that hypertension, dyslipidemia, 
and obesity are common in SLE, afflicting 30-60% of patients (99-101).  Maternal cardiovascular health at 
conception and during the beginning of pregnancy has implications for the in utero environment, with 
obesity, hypertension and increased total cholesterol being associated with an increased risk of preterm 
birth and small for gestational age infants (108-113). As SLE is a chronic inflammatory disease, it will be 
important to study the way these cardiovascular health factors affect preterm birth and fetal growth during 
SLE pregnancies. Additionally, understanding how SLE specific components of the disease, such as 
disease activity and autoantibodies, may modify the association is important in improving the outcomes of 
infants born to mothers with SLE. 
 Finally, the impact of pregnancy on the disease course in women with SLE remains debated in 
the literature. Studies to date have focused on the change in disease activity for women during their 
pregnancy, without expanding the study period for their research questions much beyond the pregnancy 
itself. It remains unknown what impact pregnancy can have on metabolic changes, kidney involvement or 
overall disease activity (as defined by a validated disease activity indices, such as SELENA SLEDAI 
(Systemic Lupus Erythematosus Disease Activity Index) or the Physician’s Global Assessment of disease 
activity (PGA)). 
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 This dissertation addressed several of the gaps in the literature relating to pregnancy in women 
with SLE and determined: 
1. if women with SLE are meeting the recommended Institute of Medicine guidelines for 
gestational weight gain, 
2. factors associated with not meeting or exceeding gestational weight gain guidelines in SLE, 
3. the proportion of women with SLE meeting the American Heart Association’s  classification of 
cardiovascular health in a cohort of pregnant SLE patients,  
4. the effects of poor and intermediate cardiovascular health on pregnancy outcomes in SLE, 
and 
5. the impact of pregnancy on the disease course of SLE. 
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CHAPTER 3: METHODS 
 
Study Population 
 The Hopkins Lupus Pregnancy Cohort is a subset of the Hopkins Lupus Cohort, which has 
prospectively followed patients with SLE since 1987, with data available through February 6, 2015. 
Patients meeting the ACR or SLICC criteria for SLE (12, 13, 133) were eligible for enrollment in the cohort 
following informed consent. Patients enrolled in the Hopkins Lupus Cohort and SLE patients seen in the 
Hopkins Obstetrics Clinics were automatically referred to the Hopkins Lupus Pregnancy Cohort. Outside 
of Johns Hopkins Hospital, local patients were referred by their local rheumatologists, the Maryland Lupus 
Foundation, and self-referral (126). Patients who were not pregnant were seen on a quarterly basis at the 
Lupus Center in Baltimore, Maryland by a single rheumatologist.  
 Pregnant women were seen every on average every 4-6 weeks throughout their pregnancy. At 
the first clinic visit, patients were given a full medical examination and self-reported their obstetrical 
history, including previous abortions (spontaneous and elective) and previous deliveries. During each 
subsequent visit, a patient’s weight was recorded, lupus disease activity was measured, medications 
were updated and laboratory tests were conducted. Laboratory tests included complete blood count 
(complement levels, autoantibodies, cholesterol and glucose) and urinalysis. Pregnancy outcome data 
were collected from women at the first postpartum visit to the Lupus Clinic or by telephone or email if a 
woman did not continue her medical care at the Lupus Clinic. Multiple pregnancies per patient were 
allowed in the analysis. 
 
Data Collection and Measurement 
 Data collected in the Hopkins Lupus Pregnancy Cohort included pregnancy complications 
(intrauterine growth restriction, premature rupture of membranes, preeclampsia, pregnancy induced 
hypertension, gestational diabetes) and pregnancy outcomes (spontaneous miscarriage, stillbirth, 
termination, live birth, birth weight, small for gestational age, and preterm birth). All additional data on co-
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morbidities (hypertension, diabetes, proteinuria, lupus nephritis), laboratory tests, patient demographics, 
SLE disease history, SLE disease activity, and treatment history were collected in the larger Hopkins 
Lupus Cohort. 
 
Exposure Classification 
 Specific Aim 1 was an exploratory analysis of adherence to gestational weight gain and correlates 
of adherence. There were no specific exposures of interest. 
 In Specific Aim 2, the exposure of interest was pre-conceptional cardiovascular health defined 
according to three of the American Heart Association (AHA)’s metrics, body mass index (BMI), total 
cholesterol, and blood pressure, using the following criteria: BMI: (1) poor health (obese): ≥30 kg/m2; (2) 
intermediate health (overweight): 25-29.9 kg/m2; (3) ideal health (underweight/normal weight): <25 kg/m2; 
total cholesterol: (1) poor health: ≥240 mg/dL; (2) intermediate health: 200–239 mg/dL or treated to goal; 
(3) ideal health: <200 mg/dL without treatment; blood pressure: (1) poor health: systolic ≥140 or diastolic 
≥90 mm Hg; (2) intermediate health: systolic 120–139 or diastolic 80–89 mm Hg or treated to goal; (3) 
ideal health: <120/<80 mm Hg without treatment. Each metric was coded as a categorical variable, with 
“ideal health” as the referent group. Due to small sample size, poor health and intermediate health were 
collapsed into one exposure category for total cholesterol and blood pressure, with ideal health remaining 
the referent group. Each metric was also analyzed as a continuous variable. BMI, total cholesterol, and 
blood pressure at the most recent clinic visit in the one-year prior to conception were used to classify 
patients’ cardiovascular health. If a clinic visit prior to conception was unavailable, the first measurement 
taken during the first trimester served as a surrogate for preconception health. 
 In Specific Aim 3, exposure was classified as pregnancy (yes/no), 1-year postpartum period 
(yes/no), or non-pregnant/non-postpartum period (unexposed). The exposure variables were included as 
time-varying covariates, so as to include all observations for an individual (including, for example, pre-
pregnancy observations on women who became pregnant between visits).  
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Outcome Classification 
 In Specific Aim 1, the outcome of interest was the proportion of women with SLE who met the 
2009 IOM guidelines for GWG based on pre-pregnancy BMI. Pre-pregnancy weight was defined as the 
most recent weight recorded at a visit within 12 months prior to pregnancy or, if not available, in the first 
trimester. The final pregnancy weight was the weight recorded closest to birth in the third trimester. 
Observed weight gain was calculated as the difference in the first and final weight measurement. The 
estimated total weight gain was calculated to account for variations in the timing of the first and final 
weight: (observed weight gain / weeks of gestation between weight measurements) x 40 weeks. 
Estimated total weight gain was classified according to IOM guidelines based on a woman’s pre-
pregnancy BMI: underweight (<18.5 kg/m2), normal weight (18.5-24.9 kg/m2), overweight (25.0-29.9 
kg/m2), obese (≥30 kg/m2). The guidelines recommend the following total weight gain during pregnancy 
(8):  
 underweight: 12.5-18 kg 
 normal weight: 11.5-16 kg 
 overweight: 7-11.5 kg 
 obese 5-9 kg.  
Total weight gain below the recommendations was considered inadequate weight gain, and total weight 
above the recommendations was considered excessive weight gain. 
 In Specific Aim 2, pregnancy outcomes of interest included gestational age at birth and birth 
weight for gestational age z-score. Gestational age at birth was based on maternally reported last 
menstrual period date and date of delivery and categorized as preterm (<37 weeks) and term (≥37 
weeks), as well as analyzed as a continuous variable. Birth weight for gestational age z-score was based 
on US population reference percentiles of birth weight for singleton infants, stratified by infant sex (134). 
Z-scores in Oken et al. 2003 were calculated based on the distribution of birth weights for all live births 
born 22 to 44 weeks gestation in the US, 1999-2000, with a potential range of -2.58 to 2.58. Birth weight 
for gestational age z-score was analyzed as a continuous variable, as well as categorized based on the 
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percentile of birth weight for gestational age: <10th percentile (small for gestational age; SGA) and >90th 
percentile (large for gestational age; LGA). 
 In Specific Aim 3, the outcome was time to disease flare (allowing for multiple flares), with a flare 
classified according to two disease activity indices. PGA is a disease activity index ranging from 0 to 3, 
with 0 being no activity and 3 being severe disease activity (135). SELENA SLEDAI is a weighted disease 
activity index for activity related to SLE present within the previous 10 days, with a score range of 0 to 
105 (118). Flares during follow-up were classified as: 
1. Change in PGA ≥1 from previous visit 
2. Change in SELENA SLEDAI ≥4 from the previous visit. 
 
Covariates 
Maternal age: Maternal age at the time of conception was analyzed as a continuous variable and 
categorized as ≤30 and >30 years in descriptive analyses in Aim 1. 
Race: Patient race was classified as black and non-black. 
Maternal education: Maternal education was based on self-reported years of education and categorized 
as ≤12 years, 13-16 years, and >16 years. 
Duration of SLE: Duration of SLE at the time of conception was analyzed as a continuous variable and 
categorized as ≤5 and >5 years. 
Infant Delivery Date: In Aims 1 and 2, infant delivery date (categorized as prior to January 1999 or 
between January 1999-February 2015) was considered a variable of interest due to changes in SLE 
prescribing patterns and general population shifts in BMI over time. 
Medication Use during Pregnancy: Medication use during pregnancy was classified as (1) yes or (0) no 
for the following medications: anti-malarial, immunosuppressants, and prednisone. High-dose prednisone 
use was further classified as prednisone ≥15 mg/day during pregnancy. In Aim 3, prednisone and anti-
malarial (hydroxychloroquine) use were analyzed as time-varying covariates. 
High Disease Activity: Disease activity during pregnancy was classified according to the Physician Global 
Assessment of disease activity (PGA) index, with a score of >2 considered high disease activity. 
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Organ System Damage: Organ system damage at conception was classified according to the Systemic 
Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage 
Index (SDI), with a score of ≥1 indicating any organ system damage. 
Renal Involvement: Renal involvement during pregnancy was defined as renal Lupus Activity Index score 
>1 at any time during pregnancy. 
Autoantibodies during Pregnancy: Autoantibodies during pregnancy included the presence of any of the 
following: low complement 3 (C3), low complement 4 (C4), and anti-double stranded DNA (anti-dsDNA; 
ever positive). 
Elevated Serum Creatinine: Elevated serum creatinine during pregnancy was defined as serum creatinine 
ever >1 mg/dl. 
 
Study Analysis Plan 
Specific Aim 1: To estimate the proportion of pregnant women with systemic lupus erythematosus 
(SLE) who meet the Institute of Medicine (IOM) guidelines for gestational weight gain (GWG) and 
to determine factors associated with adherence to IOM guidelines for GWG. 
 Sub-Aim 1A: To estimate gestational weight gain trajectories for women with SLE. 
 Adherence to the IOM recommendations was classified as a categorical variable (inadequate, 
adequate or excessive weight gain) based on pre-pregnancy BMI. An exploratory analysis determined 
factors associated with not meeting IOM guidelines by Fisher’s exact test of differences in proportions 
and ANOVA compared differences in means. A generalized logit model analysis with stepwise selection 
determined predictors of inadequate and excessive weight gain, both compared to adequate weight gain. 
Generalized estimating equation methods were used to account for the potential correlation of multiple 
pregnancies per patient being included in the analysis (136). Potential variables were entered into the 
model if α was <0.2 and remained in the model if α was <0.05. Weight trajectories for gestational weight 
gain were estimated using mixed models. Mixed models include fixed and random effects and are ideal 
for repeated measures with varying number of measurements and time between measurements per 
subject (137). The model included a random effect for the intercept and for time (weeks of gestation). The 
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fixed effects included a linear effect for time, quadratic effect for time, BMI group, and interaction for BMI 
group and time. 
 
Specific Aim 2: To estimate the effect of preconceptional cardiovascular health, as measured by 
blood pressure, total cholesterol and body mass index, on preterm birth and fetal growth (birth 
weight for gestational age z-score) in women with SLE. 
 Unadjusted differences in the prevalence of preterm birth, SGA, and LGA among live births by 
pre-conceptional cardiovascular health were analyzed descriptively by Fischer’s exact test. Differences in 
mean gestational age and mean birth weight for gestational age z-score by pre-conceptional 
cardiovascular health were analyzed by ANOVA. Multivariable logistic regression models estimated odds 
ratios (OR) and 95% confidence intervals for the association of each maternal cardiovascular health 
factor and categorical pregnancy outcomes of interest (preterm birth, SGA, and LGA). Multivariable linear 
regression models estimated associations of each maternal cardiovascular health factor with continuous 
outcome measures (gestational age at birth and birth weight for gestational age z-score). To account for 
the correlation between outcomes that would occur from patients contributing more than one pregnancy 
to this analysis, generalized estimating equations (GEE) with an exchangeable correlation structure were 
used (136). Confounders were assessed based on combined directed acyclic graph (DAG) minimally 
sufficient set that was reduced based on a 10% change in beta (β) estimates. Models with BMI as the 
exposure were adjusted for prednisone use during pregnancy and patient race, and blood pressure 
models were adjusted for renal involvement during pregnancy and patient race. For the exposure of total 
cholesterol, three adjusted models were estimated: 1) adjusted for patient race and prednisone use 
during pregnancy; 2) adjusted for patient race and anti-malarial use during pregnancy; and 3) adjusted for 
patient race, prednisone use during pregnancy, and anti-malarial use during pregnancy.  
 
Specific Aim 3: To estimate the effect of pregnancy on disease activity (i.e., disease flares) in SLE 
using a Cox proportional hazards model. 
Sub-Aim 3a: To compare traditional methods for estimating the incidence of disease flares 
to the estimates from counting process and stratified Cox proportional hazards models. 
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Sub-Aim 3b: To perform a sensitivity analysis excluding women without a pregnancy from 
the study population. 
 All women with SLE in the Hopkins Lupus Cohort between the ages of 15 and 45 were included 
in the analysis for Specific Aim 3, regardless of pregnancy status. Women with only one measurement of 
disease activity were excluded as time to event could not be determined for these women. The time of 
entry into the Hopkins Lupus Cohort was considered the initial measurement for all women. Patients were 
right censored and removed from the risk set at age 45 (end of reproductive years), menopause (if prior 
to age 45 years), death, loss to follow-up, or February 6, 2015, the end of follow-up. If patients had a gap 
of more than one year in study visits, patients were considered lost to follow-up, but were allowed to re-
enter the cohort when study visits resumed. The time between when a patient exited and re-entered the 
cohort did not contribute to person-time at risk.  
 Crude incidence rates were calculated as the observed number of flares / total person-time for 
each exposure period. Incidence rate ratios and corresponding 95% confidence intervals were calculated 
for pregnancy vs. unexposed periods and postpartum vs. unexposed periods. The analysis used two 
separate variations of Cox models to estimate the hazard rate ratio of flares in pregnancy and postpartum 
periods compared to unexposed periods: the standard counting process Cox proportional hazards model 
and the stratified Cox model. The counting process Cox proportional hazards model accounted for 
repeated measures, but did not take into account the order in which events occur. In the stratified Cox 
model, a stratum for the time interval number was included in the model so a patient was not at risk for a 
second flare without having experienced a previous flare.  
 If a woman had more than one pregnancy, all pregnancies (as well as postpartum periods) were 
included in the analysis. Due to repeated events of flares being counted in the same patient and patients 
being allowed to exit and re-enter the analytic cohort, 95% confidence intervals were estimated with 1,000 
bootstrap replications sampled with replacement (138). Using the same model, hazard ratios were 
calculated between 1) pregnant and unexposed periods and 2) postpartum and unexposed periods. To 
account for the time-varying exposures, a new patient ID was created for each patient which changed 
when the exposure changed, and both the original ID and new ID were included in the Cox models.   
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 In order to determine if all women in the Hopkins Lupus Cohort were an appropriate comparator 
group for women who became pregnant, two sensitivity analyses were performed. The first included only 
women who had a history of pregnancy or had an observed pregnancy while in the Hopkins Lupus 
Cohort. The second sensitivity analysis included only women who had an observed pregnancy while in 
the Hopkins Lupus Cohort. All analyses were conducted in SAS 9.3 (Cary, North Carolina). 
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CHAPTER 4: GESTATIONAL WEIGHT GAIN IN PREGNANT WOMEN WITH SYSTEMIC LUPUS 
ERYTHEMATOSUS 
 
Background 
 In 1990, the Institute of Medicine (IOM) published guidelines for ideal weight gain during 
pregnancy based on pre-pregnancy BMI. These guidelines were updated in 2009 due in part, to the 
concern of rising obesity rates in the population (8). Although the 2009 committee was not intended to 
develop gestational weight gain (GWG) guidelines for specific diseases or conditions, a noticeable gap in 
the literature was the availability of data on the weight gain patterns in patients with autoimmune 
diseases. Of particular interest was systemic lupus erythematosus (SLE), a disorder that largely affects 
women between the ages of 15 and 44 (1). It is not presently known if women with SLE are gaining the 
appropriate amount of weight and what factors may affect weight gain in these women.  
 Gestational weight gain is the amount of weight a mother gains throughout her pregnancy and is 
composed of maternal and fetal products of conception. The average weight gain attributable to fetal 
components is 4.8 kilograms, comprised of the fetus (~3.3 kilograms), the placenta (~0.7 kilograms) and 
amniotic fluid (~0.8 kilograms). For maternal components, the average weight gained is 7 kilograms, 
largely due to increase in fat (~4.0 kilograms), blood volume (~1.2 kilograms) and extracellular fluid (~1.2 
kilograms) (69). The pattern of weight gain during pregnancy varies greatly among women. One study 
found the average weekly weight gain for the second and third trimesters was higher for underweight and 
normal weight women, compared to overweight and obese women. Additionally, in this study, all women 
except obese women had higher weekly rates of weight gain in the second trimester than in the third 
trimester (72). 
 The appropriate amount of weight gained during pregnancy has great implications for the infant: 
gaining too much weight during pregnancy has been shown to be associated with delivering large for 
gestational age or macrosomic (>4000 g) infants (73-89), while insufficient weight gain is associated with 
the delivery of a small for gestational age infant (74, 75, 78-84, 90).  Gestational weight gain also has 
implications for preterm birth. There appears to be a U-shaped association of GWG with preterm birth, 
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with modification by pre-pregnancy BMI (10, 91-94). Among women who are underweight according to 
their pre-pregnancy BMI, insufficient GWG is associated with an increased risk of preterm birth, and this 
association weakens as pre-pregnancy BMI increases. Excessive GWG may be associated with preterm 
birth in women of all pre-pregnancy BMI categories (9, 10). Gestational weight gain also has implications 
throughout childhood, with excessive weight gain being associated with childhood obesity (94, 139, 140). 
 The vast majority of women in the general population do not meet the IOM guidelines for weight 
gain, with one study finding that 17% of mothers had inadequate, 31% had adequate, and 53% had 
excessive weight gain (11). Women classified as overweight or obese are at increased risk of gaining 
more than the recommended amount of weight during pregnancy, compared to women with normal BMI. 
Unfortunately, the proportion of women who are exceeding the guidelines for GWG is increasing (11), 
which is why the IOM committee has called for a paradigm shift in how preconception and prenatal advice 
concerning weight gain is being delivered to women of childbearing ages. The objectives of this study 
were to estimate the proportion of women with SLE who meet the IOM guidelines for GWG and to 
determine correlates of adherence to IOM guidelines for GWG. 
 
Methods 
Study population 
The Hopkins Lupus Pregnancy Cohort is a subset of the Hopkins Lupus Cohort, which has 
prospectively followed patients with SLE since 1987, with data available through February 6, 2015 
(n=515). Patients meeting the American College of Rheumatology (ACR) or Systemic Lupus International 
Collaborating Clinics (SLICC) criteria for SLE (12, 13, 133) were eligible for enrollment in the cohort 
following informed consent. Patients enrolled in the Hopkins Lupus Cohort and SLE patients seen in the 
Hopkins Obstetrics Clinics were automatically referred to the Hopkins Lupus Pregnancy Cohort. Outside 
of Johns Hopkins Hospital, local patients were referred by their local rheumatologists, the Maryland Lupus 
Foundation and self-referral (126). Pregnant women were seen every 4-6 weeks throughout their 
pregnancy at the Lupus Center in Baltimore, Maryland by a single rheumatologist (average 5.3 weeks). 
During each visit, a patient’s weight was recorded, lupus disease activity was determined by the physician 
global assessment of disease activity (PGA), medications were updated and laboratory tests were 
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conducted. Laboratory tests included complete blood count, complement levels, autoantibodies and 
urinalysis.  
 
Gestational weight gain  
 The outcome of interest was the proportion of women with SLE who met the 2009 IOM guidelines 
for GWG based on pre-pregnancy BMI. Pre-pregnancy weight was defined as the most recent weight 
recorded at a visit within 12 months prior to pregnancy (average weeks prior to pregnancy: 8.4 weeks, 
SD: 1.9) or, if not available in the first trimester (n=64, average gestational age: 8.4 weeks, SD: 3.2). The 
final pregnancy weight was the weight recorded closest to birth in the third trimester (average gestational 
age: 34.8 weeks, SD: 2.9). Observed weight gain was calculated as the difference in the first and final 
weight measurement. The estimated total weight gain was calculated to account for variations in the 
timing of the first and final weight: (observed weight gain / weeks of gestation between weight 
measurements) x 40 weeks.  
 Estimated total weight gain was classified according to IOM guidelines based on a woman’s pre-
pregnancy BMI: underweight (<18.5 kg/m2), normal weight (18.5-24.9 kg/m2), overweight (25.0-29.9 
kg/m2), obese (≥30 kg/m2). The guidelines recommend the following total weight gain during pregnancy 
(8):  
 underweight: 12.5-18 kg 
 normal weight: 11.5-16 kg 
 overweight: 7-11.5 kg 
 obese 5-9 kg.  
Total weight gain below the recommendations was considered inadequate weight gain, and total weight 
above the recommendations was considered excessive weight gain. 
 
Covariates  
Population characteristics of interest included self-reported race (black vs. non-black), education, 
age at conception and duration of SLE. Infant birth date (categorized as prior to January 1999 or between 
January 1999 and February 2015) was considered a variable of interest due to changes in SLE 
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prescribing patterns and general population shifts in BMI over time. Information on medication SLE 
treatment used during pregnancy included: anti-malarial, immunosuppressants, prednisone, and 
prednisone ≥15 mg/day. Clinical characteristics and biomarkers of SLE recorded as ever occurring during 
pregnancy were: renal involvement (renal Lupus Activity Index >1), elevated serum creatinine (>1 mg/dl), 
high Physician Global Assessment (PGA ≥2), low complement (C3 and C4), and anti-dsDNA (ever 
positive). Maternal cumulative organ system damage at conception was measured by the 
SLICC/American College of Rheumatology Index (SDI), with a score of ≥1 representing the presence of 
any organ system damage. Pre-pregnancy blood pressure on the study visit closest to conception in the 
one-year prior to pregnancy or 1st trimester was classified according to American Heart Association (AHA) 
criteria for cardiovascular health: poor/intermediate blood pressure: systolic ≥120 or diastolic ≥80 mm Hg 
or treated to goal; ideal health: <120 and <80 mm Hg without treatment (95). Pre-pregnancy cholesterol 
on the study visit closest to conception in the one-year prior to pregnancy or 1st trimester was classified 
according to AHA criteria for cardiovascular health: poor/intermediate cholesterol: ≥200 mg/dL or treated 
to goal; ideal health: <200mg/dL without treatment (95). 
Pregnancy outcomes of interest included gestational age at birth and birth weight for gestational 
age z-score. Gestational age at birth was based on maternally reported last menstrual period date and 
date of delivery and categorized as preterm (<37 weeks) and term (≥37 weeks), as well as analyzed as a 
continuous variable. Birth weight for gestational age z-score was based on US population reference 
percentiles of birth weight for singleton infants, stratified by infant sex (134). Z-scores in Oken et al. 2003 
were calculated based on the distribution of birth weights for all live births born 22 to 44 weeks gestation 
in the US, 1999-2000, with a potential range of -2.58 to 2.58. Birth weight for gestational age z-score was 
analyzed as a continuous variable, as well as categorized based on the percentile of birth weight for 
gestational age: <10th percentile (small for gestational age; SGA) and >90th percentile (large for 
gestational age; LGA). 
 
Subject selection 
 During the study period, there were 515 pregnancies in the Hopkins Lupus Cohort, of which 431 
were live births (Figure 1). More than one singleton live birth per patient was allowed in the analysis. 
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Pregnancies without a weight measurement in the one year prior to the last menstrual period pre-
pregnancy or during the first trimester, and/or without a weight measurement in the third trimester, were 
excluded.  Of the 421 singleton live births, 291 pregnancies had a weight measurement during the one 
year prior to pregnancy or during the first trimester, and of these, 211 pregnancies had an additional 
weight measurement during the third trimester. Live births excluded from the analysis (210 of 421 
singleton live births) were more frequently to mothers with a high school education and a pregnancy 
outcome date prior to 1999. Additionally, excluded births were to mothers with a lower frequency of anti-
malarial use during pregnancy and shorter disease duration. 
 
Analysis 
 Adherence to the IOM recommendations was classified as a categorical variable (inadequate, 
adequate, or excessive weight gain) based on pre-pregnancy BMI. The percent of women who had 
inadequate, adequate, or excessive weight gain, based on their pre-pregnancy BMI group, was 
estimated, and the mean estimated total weight gain was calculated. An exploratory analysis determined 
factors associated with not meeting IOM guidelines by Fisher’s exact test of differences in proportions 
and ANOVA compared differences in means. A generalized logit model analysis with stepwise selection 
determined predictors of inadequate and excessive weight gain, both compared to adequate weight gain. 
Generalized estimating equation methods were used to account for the potential correlation of multiple 
pregnancies per patient being included in the analysis (136). Potential variables were entered into the 
model if α was <0.2 and remained in the model if α was <0.05. Covariates included in model were race, 
education, infant delivery year, age at conception, duration of SLE, medication use ever during pregnancy 
(anti-malarial, immunosuppressants, prednisone, and prednisone ≥15 mg/day), SDI at conception and 
clinical characteristics ever occurring during pregnancy (renal involvement, elevated serum creatinine, 
high PGA, low complement, and anti-dsDNA). 
 Weight trajectories for gestational weight gain were estimated using mixed models. Mixed models 
include fixed and random effects and are ideal for repeated measures with varying number of 
measurements and time between measurements per subject. The model included a random effect for the 
intercept and for time (weeks of gestation). The fixed effects included a linear effect for time, quadratic 
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effect for time, BMI group, and interaction for BMI group and time. All analyses were conducted with SAS 
9.3 (Cary, North Carolina). 
 
Results 
 There were 211 pregnancies among 182 women included in the analysis. The majority of 
pregnancies were to women who were white (59%), with a median age at pregnancy of 30 years and 
median disease duration of 5 years. Overall, 34% of pregnancies had inadequate weight gain, 24% had 
adequate weight gain, and 42% had excessive weight gain (Figure 2). Differences were observed by pre-
pregnancy BMI. Among underweight women, 67% of pregnancies had inadequate GWG, and 33% had 
adequate GWG. Among normal weight women, pregnancies were fairly evenly divided, with 30%, 32%, 
and 38% having inadequate, adequate, and excessive weight gain, respectively. On the other hand, 
among overweight and obese women, few had inadequate GWG, 51% of both groups had excessive 
GWG, and only 19% and 7% of overweight and obese women, respectively, gained within the 
recommended guidelines. There were nine pregnancies in which the mother lost weight, ranging from 1.5 
kg to 16.0 kg; all had BMI in the range of overweight or obese. The mean (SD) estimated total weight gain 
was 10.9 (3.4) kg for underweight women, 14.7 (6.4) for normal weight women, 12.9 (8.8) for overweight 
women, and 8.3 (12.4) for obese women. 
 In exploratory analyses, there were observed differences in adherence to IOM guidelines by race, 
elevated creatinine during pregnancy, pre-pregnancy blood pressure, and pre-pregnancy BMI (Table 7). 
The mean pre-pregnancy BMI for patients with inadequate, adequate, and excessive weight gain was 
26.9 kg, 23.4 kg, and 26.6 kg, respectively (p=0.004). Of interest, there were no differences in weight gain 
adherence to IOM guidelines by SLE medication use during pregnancy, and adherence to GWG 
guidelines did not appear to correlate with pregnancy outcomes. 
 In exploratory analyses, no differences in guideline adherence were observed for infants who 
were small for gestational age (SGA) compared to infants who were not SGA (p=0.2), for infants who 
were large for gestational age (LGA) compared to infants who were not LGA (p=0.8), or for infants who 
were preterm compared to term (p=0.6). The mean gestational age at birth (p=0.2) and birthweight 
percentile (p=0.07) were both similar across categories of guideline adherence.  
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 In logistic regression models, stepwise selection determined continuous pre-pregnancy BMI and 
maternal education level were predictors of inadequate and excessive weight gain (Table 8). With each 1 
kg/m2 increase in pre-pregnancy BMI, the odds of inadequate weight gain and excessive weight gain both 
increased 12%. Compared to patients with a greater than college education, patients with a high school 
education had approximately three times the odds of inadequate weight gain and twice the odds of 
excessive weight gain.  
 Figure 3 illustrates the mean predicted change in maternal weight, stratified by pre-pregnancy 
BMI category (underweight/normal weight, overweight, and obese). Normal weight and underweight 
women were pooled into one category due to the small number of underweight women. The weight gain 
trajectory did not change in a sensitivity analysis removing underweight women from the analytic cohort. 
The weight gain trajectories in normal weight/underweight women and overweight women appear to be 
similar, with weight increasing steadily throughout pregnancy. The trajectories for obese women, 
however, were different from normal weight/underweight and overweight women, with a decrease in 
weight observed at the beginning of pregnancy. 
 
Discussion 
 In this study of pregnant women with SLE, 34% of pregnancies had inadequate weight gain, 24% 
of pregnancies had adequate weight gain, and 42% had excessive weight gain, rates similar to those 
observed in the general population of pregnant women in the United States (141). In a recent analysis of 
the Pregnancy Risk Assessment Monitoring System (PRAMS) 2010-2011, 21%, 32%, and 47% of women 
reported having inadequate weight gain, adequate weight gain, and excessive weight gain during 
pregnancy, respectively (141). In PRAMS, underweight women and normal weight women had decreased 
odds of excessive weight gain, while overweight and obese women had increased odds of excessive 
weight gain (141, 142). Similar patterns were observed in our cohort of SLE women, with the frequency of 
excessive weight gain lower in normal weight and underweight women than in overweight and obese 
women.  
 In exploratory analyses, some demographic and clinical characteristics were found to be 
associated with gestational weight gain, but in adjusted models, only pre-pregnancy BMI and maternal 
education were found to predict gestational weight gain. The demographic differences observed in our 
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study, increased frequency of inadequate weight gain among black patients compared to non-black 
patients, and increased frequency of inadequate weight gain among patients with a high school education 
compared to more than a college education, have also been reported in the general population (141). 
 In the general population, a previous study has reported that among normal weight women, there 
is an increased odds of excessive weight gain in patients with hypertensive conditions (141). In our 
exploratory analysis, we also observed differences by pre-pregnancy blood pressure, with an increased 
frequency of both inadequate and excessive weight gain among patients with intermediate and poor pre-
pregnancy blood pressure compared to patients with ideal pre-pregnancy blood pressure. 
 A difference was observed in exploratory analyses in IOM guideline adherence for patients who 
had elevated creatinine during pregnancy compared to patients who did not. Although the number of 
patients with elevated creatinine was small (n=15), 53% of these patients had inadequate weight gain 
compared to 33% of patients without elevated creatinine, and 0% had adequate weight gain, compared to 
26% of patients without elevated creatinine. Elevated creatinine indicates renal insufficiency (143). While 
we did not observe any differences in guideline adherence for patients with and without renal involvement 
during pregnancy, it appears that patients with elevated creatinine during pregnancy are at particular risk 
for not adhering to recommended guidelines, which may warrant further investigation. 
 Of particular interest was the lack of association of SLE medication use during pregnancy and 
gestational weight gain in exploratory analyses, including prednisone use or use of high prednisone dose 
(≥15 mg/day). This is in contrast to what was expected, given that prednisone has been found to increase 
adipose tissue among users (144). Only 21 of the 102 pregnancies with maternal exposure to prednisone 
initiated prednisone treatment during pregnancy. It may be that no increased frequency of excessive 
gestational weight gain with prednisone use was observed because patients have already experienced 
the increase in body mass associated with prednisone use, and no additional weight increase occured 
during pregnancy. 
 Results from weight gain trajectory analyses suggest that the change in weight throughout 
pregnancy is similar for underweight, normal weight, and overweight women, but varies for obese women. 
Among obese women, weight appears to decrease during the 1st trimester and then increase at the start 
of the 2nd trimester. This is of interest, as weight measurements for women in this study were based on 
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clinic measurements rather than self-report. Therefore, the weight fluctuations suggest a true initial 
decrease in weight and variability in weight gain among obese women, rather than an observed bias due 
to inaccurate reporting pre-pregnancy weight that may occur with self-reported weights.   
 Previous research has found that factors associated with non-adherence, such as race, education 
and certain co-morbidities vary by BMI group (141). A limitation of the present analysis is that the sample 
size of 211 women did not provide sufficient power to analyze interactive effects of BMI with demographic 
and clinical factors. Such analyses of interactive effects may help provide additional clarity on the 
unexpected results of no difference in guideline adherence by maternal prednisone use during 
pregnancy, which we were unable to discern due to the limited sample size. Additionally, data were 
unavailable on patients’ physical activity and diet, which may help further explain differences in weight 
gain patterns in this population. Our study was also limited by the lack of weight measurements for all live 
births in the cohort, which resulted in 210 pregnancies being excluded from the analysis. Demographic 
and clinical differences in patients included and excluded were observed, which could have implications 
for our results. 
 Despite these limitations, our study was strengthened by the prospective collection of clinically 
recorded weights, rather than relying on self-report of pre-pregnancy weight of total gestational weight 
gain by the patient, which has been found to often be inaccurately remembered at the time of delivery 
(145). Additionally, the present analysis benefits from weights being measured at multiple times during 
pregnancy, with a median of 4 visits per patient, which allowed for weight gain trajectories to be 
constructed. Although the sample size is modest, this study reports one of the largest cohorts of pregnant 
women with SLE, and it is the first study to analyze gestational weight gain patterns in SLE. 
 
Conclusion   
 The results of this analysis show that the majority of women with SLE do not meet the IOM 
guidelines for gestational weight gain. Pre-pregnancy BMI was found to be associated with not meeting 
guidelines in this study population, which is similar to what is observed in the general population. 
Targeted interventions to increase patient awareness about GWG guidelines and improve BMI prior to 
women with SLE becoming pregnant are important next steps for rheumatologists and obstetricians 
33 
treating SLE patients to adopt in order to improve guideline adherence.  Due to the observed association 
of education on adherence to GWG guidelines, it will be particularly important to focus interventions on 
the educational status of women. It has yet to be determined if the IOM guidelines for weight gain in the 
general population are appropriate for women with SLE, and future studies are necessary to determine if 
pregnancy outcomes in women with SLE are improved when IOM guidelines for gestational weight gain 
are met. As research in the general population has shown that adherence to IOM guidelines has 
significant implications for the future health of both the mother and infant, it is important to further 
understand what factors may be associated with non-adherence to guidelines in women with SLE. 
Physicians are encouraged to share the IOM physician toolbox for gestational weight gain 
(http://nationalacademies.org/hmd/activities/children/pregnancyweightdissemination/2013-sep-
09/toolkit.aspx) with their patients in order to promote proper weight gain during pregnancy. 
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Table 7. Demographic and clinical factors associated with estimated total weight gain during 
pregnancy for women with SLE in the Hopkins Lupus Pregnancy Cohort (n=211) 
  Inadequate Adequate Excessive  
 
n n (%) n (%) n (%) 
Fisher Χ2  
p-value 
Race      
Non-Black 146 41 (28.1%) 39 (26.77%) 66 (45.2%) 0.02 
Black 65 31 (47.7%) 12 (18.5%) 22 (33.9%)  
Age      
≤30 101 34 (33.7%) 26 (25.7%) 41 (40.6%) 0.9 
>30 110 38 (34.6%) 25 (22.7%) 47 (42.7%)  
Education      
HS Education (≤12 years) 57 25 (43.9%) 9 (15.8%) 23 (40.4%) 0.2 
College (13-16 years) 100 34 (34.0%) 24 (24.0%) 42 (42.0%)  
Greater than College (>16 years) 54 13 (24.1%) 18 (33.3%) 23 (42.6%)  
SLE Duration      
≤5 years 101 33 (32.7%) 23 (22.8%) 45 (44.6%) 0.7 
>5 years 110 39 (35.4%) 28 (25.5%) 43 (39.1%)  
Prednisone Use During Pregnancy      
No 109 35 (32.1%) 29 (26.6%) 45 (41.3%) 0.7 
Yes 102 37 (36.3%) 22 (21.6%) 43 (42.2%)  
Prednisone Use ≥15 mg/day  
During Pregnancy among  
Prednisone Users (n=102) 
     
No 54 18 (33.3%) 10 (18.5%) 26 (48.2%) 0.4 
Yes 48 19 (39.6%) 12 (25.0%) 17 (35.4%)  
Anti-malarial Use During Pregnancy      
No 59 19 (32.2%) 12 (20.3%) 28 (47.5%) 0.5 
Yes 152 53 (34.9%) 39 (25.7%) 60 (39.5%)  
Immunosuppressants Use  
During Pregnancy 
     
No 174 61 (35.1%) 44 (25.3%) 69 (39.7%) 0.5 
Yes 37 11 (29.7%) 7 (18.9%) 19 (51.4%)  
Highest PGA During Pregnancy      
<2 175 61 (34.9%) 44 (25.1%) 70 (40.0%) 0.6 
≥2 36 11 (30.6%) 7 (19.4%) 18 (50.0%)  
SDI at Conception      
0 132 41 (31.1%) 37 (28.0%) 54 (40.9%) 0.2 
≥1 79 31 (39.2%) 14 (17.7%) 34 (43.0%)  
Renal Involvement During  
Pregnancy 
     
No 151 51 (33.8%) 38 (25.2%) 62 (41.1%) 0.9 
Yes 60 21 (35.0%) 13 (21.7%) 26 (43.3%)  
Elevated Creatinine During  
Pregnancy 
     
No 196 64 (32.7%) 51 (26.0%) 81 (41.3%) 0.03 
Yes 15 8 (53.3%) 0 (0.0%) 7 (46.7%)  
Low C3 During Pregnancy      
No 160 54 (33.8%) 33 (20.6%) 73 (45.6%) 0.06 
Yes 51 18 (35.3%) 18 (33.3%) 15 (29.4%)  
Low C4 During Pregnancy      
No 135 45 (33.3%) 28 (20.7%) 62 (45.9%) 0.2 
Yes 76 27 (35.5%) 23 (30.3%) 26 (34.2%)  
Anti-dsDNA+ During Pregnancy      
No 128 40 (31.3%) 33 (25.8%) 55 (43.0%) 0.5 
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Yes 83 32 (38.6%) 18 (21.7%) 33 (39.8%)  
Pre-Pregnancy Blood Pressure      
Ideal 105 31 (29.5%) 34 (32.4%) 40 (38.1%) 0.02 
Intermediate/Poor 106 41 (38.7%) 17 (16.0%) 48 (45.3%)  
Pre-Pregnancy Cholesterol (n=200)      
Ideal 178 57 (32.0%) 44 (24.7%) 77 (43.3%) 0.9 
Intermediate/Poor 22 5 (22.7%) 8 (36.4%) 9 (40.9%)  
Pre-Pregnancy BMI, kg/m2      
Under weight (<18.5) 9 6 (66.7%) 3 (33.3%) 0 (0.0%) 0.001 
Normal weight (18.5-24.9) 112 34 (30.4%) 36 (32.1%) 42 (37.5%)  
Overweight (25.0-29.9) 47 14 (29.8%) 9 (19.2%) 24 (51.1%)  
Obese (≥30) 43 18 (41.9%) 3 (7.0%) 22 (51.2%)  
Infant birth date      
January 1999 – February 2015 156 49 (31.4%) 39 (25.0%) 68 (43.6%) 0.4 
Prior to January 1999 55 23 (41.8%) 12 (21.8%) 20 (36.4%)  
Small for gestational age (n=198)      
No 159 57 (35.9%) 32 (20.1%) 70 (44.0%) 0.2 
Yes 39 12 (30.8%) 13 (33.3%) 14 (35.9%)  
Large for gestational age (n=198)      
No 190 67 (35.3%) 43 (22.6%) 80 (42.1%) 0.8 
Yes 8 2 (25.0%) 2 (25.0%) 4 (50.0%)  
Preterm birth      
No 160 52 (32.5%) 41 (25.6%) 67 (41.9%) 0.6 
Yes 51 20 (39.2%) 10 (19.6%) 21 (41.2%)  
Pregnancy induced hypertension 
(n=162) 
     
No 150 48 (32.0%) 32 (21.3%) 70 (46.7%) 0.3 
Yes 12 6 (50.0%) 3 (25.0%) 3 (25.0%)  
Pre-eclampsia (n=166)      
No 151 48 (31.8%) 34 (22.5%) 69 (45.7%) 0.5 
Yes 15 7 (46.7%) 2 (13.3%) 6 (40.0%)  
Caesarian section (n=166)      
No 103 39 (37.9%) 22 (31.4%) 42 (40.8%) 0.3 
Yes 63 17 (27.9 %) 14 (22.2%) 32 (50.8%)  
Premature rupture of membranes 
(n=164) 
     
No 146 49 (33.6%) 32 (21.9%) 65 (44.5%) 0.9 
Yes 18 5 (22.8%) 4 (22.2%) 9 (50.0%)  
      
  Mean (SD) Mean (SD) Mean (SD) ANOVA  
p-value 
Age at conception, years 211 30.3 (5.1) 30.5 (5.0) 30.0 (4.4) 0.8 
Disease duration, years 211 6.5 (5.3) 7.4 (5.8) 6.2 (5.6) 0.5 
Highest PGA during pregnancy 211 1.0 (0.7) 0.9 (0.7) 1.1 (0.7) 0.4 
SDI at conception 211 0.9 (1.4) 0.4 (0.8) 0.8 (1.5) 0.2 
Highest daily prednisone dose 
 during pregnancy among  
prednisone users, mg 
102 21.0 (17.1) 16.5 (12.7) 15.5 (13.3) 0.2 
Pre-pregnancy BMI, kg/m2 211 26.9 (7.4) 23.4 (4.4) 26.6 (5.7) 0.004 
Gestational age at birth, weeks 211 37.1 (2.6) 37.6 (1.8) 37.6 (2.0) 0.2 
Birth weight percentile 198 31.3 (23.8) 31.4 (26.6) 40.1 (27.1) 0.07 
Birth weight z-score 198 -0.63 (0.84) -0.65 (0.96) -0.36 (0.97) 0.1 
BMI: body mass index; HS: high school; PGA: physician global assessment of disease activity; SD: 
standard deviation; SDI: SLICC/ACR Damage Index; SLE: systemic lupus erythematosus
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Table 8. Predictors of adherence to 2009 IOM guidelines for gestational weight gaina for women 
with SLE in the Hopkins Lupus Pregnancy Cohort (n=211). 
 Inadequate  Excessive  
 OR (95% CI)  OR (95% CI)  
Education   
HS Education (≤12 years) 3.31 (1.12, 9.75) 1.74 (0.62, 4.90) 
College (13-16 years) 2.05 (0.79, 5.32) 1.40 (0.63, 3.13) 
Greater than College (>16 years) 1.0 (ref) 1.0 (ref) 
Pre-pregnancy BMI, kg/m2 1.12 (1.03, 1.22) 1.12 (1.03, 1.21) 
aStepwise selection: entered into model if α < 0.2; remained in model if α < 0.05 
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Figure 1. Study population for the Hopkins Lupus Pregnancy Cohort, 1987 to February 2015. 
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Figure 2. Proportion of pregnancies with SLE meeting IOM recommendations for gestational 
weight gain based on maternal pre-pregnancy body mass indexA in the Hopkins Lupus Pregnancy 
Cohort (n=211). 
APre-pregnancy body mass index classified as underweight (<18.5 kg/m2), normal weight (18.5-24.9 
kg/m2), overweight (25.0-29.9 kg/m2), and obese (≥30 kg/m2)
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Figure 3. Mean predicted change in weight during pregnancy from mixed effects models with a 
random effect for individualsA, stratified by pre-pregnancy BMIB for women with SLE in the 
Hopkins Lupus Pregnancy Cohort (n=211). 
AMean weight change = 4.3358 + 0.3928(gestational age) + 0.0077 (gestational age2) - 0.5002 
(overweight) - 3.1870 (obese) - 0.0223(gestational age x overweight) - 0.1603(gestational age x obese) - 
0.0005 (gestational age2 x overweight) + 0.0005 (gestational age2 x obese) 
Bunderweight and normal weight women were combined due to small sample size 
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CHAPTER 5: PRE-CONCEPTIONAL CARDIOVASCULAR HEALTH AND PREGNANCY OUTCOMES 
IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS 
 
Introduction  
 Systemic lupus erythematosus (SLE) is an autoimmune disease which largely affects women, 
with disease onset typically occurring between ages 15 and 44 (1). Although pregnancy outcomes in 
women with SLE have improved in recent years, most likely due to a paradigm shift in the treatment of 
SLE during pregnancy, the prevalence of preterm birth (delivery prior to 37 completed weeks’ gestation) 
and infants born small for gestational age (SGA; less than the 10th percentile of weight for gestational 
age) remains two- to six-times greater in women with SLE, as compared to the general population (65, 
146, 147). Well established risk factors for adverse pregnancy outcomes in the general population have 
not been investigated among women with SLE. 
 The American Heart Association (AHA)’s 2020 Impact Goals included the development of the 
concept of “ideal cardiovascular health,” which focuses on primary prevention and is composed of seven 
modifiable cardiovascular metrics: health factors (glucose, cholesterol, and blood pressure) and health 
behaviors (body mass index, physical activity, diet, and cigarette smoking) (95). Meeting these metrics for 
ideal cardiovascular health is associated with a lower risk of cardiovascular disease and lower 
cardiovascular and all-cause mortality rates.  
 Longitudinal cohort studies report that hypertension, dyslipidemia, and obesity are common co-
morbidities in SLE, affecting 30-60% of patients (99-101). Maternal cardiovascular health at conception 
and during early pregnancy has implications for the in utero environment. Obesity at time of conception 
can lead to alterations in metabolic adjustments during gestation, affecting placental, embryonic, and fetal 
growth. Increased body fat is associated with increased levels of proinflammatory proteins, and obese 
women are more likely to enter pregnancy in a state of subclinical inflammation than non-obese women 
(102-104). In the general population, maternal obesity increases the risk of preeclampsia (148, 149), 
gestational diabetes (150, 151), and delivering a macrosomic (>4000 g) or large for gestational age infant 
(105-107). 
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 Studies have shown that hypertension is a risk factor for preterm birth in the general population 
(108, 109), even when pregnancies affected by preeclampsia were removed from the study population 
(110). Additionally, chronic hypertension is associated with fetal growth restriction and low birth weight 
(108, 111, 112), with the risk of preterm SGA births and term SGA births being 5.5 and 1.5-1.7 times 
greater, respectively, than in woman without hypertension (109).  
 Previous research, although limited, has demonstrated that increased total cholesterol during the 
first trimester is associated with preterm birth in the general population, and the association may be 
modified by maternal inflammation (110, 112, 113). One study reported the risk of very preterm birth (<34 
weeks) to be 2.8 times greater among women with high cholesterol compared to women with normal 
cholesterol (112), and another study estimated a 24% increase in the risk of preterm birth for each 40 
mg/dL increase in cholesterol (110). 
 It has been theorized that maternal risk factors for cardiovascular disease may also be risk 
factors for fetal growth restriction (114). As SLE is a chronic inflammatory disease, it is important to 
understand the way these cardiovascular health factors affect preterm birth and fetal growth during SLE 
pregnancies. We sought to determine the proportion of pregnant women with SLE that meet the AHA’s 
guidelines for ideal cardiovascular health, and to estimate associations of poor and intermediate 
cardiovascular health with adverse pregnancy outcomes. 
 
Methods 
Study population 
 The Hopkins Lupus Pregnancy Cohort is a subset of the Hopkins Lupus Cohort, which has 
prospectively followed patients with SLE since 1987, with data available through February 6, 2015. 
Patients meeting the American College of Rheumatology (ACR) or Systemic Lupus International 
Collaborating Clinics (SLICC) criteria for SLE (12, 13, 133) were eligible for enrollment in the cohort 
following informed consent. Patients enrolled in the Hopkins Lupus Cohort and SLE patients seen in the 
Hopkins Obstetrics Clinics were automatically referred to the Hopkins Lupus Pregnancy Cohort. Outside 
of Johns Hopkins Hospital, local patients were referred by their local rheumatologists, the Maryland Lupus 
Foundation and self-referral (126). Pregnant women were seen every 4-6 weeks during pregnancy at the 
Lupus Center in Baltimore, Maryland by a single rheumatologist. During each visit, a patient’s weight, 
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blood pressure, lupus disease activity [physician global assessment of disease activity (PGA) and 
SELENA SLEDAI (115, 116)] were measured, medications were updated, and laboratory tests were 
conducted. Laboratory tests included complete blood count, complement levels (C3 and C4), 
autoantibodies, total cholesterol, and urinalysis. Pregnancy outcome data were collected from patients at 
the first postpartum visit to the Lupus Center or by telephone or email, if a woman did not continue her 
medical care at the Lupus Center.  
Pre-conceptional cardiovascular health 
 Pre-conceptional cardiovascular health was defined according to three of the AHA’s metrics, body 
mass index (BMI), total cholesterol, and blood pressure, using the following criteria: BMI: (1) poor health 
(obese): ≥30 kg/m2; (2) intermediate health (overweight): 25-29.9 kg/m2; (3) ideal health 
(underweight/normal weight): <25 kg/m2; total cholesterol: (1) poor health: ≥240 mg/dL; (2) intermediate 
health: 200–239 mg/dL or treated to goal; (3) ideal health: <200 mg/dL without treatment; blood pressure: 
(1) poor health: systolic ≥140 or diastolic ≥90 mm Hg; (2) intermediate health: systolic 120–139 or 
diastolic 80–89 mm Hg or treated to goal; (3) ideal health: <120/<80 mm Hg without treatment. Each 
metric was coded as a categorical variable, with “ideal health” as the referent group. Due to small sample 
size, poor health and intermediate health were collapsed into one exposure category for total cholesterol 
and blood pressure, with ideal health remaining the referent group. Each metric was also analyzed as a 
continuous variable.  
 BMI, total cholesterol, and blood pressure at the most recent clinic visit in the one-year prior to 
conception were used to classify patients’ cardiovascular health. If a clinic visit prior to conception was 
unavailable, the first measurement taken during the first trimester served as a surrogate for preconception 
health, as it has been demonstrated that these cardiovascular health factors have minimal changes 
during the first trimester (152, 153).  
Pregnancy outcomes 
 Pregnancy outcomes of interest included gestational age at birth and birth weight for gestational 
age z-score. Gestational age at birth was based on maternally reported last menstrual period date and 
date of delivery and categorized as preterm (<37 weeks) and term (≥37 weeks), as well as analyzed as a 
continuous variable. Birth weight for gestational age z-score was based on US population reference 
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percentiles of birth weight for singleton infants, stratified by infant sex (134). Z-scores in Oken et al. 2003 
were calculated based on the distribution of birth weights for all live births born 22 to 44 weeks gestation 
in the US, 1999-2000, with a potential range of -2.58 to 2.58. Birth weight for gestational age z-score was 
analyzed as a continuous variable, as well as categorized based on the percentile of birth weight for 
gestational age: <10th percentile (small for gestational age; SGA) and >90th percentile (large for 
gestational age; LGA). 
Covariates  
 Characteristics of interest included race (black vs. non-black), education, age at conception, and 
duration of SLE. Infant birth date (prior to January 1999 and January 1999-February 2015) was 
considered a variable of interest due to changes in SLE prescribing patterns. Medication use (anti-
malarial, immunosuppressants, prednisone, and prednisone ≥7.5 mg/day) was defined as use ever during 
pregnancy. Clinical characteristics during pregnancy were defined as ever occurring during pregnancy: 
renal involvement (renal Lupus Activity Index >1), elevated serum creatinine (>1 mg/dl), high PGA (PGA 
≥2), low C3, low C4, and anti-dsDNA (ever positive). Organ system damage at conception was measured 
by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage 
Index (SDI), with a score of ≥1 representing the presence of any irreversible organ system damage.  
Subject selection 
 During the study period, there were 515 pregnancies in the Hopkins Lupus Cohort, of which 421 
were singleton live births (Figure 4). Pregnancies without any cardiovascular metrics available in the one 
year prior to conception or first trimester were excluded. Of the 421 births, 309 (73%) had at least one 
cardiovascular measure (n=291 BMI, n=275 total cholesterol, n=309 blood pressure). Of these 309 births 
included in our analysis, 63% had a cardiovascular health measurement in the one-year prior to 
conception; the remaining had the measure during the first trimester. More than one singleton live birth 
per patient was allowed in the analysis, and these 309 births were from 261 patients, 
 A greater proportion of live births excluded from the analysis due to missing cardiovascular health 
data were black and had an infant birth date prior to 1999, compared to the final analysis population. 
Additionally, excluded births were to patients who had shorter disease duration, lower frequency of anti-
malarial use during pregnancy and lower frequency of low C3/C4 (data not shown). Compared to patients 
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with cardiovascular measures in the year prior to conception, those with measures from the first trimester 
had shorter disease duration, greater highest PGA during pregnancy, higher frequency of prednisone use 
during pregnancy, and less often took anti-malarial or immunosuppressants in pregnancy. No differences 
were seen in live birth outcomes or AHA classification of pre-conceptional cardiovascular health, although 
patients with pre-pregnancy data had a higher mean total cholesterol and higher mean diastolic blood 
pressure compared to patients with measures in the first trimester (Appendix 5).  
Analysis 
 Differences in the prevalence of preterm birth, SGA, and LGA among live births by pre-
conceptional cardiovascular health were analyzed descriptively by Fischer’s exact test. Unadjusted 
differences in mean gestational age and mean birth weight for gestational age z-score by pre-
conceptional cardiovascular health were analyzed by ANOVA. Multivariable logistic regression models 
estimated odds ratios (OR) and 95% confidence intervals for the association of each maternal 
cardiovascular health factor and categorical pregnancy outcomes of interest (preterm birth, SGA, and 
LGA). Multivariable linear regression models estimated associations of each maternal cardiovascular 
health factor with continuous outcome measures (gestational age at birth and birth weight for gestational 
age z-score). To account for the correlation between outcomes that would occur from patients 
contributing more than one pregnancy to this analysis, generalized estimating equations (GEE) with an 
exchangeable correlation structure were used (136). Confounders were assessed based on combined 
directed acyclic graph (DAG) minimally sufficient set that was reduced based on a 10% change in beta 
(β) estimates for parsimony. Models with BMI as the exposure were adjusted for prednisone use during 
pregnancy and patient race, and blood pressure models were adjusted for renal involvement during 
pregnancy and patient race. For the exposure of total cholesterol, three adjusted models were estimated: 
1) adjusted for patient race and prednisone use during pregnancy; 2) adjusted for patient race and anti-
malarial use during pregnancy; and 3) adjusted for patient race, prednisone use during pregnancy, and 
anti-malarial use during pregnancy. All analyses were conducted with SAS 9.3 (Cary, North Carolina).  
 45 
 
Results 
 The majority of pregnancies were to patients who were white, with a median age at conception of 
30 years (Table 9). Anti-malarial, prednisone, and immunosuppressant use during pregnancy were 
reported in 60%, 51%, and 15% of pregnancies, respectively. The median highest PGA during pregnancy 
was 1.0, and maternal renal involvement was reported in 26% of pregnancies. There were 95 preterm 
births (31%), and of the 293 pregnancies with birth weights, 18% were SGA and 4% were LGA (Table 
10).  
 Ideal BMI, total cholesterol, and blood pressure were observed in 56%, 86%, and 51% of 
pregnancies, respectively (Figure 5). Patients with ideal levels of these 3 cardiovascular risk factors more 
often had other parameters associated with improved pregnancy outcomes. Patients who were 
underweight or normal weight (ideal) had higher education, a lower prevalence of renal involvement, 
lower blood pressure, and were more frequently non-black compared to overweight and obese patients. 
Patients with ideal total cholesterol had higher education, higher frequency of anti-malarial use, and lower 
BMI, compared to patients with intermediate/poor total cholesterol. Patients with ideal blood pressure had 
higher education, lower frequency of prednisone use, lower PGA, lower BMI, and were more frequently 
non-black, compared to patients with intermediate/poor blood pressure.  
 In descriptive models, there was a lower frequency of preterm birth among patients who were 
obese (20%) compared to patients who were overweight and underweight/normal weight (39% and 31%, 
respectively). Frequency of SGA was lowest in patients who were overweight (8%) compared to obese 
and underweight/normal weight (22% and 21%, respectively). The frequency of preterm birth was highest 
in patients with poor total cholesterol (75%) compared to patients with intermediate and ideal total 
cholesterol (38% and 27%, respectively). The mean gestational age at birth was lower in patients with 
poor blood pressure (35.8 weeks) compared to patients with intermediate and ideal blood pressure (36.4 
weeks and 37.4 weeks, respectively; Table 11). When only patients with a pre-pregnancy cardiovascular 
measurement were analyzed (n=195), the associations between cardiovascular health and pregnancy 
outcomes persisted (Appendix 5).  
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 In logistic regression models (Table 12), when adjusted for race and prednisone use, overweight 
was associated with increased odds of preterm birth compared to underweight/normal weight (OR: 1.38; 
95% CI: 0.70, 2.71), while obese was associated with decreased odds of preterm birth compared to 
underweight/normal weight (OR: 0.50; 95% CI: 0.21, 1.18). Additionally, overweight was associated with 
decreased odds of SGA compared to underweight/normal weight (OR: 0.26; 95% CI: 0.11, 0.63), 
adjusted for race and prednisone use. In linear regression models (Table 14), after adjusting for race and 
prednisone use, gestational age at birth increased with each 1 kg/m2 increase in BMI (β: 0.06; 95% CI: 
0.001, 0.11), and overweight was associated with a higher birth weight-for-gestational age z-score (β: 
0.32; 95% CI: 0.06, 0.59).  
 In logistic regression models adjusted for race and anti-malarial use (Table 12), intermediate/poor 
total cholesterol was associated with increased odds of preterm birth (OR: 1.91; 95% CI: 0.96, 3.79). No 
association was seen between cholesterol and SGA. In linear regression models (Table 14), no 
associations were observed between cholesterol and gestational age at birth or birth-weight-for-
gestational age z-score. 
 The odds of preterm birth was only slightly increased for patients with intermediate/poor blood 
pressure in logistic regression models (Table 12) after adjustment for race and renal involvement (OR: 
1.10; 95% CI: 0.67, 1.79), and no association was observed between blood pressure and SGA. In linear 
regression models (Table 13), intermediate/poor blood pressure was associated with decreased 
gestational age at birth (β: -0.96; 95% CI: -1.62, -0.29), adjusted for race and renal involvement.  
 
Discussion 
 The results of this analysis indicate that pre-conceptional cardiovascular health may have 
implications for preterm birth in women with SLE. In univariate analyses, women who had ideal levels of 
weight, cholesterol, or blood pressure had fewer preterm deliveries. Infant size did not appear to be 
associated with maternal cholesterol or blood pressure, but overweight women had the fewest small for 
gestational age infants. In multivariable logistic regression models, overweight women had an almost 
40% increased risk of preterm birth compared to underweight/normal weight women; however, somewhat 
surprisingly, overweight women had a 74% decreased risk of a SGA infant compared to 
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underweight/normal weight women. In linear models, overweight women had a greater birthweight for 
gestational age z-score compared to underweight/normal weight women in linear models. Of particular 
interest, there was no observed difference in the frequency of LGA births by pre-conceptional BMI, which 
is in contrast to pregnancies in the general population (106, 154, 155). However, as power is limited by 
the low frequency of LGA births in the analysis, these results should be considered preliminary. 
 In the general population, an analysis of women of reproductive age (20-44 years) from the 
National Health and Nutrition Examination Survey (NHANES) estimated the prevalence of overweight and 
obesity in the United States in 2003-2008 to be 23% and 29%, respectively (156). Our cohort had a 
similar distribution of pre-pregnancy BMI, with 24% and 20% of women overweight and obese, 
respectively. Analyses of the Nationwide Inpatient Sample reported that the diagnosis of hypertension 
prior to pregnancy is more common among women with SLE than women without SLE (147). Additionally, 
among women who gave birth in the United States in 2002, women with SLE had almost three times the 
prevalence of hypertensive disorders than women of the general population, with 8% of the general 
population having a hypertensive disorder (157). As expected, the prevalence of poor and intermediate 
pre-pregnancy blood pressure was high in this cohort, with approximately half of patients having blood 
pressure ≥120/≥80 mm Hg or blood pressure treated to goal.  
 The effects of pre-conceptional cardiovascular health on pregnancy outcomes seen in this 
analysis were consistent with studies of the general population. In the general population, there is an 
association of pre-pregnancy BMI and preterm birth, with the frequency of preterm birth being highest 
among underweight women and obese women (105, 158). It is important to note, however, that the 
indication of preterm birth should be considered in its association of pre-pregnancy BMI. Reasons for a 
medically indicated preterm delivery in SLE include maternal blood pressure, preeclampsia, proteinuria, 
decreased amniotic fluid volume, intrauterine growth restriction, and HELLP syndrome (hemolysis, 
elevated liver enzymes and low platelets) (6). Several studies have demonstrated an increased risk of 
indicated preterm birth but decreased risk of spontaneous preterm birth in obese patients in the general 
population (159-161). One study estimated a 43% decrease in the risk of spontaneous preterm birth 
compared to women with normal BMI; however, a higher frequency of preterm births in obese women 
were indicated compared to women with normal BMI (161). Although data are limited, one study reported 
 48 
that 75% of preterm births in women with SLE were medically indicated (50). A limitation of the present 
analysis is data specifying indication of preterm births were not collected; therefore, we were unable to 
determine if pre-conception cardiovascular health increased the risk of spontaneous preterm birth, 
indicated preterm birth, or both. 
 Our findings of increased risk of preterm birth in patients with intermediate and poor pre-
conception cholesterol are supported by previous general population studies. An analysis of the Coronary 
Artery Risk Development in Young Adults Study (CARDIA) study reported a U-shaped association of pre-
pregnancy cholesterol and preterm birth, with the lowest and highest tertiles of pre-pregnancy cholesterol 
increasing the risk of preterm birth (162). This association was supported by a case-control analysis in the 
Pregnancy Exposures and Preeclampsia Prevention (PEPP) study, which found the risk of preterm birth 
in patients with high cholesterol during the first 15 weeks of pregnancy to be almost three times the risk of 
patients with normal cholesterol (112). The results of our linear regression models show a decrease in 
gestational age at birth in patients with intermediate and poor pre-conception blood pressure. This 
supports previous findings in both the general population and SLE cohorts that hypertension is associated 
with gestational age at birth (108-110, 163).  
 Our study suffered from some limitations. Cardiovascular health data were not available for all 
live births in the cohort, and it is unknown how the cardiovascular health of these patients differed. Data 
were also unavailable in the cohort for the four remaining AHA cardiovascular metrics (glucose, physical 
activity, diet, and cigarette smoking); therefore, we were unable to assess the combined effects of 
cardiovascular risk factors. Additionally, the data were collected at a single academic center. While this is 
favorable with respects to consistency in the treatment of patients and data collection, the cohort 
described in this analysis may not be representative of all SLE patients. Finally, the sample size of the 
analytic cohort limited our statistical power, particularly for discrete outcomes (preterm birth, SGA, and 
LGA). While the cohort is larger than other SLE pregnancy cohorts, the modest sample size does not 
provide sufficient power to detect small differences in outcomes. Even so, the results of analyses with 
continuous variable mirrored that of categorical variables, giving us confidence in our results.  
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Conclusions 
 The findings of our analysis have important implications for SLE patients during pregnancy. Of 
particular interest is the apparent inverse association of preterm birth in obese patients, but an increased 
risk of preterm birth in overweight patients. This suggests that efforts to normalize maternal weight prior to 
pregnancy may improve pregnancy outcomes. Additionally, having a further understanding of SLE 
patients who are able to maintain ideal cardiovascular health will be important in order to develop future 
targeted treatments. Previous studies have found that among patients with SLE, pregnancy increases the 
risk of future major cardiovascular events and a poor pregnancy outcome increases the risk 
cardiovascular mortality (164). Interventions to improve the cardiovascular health of patients prior to 
pregnancy would improve pregnancy outcomes, as well as benefit the long-term health of SLE patients. 
 This analysis is the first to examine the AHA’s guidelines for cardiovascular health in patients with 
SLE prior to conception, as well as determine the effects of suboptimal pre-conceptional cardiovascular 
health on live birth outcomes. The analysis highlights the importance of SLE patients having BMI, total 
cholesterol, and blood pressure within the ideal range prior to pregnancy in order to reduce the risk of 
preterm births and improve the overall cardiovascular health of SLE patients. 
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Table 9. Population characteristics in the Hopkins Lupus Pregnancy Cohort (n=309) 
 N=309 pregnancies N = 261 patients 
 n (%) n (%) 
Race   
White 184 (60%) 151 (58%) 
Black 93 (30%) 80 (31%) 
Other 32 (10%) 30 (11%) 
Education   
HS Education (≤12 years) 101 (33%) 81 (31%) 
College (13-16 years) 141 (46%) 120 (46%) 
Greater than College (>16 years) 67 (22%) 60 (23%) 
Infant birth date   
Prior to January 1999 117 (38%)  
January 1999 – February 2015 192 (62%)  
Medication use during pregnancy1   
Anti-malarial 184 (60%)  
Immunosuppressant  48 (15%)  
Prednisone  160 (51%)  
Prednisone ≥7.5 mg/day among prednisone users 116 (73%)  
Clinical characteristicsA    
Renal involvement during pregnancy (LAI>1)  79 (26%)  
Elevated serum creatinine during pregnancy (>1) 24 (8%)  
High PGA during pregnancy (PGA ≥2) 49 (16%)  
SDI ≥1 at conception 114 (37%)  
Low C3 during pregnancy 74 (24%)  
Low C4 during pregnancy 106 (34%)  
Anti-dsDNA+ during pregnancy 115 (37%)  
   
 Median (IQR)  
Age at conception, years 29.9 (26.7-33.2)  
Disease duration, years 5.5 (2.1-9.3)  
Highest PGA during pregnancy (scale: 0-3) 1.0 (0.5-1.5)  
SDI at conception 0 (0-3)  
Highest daily prednisone dose during pregnancy, mg 2.5 (0-15.0)  
BMI, kg/m2 24.3 (21.3-29.2)  
Total cholesterol, mg/dL 162.0 (142.0-184.0)  
Systolic blood pressure, mm Hg 116.0 (106.0-126.0)  
Diastolic blood pressure, mm Hg 70.0 (64.0-80.0)  
Acategories not mutually exclusive; women can be in multiple categories, therefore, percentages add up 
to more than 100% 
Abbreviations: BMI, body mass index; C3, complement 3; C4, complement 4; HS, high school; LAI, Lupus 
Activity Index; PGA: Physician Global Assessment of Disease Activity; SDI: SLICC/ACR Damage Index 
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Table 10. Live birth outcomes in the Hopkins Lupus Pregnancy Cohort (n=309) 
 n (%) 
Small for gestational age (n=293) 53 (18%) 
Large for gestational age (n=293) 12 (4%) 
Preterm birth 95 (31%) 
Pregnancy induced hypertension (n=252) 15 (6%) 
Preeclampsia (n=257) 30 (12%) 
Caesarian section (n=256) 100 (39%) 
Premature rupture of membranes (n=255) 39 (15%) 
  
 Median (IQR) 
Gestational age at birth (weeks) 38.0 (36.0-39.0) 
Birth weight percentile (n=293) 31.0 (12.0-53.0) 
Birth weight z-score (n=293) -0.51 (-1.20 – 0.06) 
Birth weight (g) (n=293) 2920.0 (2506.1 – 3309.0) 
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Table 11. Mean gestational age and birth weight z-scores by pre-conceptional cardiovascular 
health, with ANOVA tests for differences in means in the Hopkins Lupus Pregnancy Cohort 
(n=309) 
 Gestational Age Birth Weight Z-Score 
 Mean Weeks (SD) Mean (SD) 
Body mass index   
Ideal health (under/normal weight; <25 kg/m2) 36.7 (3.9) -0.58 (0.92) 
Intermediate health (overweight; 25-29.9 kg/m2) 36.8 (2.6) -0.28 (0.82) 
Poor health (obese; ≥30 kg/m2) 37.4 (3.1) -0.51 (1.06) 
ANOVA p-value 0.3 0.09 
Total cholesterol   
Ideal health (<200 mg/dL) 37.0 (3.2) -0.48 (0.94) 
Intermediate health (200–239 mg/dL 
 or treated to goal) 
36.8 (2.3) -0.48 (0.95) 
Poor health (≥240 mg/dL) 34.9 (3.9) -0.53 (0.60) 
ANOVA p-value 0.2 1.0 
Blood pressure   
Ideal health (<120/<80 mm Hg) 37.4 (2.6) -0.48 (0.98) 
Intermediate health (Systolic 120–139 or  
Diastolic 80–89 mm Hg or treated to goal) 
36.4 (3.3) -0.50 (0.91) 
Poor health (Systolic ≥140  
or Diastolic ≥90 mm Hg) 
35.8 (4.1) -0.55 (0.72) 
ANOVA p-value 0.003 0.9 
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Table 12. Multivariable logistic regression models for association of pre-conceptional cardiovascular health and pregnancy outcomes in 
SLE in the Hopkins Lupus Pregnancy Cohort. 
 Preterm Birth SGA 
 OR (95% CI) AOR (95% CI) OR (95% CI) AOR (95% CI) 
Body Mass IndexA     
Ideal Health (under/normal weight; n=163) 1.0 1.0 1.0 1.0 
Intermediate (overweight; n=69) 1.39 (0.82, 2.36)  1.38 (0.70, 2.71)D  0.35 (0.15, 0.82)  0.26 (0.11, 0.63)D  
Poor Health (obese; n=59) 0.56 (0.28, 1.13)  0.50 (0.21, 1.18)D  0.95 (0.44, 2.05)  0.92 (0.42, 2.05)D 
Total CholesterolB     
Ideal Health (n=235) 1.0 1.0 1.0 1.0 
Intermediate/Poor Health (n=40) 2.27 (1.15, 4.46) 2.21 (1.06, 4.62)D 0.57 (0.21, 1.54) 0.41 (0.14, 1.26)D 
  1.91 (0.96, 3.79)E  0.58 (0.21, 1.61)E 
  1.93 (0.92, 4.04)F  0.44 (0.14, 1.38)F 
Blood PressureC     
Ideal Health (n=158) 1.0 1.0 1.0 1.0 
Intermediate/Poor Health (=151) 1.32 (0.82, 2.12) 1.10 (0.67, 1.79)G 0.68 (0.39, 1.20) 0.60 (0.33, 1.10)G 
Continuous variables     
BMI, kg/m2 (n=291) 0.97 (0.93, 1.01) 0.95 (0.91, 1.00)D 0.99 (0.94, 1.04) 0.98 (0.93, 1.04)D 
Total cholesterol, 10 mg/dL (n=275) 1.11 (1.03, 1.19) 1.10 (1.01, 1.19)D 0.91 (0.82, 1.02) 0.90 (0.80, 1.01)D 
  1.08 (1.01, 1.16)E  0.92 (0.82, 1.02)E 
  1.09 (1.00, 1.18)F  0.90 (0.80, 1.01)F 
Systolic blood pressure, 10 mmHg (n=309) 1.15 (0.99, 1.34) 1.08 (0.92, 1.28)G 0.88 (0.73, 1.06) 0.85 (0.70, 1.04)G 
Diastolic blood pressure, 10 mmHg (n=309) 1.25 (0.99, 1.58) 1.18 (0.93, 1.50)G 0.79 (0.59, 1.06) 0.75 (0.56, 1.02)G 
A Body mass index: (1) poor health: ≥30 kg/m2; (2) intermediate health: 25-29.9 kg/m2; (3) ideal health: <25 kg/m2 
B Total cholesterol: (1) poor health: ≥240 mg/dL; (2) intermediate health: 200–239 mg/dL or treated to goal; (3) ideal health: <200 mg/Dl 
C Blood pressure: (1) poor health: Systolic ≥140 or Diastolic ≥90 mm Hg; (2) intermediate health: Systolic 120–139 or Diastolic 80–89 mm Hg or 
treated to goal; (3) ideal health: <120/<80 mm Hg 
D Adjusted for race (black vs. non-black) and prednisone use ever during pregnancy 
E Adjusted for race (black vs. non-black) and anti-malarial use ever during pregnancy 
F Adjusted for race (black vs. non-black), prednisone use ever during pregnancy, and anti-malarial use ever during pregnancy 
G Adjusted for race (black vs. non-black) and renal involvement during pregnancy (Renal LAI ≥1) 
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Table 13. Multivariable linear regression models for association of pre-conceptional cardiovascular health and pregnancy outcomes in 
SLE in the Hopkins Lupus Pregnancy Cohort. 
 
Gestational Age 
Birthweight for  
Gestational Age Z-Score 
 β (95% CI) Adjusted β (95% CI) β (95% CI) Adjusted β (95% CI) 
Body Mass IndexA     
Ideal Health (under/normal weight; n=163) Ref Ref Ref Ref 
Intermediate (overweight; n=69) 0.19 (-0.65, 1.01) 0.14 (-0.63, 0.93)D 0.29 (0.03, 0.56) 0.32 (0.06, 0.59)D 
Poor Health (obese; n=59) 0.75 (-0.21, 1.71) 0.70 (-0.24, 1.65)D 0.08 (-0.24, 0.41) 0.14 (-0.18, 0.45)D 
Total CholesterolB     
Ideal Health (n=235) Ref Ref Ref Ref 
Intermediate/Poor Health (n=40) -0.53 (-1.46, 0.40) -0.43 (-1.28, 0.41)D 0.02 (-0.29, 0.33) 0.03 (-0.28, 0.34)D 
  -0.39 (-1.30, 0.51)E  -0.02  (-0.32, 0.29)E 
  -0.37 (-1.22, 0.48)F  -0.02 (-0.33, 0.30)F 
Blood PressureC     
Ideal Health (n=158) Ref Ref Ref Ref 
Intermediate/Poor Health (=151) -1.14 (-1.83, -0.45) -0.96 (-1.62, -0.29)G 0.02 (-0.19, 0.24) 0.09 (-0.12, 0.31)G 
Continuous variables     
BMI, kg/m2 (n=291) 0.05 (-0.004, 0.11) 0.06 (0.001, 0.11)D 0.01 (-0.01, 0.03) 0.02 (-0.01, 0.04)D 
Total cholesterol, 10 mg/dL (n=275) -0.07 (-0.18, 0.04) -0.06 (-0.15, 0.04)D 0.01 (-0.02, 0.03) 0.01 (-0.02, 0.04)D 
  -0.06 (-0.16, 0.04)E  0.004 (-0.02, 0.03)E 
  -0.05 (-0.14, 0.04)F  0.005 (-0.02, 0.03)F 
Systolic blood pressure, 10 mmHg (n=309) -0.46 (-0.71, -0.21) -0.39 (-0.63, -0.15)G 0.004 (-0.06, 0.07) 0.03 (-0.04, 0.10)G 
Diastolic blood pressure, 10 mmHg (n=309) -0.60 (-0.98, -0.22) -0.52 (-0.89, -0.14)G 0.01 (-0.09, 0.11) 0.04 (-0.06, 0.15)G 
A Body mass index: (1) poor health: ≥30 kg/m2; (2) intermediate health: 25-29.9 kg/m2; (3) ideal health: <25 kg/m2 
B Total cholesterol: (1) poor health: ≥240 mg/dL; (2) intermediate health: 200–239 mg/dL or treated to goal; (3) ideal health: <200 mg/Dl 
C Blood pressure: (1) poor health: Systolic ≥140 or Diastolic ≥90 mm Hg; (2) intermediate health: Systolic 120–139 or Diastolic 80–89 mm Hg or 
treated to goal; (3) ideal health: <120/<80 mm Hg 
D Adjusted for race (black vs. non-black) and prednisone use ever during pregnancy 
E Adjusted for race (black vs. non-black) and anti-malarial use ever during pregnancy 
F Adjusted for race (black vs. non-black), prednisone use ever during pregnancy, and anti-malarial use ever during pregnancy 
G Adjusted for race (black vs. non-black) and renal involvement during pregnancy (Renal LAI ≥1) 
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Figure 4. Aim 2 Study population for the Hopkins Lupus Pregnancy Cohort, 1987 to February 2015. 
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Figure 5. Pre-conceptional cardiovascular health according to American Heart Association 
criteria* in the Hopkins Lupus Pregnancy Cohort.  
*Body mass index: (1) poor health (obese): ≥30 kg/m2; (2) intermediate health (overweight): 25-29.9 
kg/m2; (3) ideal health (under/normal weight): <25 kg/m2 
Total cholesterol: (1) poor health: ≥240 mg/dL; (2) intermediate health: 200–239 mg/dL or treated to goal; 
(3) ideal health: <200 mg/dL 
Blood pressure: (1) poor health: Systolic ≥140 or Diastolic ≥90 mm Hg; (2) intermediate health: Systolic 
120–139 or Diastolic 80–89 mm Hg or treated to goal; (3) ideal health: <120/<80 mm Hg 
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CHAPTER 6: EFFECT OF PREGNANCY ON DISEASE FLARES IN PATIENTS WITH SYSTEMIC 
LUPUS ERYTHEMATOSUS 
 
Introduction  
 Systemic lupus erythematosus (SLE) is characterized by fluctuations of disease activity, with 
periods of high disease activity (i.e., flares) followed by periods of low disease activity. Disease indices 
have been designed and validated to describe the degree of a patient’s disease activity, including the 
SELENA revision of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) (115-118), 
British Isles Lupus Assessment Group (BILAG) index (119, 120), Systemic Lupus Activity Measure 
(SLAM) Index (121, 122) and European Consensus Lupus Activity Measurement (ECLAM) index (123-
125). The effect of pregnancy on disease activity and flares in SLE has long been debated. Previous 
research has found that between 19 and 68% of women with SLE experience a flare during pregnancy (7, 
39, 50-53, 57, 126-129). Risk factors for flare during pregnancy include active disease at conception, 
prednisone use, kidney disease and previous flares (52, 53, 57). 
 There are conflicting results about the effect pregnancy has on the health of SLE women. Some 
studies report an increased rate of flares during pregnancy, while others report no difference in disease 
activity during pregnancy or postpartum. The rate of flares per person-month in pregnancy ranges from 
0.06 – 0.14, compared to 0.04 – 0.05 in non-pregnant SLE patients (126, 127, 130, 131). A study by 
Lockshin et al. (132) analyzed flare characteristics of pregnant and non-pregnant SLE patients, including 
laboratory values (urine protein, anti-dsDNA, complement, hemoglobin, etc.) and symptoms (rash, fever, 
serositis, arthritis, neurologic events, etc.), and did not find a difference between women who were 
pregnant and women who were not. In contrast, Petri et al. (126) found that the rate of flare was greater 
during pregnancy than in non-pregnant controls, and a subsequent analysis by Ruiz-Irastorza et al. (127) 
found that the rates of flare during pregnancy and a 6-week postpartum period were increased compared 
to non-pregnant, age-matched controls.  
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 A limitation of the current literature is the inconsistency in which flares are defined. Different 
scales or sets of parameters are used in each study, making it difficult to make comparisons across 
studies. Many previous studies were also limited by a small sample size, which reduced power to 
determine differences in the rate of flares between pregnant and non-pregnant SLE patients. Additionally, 
previous studies did not included patients followed by protocol at set intervals during pregnancy. 
Understanding the effect pregnancy has on disease activity is clinically significant for the patient, as 
previous research has found that high disease activity during pregnancy is associated with preterm births 
and pregnancy loss (6, 7, 54). Additionally, examining the rate of flares during the postpartum period 
compared to unexposed periods will be important in determining if patients need to be more closely 
monitored in the year following pregnancy. The objective of the current analysis was to estimate the effect 
of pregnancy on disease activity (i.e., disease flares) in SLE using two variations of Cox proportional 
hazards models, the counting process Cox and the standard Cox. Models included two exposures, 
pregnancy and a 1-year postpartum period, and the rates of flares during each of these periods were 
compared to the rate of flares when women were neither pregnant nor in a postpartum period (>12 
months after delivery). 
 
Methods 
Study population 
The Hopkins Lupus Pregnancy Cohort is a subset of the Hopkins Lupus Cohort, which has 
prospectively followed patients with SLE since 1987, with data available through February 6, 2015. Patients 
meeting the American College of Rheumatology (ACR) or Systemic Lupus International Collaborating 
Clinics (SLICC) criteria for SLE (12, 13, 133) were eligible for enrollment in the cohort following informed 
consent. Patients enrolled in the Hopkins Lupus Cohort and SLE patients seen in the Hopkins Obstetrics 
Clinics were automatically referred to the Hopkins Lupus Pregnancy Cohort. Outside of Johns Hopkins 
Hospital, local patients were referred by their local rheumatologists, the Maryland Lupus Foundation and 
self-referral (126). Pregnant women were seen every 4-6 weeks during pregnancy at the Lupus Center in 
Baltimore, Maryland by a single rheumatologist. During each visit, a patient’s weight, blood pressure, lupus 
disease activity [Physician Global Assessment of disease activity (PGA) and SELENA SLEDAI (115, 116)] 
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were measured, medications were updated, and laboratory tests were conducted. Laboratory tests included 
complete blood count, complement levels (C3 and C4), anti-dsDNA, antiphospholipid antibodies, total 
cholesterol, and urinalysis. Pregnancy outcome data were collected from patients at the first postpartum 
visit to the Lupus Center or by telephone or email, if a woman did not continue her medical care at the 
Lupus Center.  
 
Exposures 
 Exposure was classified as pregnancy (yes/no), 1-year postpartum period (yes/no), or non-
pregnant/non-postpartum period (unexposed). The exposure variables were included as time-varying 
covariates, so as to include all observations for an individual (including, for example, pre-pregnancy 
observations on women who became pregnant).  
 
Outcomes 
Disease flares can be analyzed according to several disease indices, and this analysis used PGA and 
SELENA SLEDAI. PGA is a disease activity index ranging from 0 to 3, with 0 being no activity and 3 being 
severe disease activity (135). SELENA SLEDAI is a weighted disease activity index for activity related to 
SLE present within the previous 10 days, with a score range of 0 to 105 (118). Flares during follow-up were 
classified according to two different criteria: 
3. Change in PGA ≥1 from previous visit 
4. Change in SELENA SLEDAI ≥4 from the previous visit. 
 
Subject selection 
During the study period, there were 2417 SLE patients observed in the Hopkins Lupus Cohort, of 
which 2229 were female. Fifteen female patients were removed due to lack of complete information on 
pregnancies, and an additional 350 patients were removed because SLE diagnosis occurred after age 45 
years. Of these patients, 1426 had more than one study visit to calculate flares; however, 77 of patients 
were observed only during pregnancy and were removed from the study population due to never 
contributing to unexposed person-time. A sensitivity analysis including these 77 patients can be found in 
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Appendix 6. The final analytic cohort consisted of 1349 women; 999 of these women had a history of 
pregnancy or an observed pregnancy during the study period. Of the 515 pregnancies in the Hopkins Lupus 
Cohort, n=398 pregnancies in 304 patients were included. There were n=381 observed 1-year postpartum 
periods, with at least one visit during the postpartum period. 
 
Analysis 
 All women with SLE in the Hopkins Lupus Cohort between the ages of 15 and 45 were included 
in the analysis, regardless of pregnancy status. Women with only one measurement of disease activity 
were excluded. The time of entry into the Hopkins Lupus Cohort was considered the initial measurement 
for all women. Patients were right censored and removed from the risk set at age 45 (end of reproductive 
years), menopause (if prior to age 45 years), loss to follow-up, death, or February 6, 2015, the end of 
follow-up. If patients had a gap of more than one year in study visits, patients were considered lost to 
follow-up, but were allowed to re-enter the cohort when study visits resumed. The time between when a 
patient exited and re-entered the cohort did not contribute to person-time at risk. This method was utilized 
due to a disease activity measurement from more than a year previous not being a suitable comparator to 
calculate disease flare.  
 Crude incidence rates were calculated as the observed number of flares / total person-time for 
each exposure period. Incidence rate ratios and corresponding 95% confidence intervals were calculated 
for pregnancy vs. unexposed periods and postpartum vs. unexposed periods. The analysis used two 
separate variations of Cox models to estimate the hazard rate ratio of flares in pregnancy and postpartum 
periods compared to unexposed periods. The first model was the standard counting process Cox 
proportional hazards model, which accounted for repeated measured and assumed that the order of the 
events of flares did not need to be taken into consideration. The second model was a stratified Cox 
model, a conditional model that did not assume independence of multiple events of flare (165). Instead, a 
stratum for the time interval number was included in the model so a patient was not at risk for a second 
flare without having experienced a previous flare. Hazard ratios and 95% confidence intervals (95% CI) 
were estimated for each model.  
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 If a woman had more than one pregnancy, all pregnancies (as well as postpartum periods) were 
included in the analysis. Due to repeated events of flares being counted in the same patient and patients 
being allowed to exit and re-enter the analytic cohort, 95% confidence intervals were estimated with 1,000 
bootstrap replications sampled with replacement (138). Using the same model, relative hazard rates of 
flare were calculated between 1) pregnant and unexposed periods and 2) postpartum and unexposed 
periods. To account for the time-varying exposures, a new patient ID was created for each patient which 
changed when the exposure changed, and both the original ID and new ID were included in the Cox 
models. Potential covariates of interest included patient race (black vs. non-black), age at SLE diagnosis, 
age at baseline, and duration of disease at baseline. Prednisone and hydroxychloroquine were explored 
as time-varying covariates. Confounders were defined by a 10% change in beta (β) estimates when 
included in the model. None of the covariates were found to be confounders in any models. Effect 
measure modifiers were identified by likelihood ratio test (α=0.20). To determine if the association of 
pregnancy and the postpartum period with flares has changed over time, we conducted a sensitivity 
analysis limited to person-time since the year 2000 through the end of follow-up (February 6, 2015).  
 In order to determine if all women in the Hopkins Lupus Cohort were an appropriate comparator 
group for women who became pregnant, two sensitivity analyses were performed. The first included only 
women who had a history of pregnancy or had an observed pregnancy while in the Hopkins Lupus Cohort 
(n=999). The second sensitivity analysis included only women who had an observed pregnancy while in 
the Hopkins Lupus Cohort (n=304). All analyses were conducted in SAS 9.3 (Cary, North Carolina). 
 
Results 
 The median age at baseline was 30.6 years of the 1349 patients in the total cohort and 29.4 
years at the first pregnancy observed in the cohort (Table 14). The majority of patients were white (49% 
of the total cohort and 57% of pregnant women), and the median duration of SLE at baseline was 2.0 
years. The median follow-up was 3.9 years (IQR: 1.3-10.4 years). Of the 398 pregnancies, 85% were live 
births, of which 29% were preterm and 24% were small for gestational age (Table 15).  
 For the total cohort, the incidence of flares based on the PGA definition was 60.7 per 100 person-
years (PY) during pregnancy compared to 40.2 per 100 PY (Table 16) during unexposed periods (crude 
IRR: 1.51; 95% CI: 1.27, 1.80). The incidence of flare during the postpartum period was 39.9 per 100 PY, 
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and no increased incidence was observed during postpartum periods compared to unexposed periods 
(crude IRR: 0.99; 95% CI: 0.84, 1.17). Rate ratios were also estimated in counting process Cox models 
(Table 17), where there was an increased rate of flare during pregnancy (HR: 1.44; 95% CI: 1.14, 1.75) 
but no evidence of an increased rate during postpartum period (HR: 0.94; 95% CI: 0.76, 1.13), when 
compared to unexposed periods. In stratified Cox models, the increased rate of flare during pregnancy 
persisted (HR: 1.59; 95% CI: 1.27, 1.96), and there was no evidence of an increased rate during the 
postpartum periods compared to unexposed periods.  
 In sensitivity analyses, the incidence of PGA flares during unexposed periods decreased when 
only patients with a history of pregnancy or observed pregnancy were in the analysis (39.3 per 100 PY) 
and when only patients with an observed pregnancy were in the analysis (35.9 per 100 PY). Point 
estimates for pregnancy compared to unexposed periods, as well as postpartum compared to unexposed 
periods, increased in both sensitivity analyses compared to the primary analysis in the total cohort. When 
the 77 patients with no observed unexposed periods were included in the analysis (see Appendix 6), 
results were similar, with an increased rate of flare observed during pregnancy compared to unexposed 
times. However, hazards ratios for postpartum compared to unexposed periods showed no evidence of 
an increased incidence of flare during postpartum periods.     
 When flares were defined as a ≥4 change in SELENA SLEDAI score, results were comparable to 
the PGA definition of flare. In the overall cohort, the crude incidence of flare during pregnancy was 63.4 
per 100 PY (Table 16), compared to 47.3 per 100 PY during unexposed periods (crude IRR: 1.34; 95% 
CI: 1.13, 1.59). No increased rate of flares was observed during postpartum periods compared to 
unexposed periods (IRR: 0.97; 95% CI: 0.83, 1.13). Counting process Cox models estimated similar 
associations (Table 18), with an increased rate of flare during pregnancy (HR: 1.30; 95% CI: 1.04, 1.62) 
compared to unexposed periods, but no evidence of an increased rate during postpartum periods (HR: 
0.93; 95% CI: 0.75, 1.12). In stratified Cox models, the increased rate of flare during pregnancy remained 
(HR: 1.57; 95% CI: 1.25, 1.92), and there was no evidence of an increased rate of flare during postpartum 
periods compared to unexposed periods (HR: 1.09; 95% CI: 0.89, 1.32).  
 Similar to models of PGA flares, hazard ratios increased in sensitivity analyses, as the crude 
incidence of SELENA SLEDAI flare decreased during unexposed periods (44.7 per 100 PY when only 
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women with a history of pregnancy or ≥1 observed pregnancy were included and 39.5 per 100 PY when 
only women with ≥1 observed pregnancy were included). When the 77 patients with no observed 
unexposed periods were included in the analysis (see Appendix 6), the increased rate of flare during 
pregnancy compared to unexposed periods persisted. The hazard ratio of flares in postpartum periods to 
unexposed periods decreased from the estimates in the primary analysis, although an increased rate of 
flare was still estimated in stratified Cox models. 
 In counting process Cox models limited to only women with ≥1 observed pregnancy, race was 
found to be an effect modifier in the association when flares were measured according to SELENA 
SLEDAI, but not PGA. For the association of pregnancy compared to unexposed periods, the HR was 
1.36 (95% CI: 0.88, 1.96) in black patients and 1.70 (95% CI: 1.18, 2.31) in non-black patients. In the 
association of postpartum vs. unexposed periods, the HR was 0.91 (95% CI: 0.65, 1.23) in black patients 
and 1.27 (95% CI: 0.92, 1.68) in non-black patients.  
 Hydroxychloroquine use was found to be an effect modifier in the association of pregnancy and 
flares. When flares were measured by PGA, counting process Cox models estimated the HR of flares in 
pregnancy compared to unexposed periods to be 1.74 (95% CI: 1.27, 2.29) for patients with no 
hydroxychloroquine use and 1.15 (95% CI: 0.81, 1.54) for patients with hydroxychloroquine use 
(likelihood ratio p-value: 0.02; Table 19). This modification by hydroxychloroquine use was also observed 
in stratified Cox models. There was no evidence in any models that hydroxychloroquine use modified the 
association of flares in the postpartum period compared to unexposed periods. When flares were 
measured by SELENA SLEDAI, counting process Cox models estimated the HR of flares in pregnancy 
compared to unexposed periods to be 1.50 (95% CI: 1.11, 1.98) for patients with no hydroxychloroquine 
use and 1.14 (95% CI: 0.80, 1.52) for patients with hydroxychloroquine use (likelihood ratio p-value=0.12; 
Table 20). There was no evidence of modification in the overall cohort by hydroxychloroquine use in 
stratified models.  
 Prednisone use was only found to be an effect modifier in the association of pregnancy and flares 
in the sensitivity cohort patients with an observed pregnancy when flares were defined by SELENA 
SLEDAI (Appendix 6). Counting process Cox models estimated the HR of flares in pregnancy compared 
to unexposed periods to be 1.84 (95% CI: 1.19, 2.65) in patients with no prednisone use and 1.38 (95% 
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CI: 0.99, 1.85) in patients with prednisone use (likelihood ratio p-value: 0.14). This association persisted 
in stratified Cox models. There was no evidence for modification by prednisone use in PGA models or 
other SELENA SLEDAI models. 
 When the cohort was limited to only visits after the year 2000, results were similar for flares 
defined by PGA (Table 21). Counting process Cox models estimated the HR of flares in pregnancy 
compared to unexposed periods to be 1.31 (95% CI: 0.93, 1.72), and there was no evidence of an 
increased rate of flare during the postpartum period (HR: 0.95; 95% CI: 0.68, 1.25). In contrast, when 
flares were defined by SELENA SLEDAI (Table 22), there was no evidence of an increased rate of flare 
during pregnancy (HR: 1.09; 95% CI: 0.72, 1.26). 
 In the sensitivity analysis limited to time since the year 2000, we found the modification of HCQ 
use remained when flares were measured by PGA (Table 23), with counting process Cox models 
estimating a HR of 1.68 (95% CI: 0.95, 2.64) among patients without HCQ use in pregnancy compared to 
unexposed periods and a HR of 1.16 (95% CI: 0.77, 1.61) among patients with HCQ use (likelihood ratio 
p-value=0.18). In contrast, when flares were measured by SELENA-SLEDAI (Table 24), there was no 
evidence of an association in counting process Cox models for pregnancy compared to unexposed or 
postpartum compared to unexposed among patients who were exposed and among patients who 
unexposed to HCQ. Of interest, there appeared to be a decreased association among patients who were 
not exposed to HCQ. The number of flares and total person-time for each time period stratified by HCQ 
use can be found in Appendix 6.4 for PGA flares and Appendix 6.5 for SELENA-SLEDAI flares. Prior to 
2000, the majority of person-time during pregnancy was unexposed to HCQ (63.2 person-years 
compared to 20.9 person-years exposed to HCQ). After 2000, standard of care practices changed, and 
the majority of patients during pregnancy, as well as the majority of patients during unexposed time and 
postpartum periods, were treated with HCQ (102.6 person-years compared to 34.1 person-years 
unexposed to HCQ during pregnancy).  
The lack of consistency in the association for PGA flares compared to SELENA SLEDAI flares, 
particularly after the year 2000, may be due to the apparent lack of correlation between the two indices. 
Prior to 2000, the correlation between the two indices was 0.34 (Table 25). After 2000, the correlation 
decreased to 0.28.  
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Discussion 
 The present analysis from the Hopkins Lupus Cohort was one of the largest cohort studies to 
date to analyze the effect of pregnancy and the postpartum period on SLE disease flares. Including two 
disease activity indices, PGA and SELENA SLEDAI, in the same analytic cohort allowed us to compare 
how results may differ depending on the index used. We found that although the rates of flares differed 
slightly between the two indices, the hazard ratios for both exposures were similar. The results indicate 
that there is an increased incidence of flare during pregnancy compared to unexposed periods in women 
with SLE, and this association was seen across all models and sensitivity analytic cohorts. The results 
support what has previously been reported in the literature (7, 126, 127, 131). A previous analysis in this 
cohort by Clowse et al. (7) reported that among patients seen at least 6 months prior to pregnancy, 12.5% 
had high disease activity (PGA ≥2) compared to 21.3% of patients during pregnancy. Additionally, Petri 
and colleagues (126) found among 40 pregnant patients in this same cohort, rate of flare was greater 
during pregnancy than in non-pregnant controls, 1.6 flares per PY compared to 0.7 flares per PY, 
respectively. In a SLE cohort in the UK, Ruiz-Irastorza et al. (127) found that the rates of flare during 
pregnancy and a 6-week postpartum period were increased compared to non-pregnant, age-matched 
controls. The rate of flare during pregnancy was 0.082 per person-month compared to 0.039 per person-
month in the control group. A study of 29 pregnancies in Hong Kong estimated a higher rate of flares 
during pregnancy compared to non-pregnant patients (0.08 per person-month compared to 0.04 per 
person-month, respectively) (131). However, our results are in contrast to other previous studies, which 
have found no evidence of an increased rate of flare during pregnancy (128, 132, 166), potentially due to 
differences in study design, sample size, or definition of flare. 
 Fewer studies have examined flares during the postpartum period, which is an important 
contribution of our study. Definitions of the postpartum period used previously in the literature have been 
inconsistent. In this same cohort, Petri et al. (126) reported a lower mean rate of flare per person-year 
after delivery than during pregnancy among 42 patients, with the rate of flare decreasing from 1.6 flares 
per PY during pregnancy to 0.7 per PY in the year after delivery. A study of 72 SLE patients in Argentina 
observed 19% of patients had flares during pregnancy, compared to 4% in the puerperium (51). Ruiz-
Irastorza et al. (127) estimated a rate of flare during pregnancy of 0.08 per person-month, compared to 
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0.15 per person-month during the puerperium (defined as 8 weeks after pregnancy outcome), which 
decreased to 0.05 in the one year after puerperium. Age-matched controls in Ruiz-Irastorza’s study had a 
lower rate of flare than both pregnancy and puerperium periods, with a mean incidence of 0.04 flares per 
person-month. 
 We observed no evidence of an increased rate of flare during the postpartum period compared to 
unexposed periods in crude, counting process Cox models, or stratified Cox models, with the incidence of 
flare in the 1-year postpartum period being similar to the incidence of flare during unexposed periods. 
However, this changed slightly in sensitivity analyses, where the incidence of flare based on PGA in 
unexposed periods decreased from 40.2 per 100 PY for the total cohort to 35.9 per 100 PY when the 
analysis was limited to only women with an observed pregnancy. A decrease in incidence in the 
unexposed period was also estimated when the incidence of flare was based on SELENA SLEDAI (47.3 
per 100 PY in the total cohort compared to 39.5 per 100 PY when the analysis was limited to only women 
with an observed pregnancy). The decrease in the flare incidence in the sub-cohort resulted in the 
incidence rate ratio of flares in the postpartum period compared to unexposed periods to shift from a null 
association to a modestly increased association. This stresses the importance of the appropriate 
comparator group when analyzing flares during pregnancy and the postpartum periods. 
 Effect modification by medication use was observed. Among patients with no hydroxychloroquine 
use, there was an increased rate of flare during pregnancy compared to unexposed periods, but for 
patients taking hydroxychloroquine there was no evidence of an increased rate of flare during pregnancy. 
This is supported by a previous study in this cohort that found disease activity was increased during 
pregnancy for patients who discontinued hydroxychloroquine (7). Our results found that the hazard ratio 
of flare in pregnancy compared to unexposed periods when defined by PGA did not change when the 
cohort was limited to time since 2000. However, results from SELENA SLEDAI models suggest there is 
no evidence of an increased rate of flare during pregnancy compared to unexposed periods when time 
was restricted to 2000-2015. The observed differences between the two indices may be attributable to 
SELENA SLEDAI being an index with set values for disease activity that do not change over time, while a 
physician’s perception of disease activity, as measured by PGA, can potentially change over time. 
 67 
Additionally, we found that SELENA SLEDAI and PGA indices were not well correlated, with a correlation 
coefficient of 0.30 overall. 
 We included two variations of Cox models in our analysis: the stratified Cox model and the 
counting process Cox model. The stratified Cox model, unlike the counting process Cox model, takes into 
consideration the order in which flares occur, and different baseline hazards were allowed for the number 
of previous flares a patient had in the cohort (165). Given that a patient with no history of previous flares 
likely has a different baseline hazard of flare than a patient who has had multiple previous flares, a model 
that takes this into account seems more appropriate than an unadjusted model, such as the counting 
process Cox model. Therefore, we believe the results of the stratified Cox model are more representative 
of the true association of pregnancy and postpartum periods with flares than results from the counting 
process Cox models. A limitation of our study design was patients were censored in the model when the 
exposure changed. We accounted for this by creating a new ID variable when a patient’s exposure 
changed, and included the original and new IDs in the model. However, this causes a patient’s stratum for 
previous flares to be limited to the current exposure period, which may result in some residual 
confounding. Even so, we view this residual confounding to be preferable to the potentially biased 
estimates of the unadjusted counting process Cox models that do not account for or adjust for any 
previous flares. 
 The present analysis benefited from being able to use data from all women enrolled in the 
Hopkins Lupus Cohort, which allowed us to analyze more of the disease history of patients. Because all 
SLE patients may not be the most appropriate comparator group for women who become pregnant, we 
conducted a sensitivity analysis restricted to women with at least one observed pregnancy. The sensitivity 
analyses revealed that unexposed flare rates do change depending on the group of women analyzed – all 
women, women with a history of pregnancy, or women with an observed pregnancy. Additionally, we 
were limited by having to remove 77 patients from the analysis due to lack of unexposed period data for 
these patients, which resulted in removing 83 pregnancies. Sensitivity analyses including these patients 
did not reveal substantial changes to hazard ratios, but it is unknown how these patients differed during 
unexposed periods of time, which could influence our results. We also considered patients who had more 
than a one year gap between study visits to be considered lost to follow-up, although patients were 
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allowed to re-enter the analytic cohort when study visits resumed. This was done to include patients who 
were under routine care and to allow for an appropriate comparator PGA or SELENA SLEDAI score for 
the calculation of disease flare. The disease activity of these patients during unobserved periods is 
unknown, and if a gap in visits was due to remission of the disease, it is possible we underestimated the 
person-time for low disease activity periods for these patients. Additionally, flares captured in the analysis 
were based on flares observed while the patient was seen at the Lupus Center; therefore, we were 
unable to include flares that occurred while a patient was hospitalized and potentially underestimated the 
total number flares patients in the cohort experienced. 
 
Conclusions 
 
 Our study supports and extends previous findings that the incidence of flare is increased during 
pregnancy compared to unexposed periods, and pregnant patients should continue to be closely 
observed during this time. Additionally, our analysis supported previous research that hydroxychloroquine 
should be continued to be used during pregnancy, as it appeared that among patients who used 
hydroxychloroquine, there was no evidence for an increased rate of flare during pregnancy compared to 
unexposed periods. We did not find evidence of an increased rate of flare during postpartum periods 
compared to unexposed periods, suggesting that patients may resume their standard rheumatologic care 
following pregnancy and do not need to be monitored as closely as they are during pregnancy.  
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Table 14. Demographics for SLE patients at baseline and pregnant women at time of first 
pregnancy in cohort in the Hopkins Lupus Cohort, 1987-2015. 
 
Total Cohort 
at Baseline 
n =1349 
Pregnant Women at 
First Pregnancy in Cohort 
n =304 
Race n (%) n (%) 
White 656 (48.6%) 173 (56.9%) 
Black 546 (40.5%) 102 (33.6%) 
Other 147 (10.9%) 29 (9.5%) 
   
 Median (IQR) Median (IQR) 
Age, years 30.6 (25.5-36.8) 29.4 (26.1-33.2) 
Duration of SLE, years 2.0 (0.3-6.7) 4.8 (1.7-9.6) 
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Table 15. Pregnancy outcomes observed in the Hopkins Lupus Pregnancy Cohort, 1987-2015 
(n=398 pregnancies in n=304 patients) 
 n (%) 
Live Birth 340 (85.4%) 
Preterm birthA 98 (28.8%) 
Small for gestational ageB 83 (24.4%) 
Large for gestational ageC 12 (3.5%) 
Fetal loss 46 (11.6%) 
MiscarriageD 29 (63.0%) 
StillbirthE 17 (37.0%) 
Elective termination 12 (3.0%) 
Alive birth at <37 weeks gestational age 
Blive birth with birth weight <10th percentile for gestational age 
Clive birth with birth weight <90th percentile for gestational age 
Dfetal loss at <20 weeks gestation 
Efetal loss at ≥20 weeks gestation 
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Table 16. Number and crude incidence of flares during pregnancy, 1-year postpartum period, and 
unexposed periods of time for women with SLE in the Hopkins Lupus Cohort, 1987-2015 (n=1349). 
 
Flares PY 
Crude incidence  
per 100 PY Crude IRR (95% CI)  
PGAA    
All patients (n=1349) 
Unexposed 2246 5583.0 40.2 1.0 (ref) 
Pregnancy 134 220.8 60.7 1.51 (1.27, 1.80) 
Postpartum 148 370.9 39.9 0.99 (0.84, 1.17) 
     
Patients with history of pregnancy or ≥1 observed pregnancy (n=999) 
Unexposed 1713 4355.9 39.3 1.0 (ref) 
Pregnancy 134 220.8 60.7 1.54 (1.29, 1.84) 
Postpartum 148 370.9 39.9 1.01 (0.86, 1.20) 
     
Patients with ≥1 observed pregnancy in the cohort (n=304) 
Unexposed 642 1790.4 35.9 1.0 (ref) 
Pregnancy 134 220.8 60.7 1.69 (1.40, 2.04) 
Postpartum 148 370.9 39.9 1.11 (0.93, 1.33) 
     
SELENA SLEDAIB     
All patients (n=1349) 
Unexposed 2641 5583.0 47.3 1.0 (ref) 
Pregnancy 140 220.8 63.4 1.34 (1.13, 1.59) 
Postpartum 170 370.9 45.8 0.97 (0.83, 1.13) 
     
Patients with history of pregnancy or ≥1 observed pregnancy (n=999) 
Unexposed 1945 4355.9 44.7 1.0 (ref) 
Pregnancy 140 220.8 63.4 1.42 (1.20, 1.69) 
Postpartum 170 370.9 45.8 1.03 (0.88, 1.20) 
     
Patients with ≥1 observed pregnancy in the cohort (n=304) 
Unexposed 708 1790.4 39.5 1.0 (ref) 
Pregnancy 140 220.8 63.4 1.60 (1.34, 1.92) 
Postpartum 170 370.9 45.8 1.16 (0.98, 1.37) 
Aflare defined as change in ≥1 from PGA score at previous visit  
Bflare defined as change in ≥4 from SELENA SLEDAI score at previous visit  
CI: confidence interval; PGA: Physician Global Assessment of disease activity; PY: person-years; SLE: 
systemic lupus erythematosus; SLEDAI: SLE Disease Activity Index 
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Table 17. Hazard ratios of flares based on PGAA during pregnancy and 1-year postpartum period 
compared to unexposed periods for women with SLE in the Hopkins Lupus Cohort, 1987-2015 
(n=1349). 
 Counting Process Cox  
Proportional HazardB 
Stratified CoxC 
 HR (95% CI) HR (95% CI) 
All patients (n=1349) 
Unexposed 1.0 (ref) 1.0 (ref) 
Pregnancy 1.44 (1.14, 1.75) 1.59 (1.27, 1.96)  
Postpartum 0.94 (0.76, 1.13) 1.02 (0.83, 1.25)  
   
Patients with history of pregnancy or ≥1 observed pregnancy (n=999) 
Unexposed 1.0 (ref) 1.0 (ref) 
Pregnancy 1.49 (1.17, 1.86) 1.69 (1.36, 2.07)  
Postpartum 0.98  (0.76, 1.21) 1.10 (0.91, 1.35)  
   
Patients with ≥1 observed pregnancy in the cohort (n=304) 
Unexposed 1.0 (ref) 1.0 (ref) 
Pregnancy 1.58 (1.24, 2.01) 1.88 (1.48, 2.49)  
Postpartum 1.04 (0.80, 1.36) 1.24 (0.96, 1.66)  
Aflare defined as change in ≥1 from PGA score at previous visit  
CI: confidence interval; HR: hazard ratio; PGA: Physician Global Assessment of disease activity; SLE: 
systemic lupus erythematosus  
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Table 18. Hazard ratios of flares based on SELENA SLEDAIA during pregnancy and 1-year 
postpartum period compared to unexposed periods for women with SLE in the Hopkins Lupus 
Cohort, 1987-2015 (n=1349). 
 Counting Process Cox  
Proportional HazardB 
Stratified CoxC 
 HR (95% CI) HR (95% CI) 
All patients (n=1349) 
Unexposed 1.0 (ref) 1.0 (ref) 
Pregnancy 1.30 (1.04, 1.62) 1.57 (1.25, 1.92)  
Postpartum 0.93 (0.75, 1.12) 1.09 (0.89, 1.32)  
   
Patients with history of pregnancy or ≥1 observed pregnancy (n=999) 
Unexposed 1.0 (ref) 1.0 (ref) 
Pregnancy 1.38 (1.09, 1.71) 1.65 (1.30, 2.06)  
Postpartum 0.99 (0.79, 1.21) 1.17 (0.95, 1.46)  
   
Patients with ≥1 observed pregnancy in the cohort (n=304) 
Unexposed 1.0 (ref) 1.0 (ref) 
Pregnancy 1.50 (1.13, 1.88) 1.82 (1.34, 2.38)  
Postpartum 1.08 (0.86, 1.35) 1.32 (1.03, 1.69)  
Aflare defined as change in ≥4 from SELENA SLEDAI score at previous visit  
CI: confidence interval; HR: hazard ratio; SLE: systemic lupus erythematosus; SLEDAI: SLE Disease 
Activity Index 
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Table 19. Modification by hydroxychloroquine of hazard ratios of flares based on PGAA during 
pregnancy and 1-year postpartum period compared to unexposed periods for women with SLE in 
the Hopkins Lupus Cohort, 1987-2015 (n=1349). 
 Counting Process Cox  
Proportional HazardB 
Stratified CoxC 
 No HCQ Use  HCQ Use  No HCQ Use  HCQ Use  
 HR (95% CI)  HR (95% CI)  HR (95% CI)  HR (95% CI)  
All patients (n=1349)  
Unexposed  1.0 (ref)  1.0 (ref)  1.0 (ref)  1.0 (ref)  
Pregnancy  1.74 (1.27, 2.29)  1.15 (0.81, 1.54)  1.83 (1.34, 2.45)  1.26 (0.88, 1.69)  
Postpartum  0.93 (0.64, 1.23)  0.96 (0.69, 1.23)  0.98 (0.67, 1.31)  1.02 (0.72, 1.32)  
     
Patients with history of pregnancy or ≥1 observed pregnancy (n=999)  
Unexposed  1.0 (ref)  1.0 (ref)  1.0 (ref)  1.0 (ref)  
Pregnancy  1.89 (1.39, 2.49)  1.17 (0.78, 1.56)  1.89 (1.46, 2.62)  1.32 (0.87, 1.77)  
Postpartum  1.01 (0.70, 1.33)  0.97 (0.71, 1.28)  1.05 (0.73, 1.43)  1.05 (0.78, 1.40)  
     
Patients with ≥1 observed pregnancy in the cohort (n=304)  
Unexposed  1.0 (ref)  1.0 (ref)  1.0 (ref)  1.0 (ref)  
Pregnancy  2.09 (1.48, 2.98)  1.22 (0.80, 1.69)  2.25 (1.58, 3.39)  1.45 (0.96, 2.09)  
Postpartum  1.11 (0.76, 1.59)  1.05 (0.72, 1.43)  1.24 (0.84, 1.84)  1.20 (0.82, 1.65)  
Aflare defined as change in ≥1 from PGA score at previous visit  
BCounting process Cox proportional hazards model assumes the order of the events of flares did not 
need to be taken into consideration 
CStratified Cox model is a conditional model that does not assume independence of multiple events of 
flares and allows different baseline hazards based on the number of previous flares a patient experienced 
CI: confidence interval; HCQ: hydroxychloroquine; HR: hazard ratio; PGA: Physician Global Assessment 
of disease activity; SLE: systemic lupus erythematosus 
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Table 20. Modification by hydroxychloroquine of hazard ratios of flares based on SELENA 
SLEDAIA during pregnancy and 1-year postpartum period compared to unexposed periods for 
women with SLE in the Hopkins Lupus Cohort, 1987-2015 (n=1349). 
 Counting Process Cox 
Proportional HazardB 
Stratified CoxC 
 No HCQ Use  HCQ Use  No HCQ Use  HCQ Use  
 HR (95% CI)  HR (95% CI)  HR (95% CI)  HR (95% CI)  
All patients (n=1349)  
Unexposed  1.0 (ref)  1.0 (ref)  1.0 (ref)  1.0 (ref)  
Pregnancy  1.50 (1.11, 1.98)  1.14 (0.80, 1.52)  1.59 (1.17, 2.09)  1.35 (0.92, 1.81)  
Postpartum  0.85 (0.60, 1.12)  1.01 (0.77, 1.27)  0.91 (0.64, 1.20)  1.13 (0.88, 1.44)  
     
Patients with history of pregnancy or ≥1 observed pregnancy (n=999)  
Unexposed  1.0 (ref)  1.0 (ref)  1.0 (ref)  1.0 (ref)  
Pregnancy  1.67 (1.23, 2.23)  1.20 (0.83, 1.64)  1.71 (1.25, 2.28)  1.40 (0.97, 1.92)  
Postpartum  0.95 (0.69, 1.27)  1.06 (0.80, 1.34)  1.00 (0.72, 1.34)  1.19  (0.90, 1.53)  
     
Patients with ≥1 observed pregnancy in the cohort (n=304)  
Unexposed  1.0 (ref)  1.0 (ref)  1.0 (ref)  1.0 (ref)  
Pregnancy  1.97 (1.38, 2.76)  1.26 (0.83, 1.70)  2.09 (1.39, 2.97)  1.49 (0.92, 2.08)  
Postpartum  1.10 (0.77, 1.55)  1.13 (0.83, 1.48)  1.18 (0.79, 1.69)  1.29  (0.93, 1.73)  
Aflare defined as change in ≥4 from SELENA SLEDAI score at previous visit  
BCounting process Cox proportional hazards model assumes the order of the events of flares did not 
need to be taken into consideration 
CStratified Cox model is a conditional model that does not assume independence of multiple events of 
flares and allows different baseline hazards based on the number of previous flares a patient experienced 
CI: confidence interval; HCQ: hydroxychloroquine; HR: hazard ratio; SLE: systemic lupus erythematosus; 
SLEDAI: SLE Disease Activity Index 
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Table 21. Hazard ratios of flares based on PGAA during pregnancy, 1-year postpartum period, and 
unexposed periods of time for women with SLE in the Hopkins Lupus Cohort, 2000-2015 (n=1073). 
 Counting Process Cox  
Proportional HazardB 
Stratified CoxC 
 HR (95% CI)  HR (95% CI)  
All patients (n=1073)  
Unexposed  1.0 (ref)  1.0 (ref)  
Pregnancy  1.31 (0.93, 1.72)  1.47 (1.01, 2.02)  
Postpartum  0.95 (0.68, 1.25)  1.05 (0.73, 1.43)  
   
Patients with history of pregnancy or ≥1 observed pregnancy (n=787)  
Unexposed  1.0 (ref)  1.0 (ref)  
Pregnancy  1.34 (0.96, 1.80)  1.57 (1.14, 2.13)  
Postpartum  0.98  (0.69, 1.31)  1.13 (0.81, 1.52)  
   
Patients with ≥1 observed pregnancy in the cohort (n=268)  
Unexposed  1.0 (ref)  1.0 (ref)  
Pregnancy  1.47 (1.02, 2.03)  1.85 (1.24, 2.59)  
Postpartum  1.11 (0.76, 1.55)  1.33 (0.90, 1.88)  
Aflare defined as change in ≥1 from PGA score at previous visit  
BCounting process Cox proportional hazards model assumes the order of the events of flares did not 
need to be taken into consideration 
CStratified Cox model is a conditional model that does not assume independence of multiple events of 
flares and allows different baseline hazards based on the number of previous flares a patient experienced 
CI: confidence interval; HR: hazard ratio; PGA: Physician Global Assessment of disease activity; SLE: 
systemic lupus erythematosus 
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Table 22. Hazard ratios of flares based on SELENA SLEDAIA during pregnancy, 1-year postpartum 
period, and unexposed periods of time for women with SLE in the Hopkins Lupus Cohort, 2000-
2015 (n=1073). 
 Counting Process Cox 
Proportional HazardB  
Stratified CoxC  
 HR (95% CI)  HR (95% CI)  
All patients (n=1073)  
Unexposed  1.0 (ref)  1.0 (ref)  
Pregnancy  1.09 (0.75, 1.46)  1.45 (0.99, 1.92)  
Postpartum  0.99 (0.72, 1.26)  1.24 (0.92, 1.57)  
   
Patients with history of pregnancy or ≥1 observed pregnancy (n=787)  
Unexposed  1.0 (ref)  1.0 (ref)  
Pregnancy  1.18 (0.83, 1.57)  1.56 (1.12, 2.08)  
Postpartum  1.07 (0.81, 1.34)  1.36 (1.03, 1.73)  
   
Patients with ≥1 observed pregnancy in the cohort (n=268)  
Unexposed  1.0 (ref)  1.0 (ref)  
Pregnancy  1.35 (0.91, 1.84)  1.77 (1.14, 2.43)  
Postpartum  1.23 (0.88, 1.60)  1.58 (1.16, 2.11)  
Aflare defined as change in ≥4 from SELENA SLEDAI score at previous visit  
BCounting process Cox proportional hazards model assumes the order of the events of flares did not 
need to be taken into consideration 
CStratified Cox model is a conditional model that does not assume independence of multiple events of 
flares and allows different baseline hazards based on the number of previous flares a patient experienced 
CI: confidence interval; HR: hazard ratio; SLE: systemic lupus erythematosus; SLEDAI: SLE Disease 
Activity Index 
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Table 23. Modification by hydroxychloroquine of hazard ratios of flares based on PGAA during 
pregnancy and 1-year postpartum period compared to unexposed periods for women with SLE in 
the Hopkins Lupus Cohort, 2000-2015 (n=1073). 
 Counting Process Cox  
Proportional HazardB 
Stratified CoxC 
 No HCQ Use  HCQ Use  No HCQ Use  HCQ Use  
 HR (95% CI)  HR (95% CI)  HR (95% CI)  HR (95% CI)  
All patients (n=1073)  
Unexposed  1.0 (ref)  1.0 (ref)  1.0 (ref)  1.0 (ref)  
Pregnancy  1.68 (0.95, 2.64) 1.16 (0.77, 1.61) 1.75 (0.99, 2.91) 1.29 (0.87, 1.83) 
Postpartum  0.97 (0.50, 1.63) 0.95 (0.62, 1.36) 1.02 (0.53, 1.75) 1.02 (0.69, 1.49) 
     
Patients with history of pregnancy or ≥1 observed pregnancy (n=787)  
Unexposed  1.0 (ref)  1.0 (ref)  1.0 (ref)  1.0 (ref)  
Pregnancy  1.76 (0.93, 2.73) 1.18 (0.76, 1.66) 1.89 (1.08, 3.06) 1.35 (0.92, 2.00) 
Postpartum  1.03 (0.49, 1.74) 0.96 (0.64, 1.38) 1.11 (0.52, 1.91) 1.06 (0.74, 1.66) 
     
Patients with ≥1 observed pregnancy in the cohort (n=268)  
Unexposed  1.0 (ref)  1.0 (ref)  1.0 (ref)  1.0 (ref)  
Pregnancy  2.24 (1.15, 4.07) 1.25 (0.75, 1.84) 2.56 (1.24, 4.75) 1.49 (0.99, 2.41) 
Postpartum  1.36 (0.59, 2.69) 1.05 (0.65, 1.54) 1.47 (0.64, 3.01) 1.20 (0.78, 1.87) 
Aflare defined as change in ≥1 from PGA score at previous visit  
BCounting process Cox proportional hazards model assumes the order of the events of flares did not 
need to be taken into consideration 
CStratified Cox model is a conditional model that does not assume independence of multiple events of 
flares and allows different baseline hazards based on the number of previous flares a patient experienced 
CI: confidence interval; HCQ: hydroxychloroquine; HR: hazard ratio; PGA: Physician Global Assessment 
of disease activity; SLE: systemic lupus erythematosus 
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Table 24. Modification by hydroxychloroquine of hazard ratios of flares based on SELENA 
SLEDAIA during pregnancy and 1-year postpartum period compared to unexposed periods for 
women with SLE in the Hopkins Lupus Cohort, 2000-2015 (n=1073). 
 Counting Process Cox 
Proportional HazardB 
Stratified CoxC 
 No HCQ Use  HCQ Use  No HCQ Use  HCQ Use  
 HR (95% CI)  HR (95% CI)  HR (95% CI)  HR (95% CI)  
All patients (n=1073)  
Unexposed  1.0 (ref)  1.0 (ref)  1.0 (ref)  1.0 (ref)  
Pregnancy  0.78 (0.29, 1.40) 1.20 (0.81, 1.68) 0.90 (0.38, 1.77) 1.48 (1.08, 2.26) 
Postpartum  0.63 (0.28, 1.02) 1.12 (0.80, 1.46) 0.73 (0.34, 1.26) 1.30 (1.03, 1.86) 
     
Patients with history of pregnancy or ≥1 observed pregnancy (n=787)  
Unexposed  1.0 (ref)  1.0 (ref)  1.0 (ref)  1.0 (ref)  
Pregnancy  0.92 (0.35, 1.68) 1.26 (0.86, 1.74) 1.02 (0.43, 2.07) 1.57 (1.14, 2.43) 
Postpartum  0.78 (0.35, 1.31) 1.18 (0.85, 1.57) 0.85 (0.42, 1.65) 1.39 (1.10, 2.00) 
     
Patients with ≥1 observed pregnancy in the cohort (n=268)  
Unexposed  1.0 (ref)  1.0 (ref)  1.0 (ref)  1.0 (ref)  
Pregnancy  1.30 (0.50, 2.57) 1.37 (0.88, 1.95) 1.34 (0.56, 2.96) 1.69 (1.13, 2.73) 
Postpartum  1.04 (0.45, 1.89) 1.30 (0.95, 1.78) 1.14 (0.49, 2.23) 1.54 (1.23, 2.38) 
Aflare defined as change in ≥4 from SELENA SLEDAI score at previous visit  
BCounting process Cox proportional hazards model assumes the order of the events of flares did not 
need to be taken into consideration 
CStratified Cox model is a conditional model that does not assume independence of multiple events of 
flares and allows different baseline hazards based on the number of previous flares a patient experienced 
CI: confidence interval; HCQ: hydroxychloroquine; HR: hazard ratio; SLE: systemic lupus erythematosus; 
SLEDAI: SLE Disease Activity Index 
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Table 25. Correlation of flares defined by PGAA and SELENA-SLEDAIB for women with SLE in the 
Hopkins Lupus Cohort, 1987-2015 (n=1349). 
 Pearson Correlation Coefficient 
Overall 0.30 
Prior to 2000 0.34 
2000 and after 0.28 
Aflare defined as change in ≥1 from PGA score at previous visit  
Bflare defined as change in ≥4 from SELENA SLEDAI score at previous visit  
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CHAPTER 7: CONCLUSIONS 
 
 The objective of this dissertation was to further understand how SLE affects pregnancy, including 
gestational weight gain patterns and pregnancy outcomes, such as preterm birth and birth weight for 
gestational age z-score. Additionally, we sought advance the current knowledge about how pregnancy 
affects SLE disease activity, as measured by flares. The key findings of our study, the study’s strengths 
and limitations, public health significance and direction of future research are summarized in the following 
section.  
 
Summary of Findings 
 In the first specific aim, we estimated the proportion of pregnant women with SLE who met 
Institute of Medicine (IOM) guidelines for gestational weight gain (GWG) and determined correlates of 
adherence to IOM guidelines. Using a pre-pregnancy weight measured during the 12 months prior to 
pregnancy or in the first trimester and a final weight measurement closest to birth in the third trimester, we 
classified GWG as inadequate, adequate, or excessive based on pre-pregnancy BMI. We found that of 
211 pregnancies, 34.1% of women had inadequate, 24.2% had adequate, and 41.7% had excessive 
weight gain. In descriptive analyses, differences in IOM adherence were observed by pre-pregnancy BMI, 
race, elevated creatinine during pregnancy, and pre-pregnancy blood pressure. In logistic regression 
models, stepwise selection determined continuous pre-pregnancy BMI and maternal education level to be 
predictors of inadequate and excessive weight gain. With each 1 kg/m2 increase in pre-pregnancy BMI, 
the odds of inadequate weight gain and excessive weight gain both increased 12%. Compared to patients 
with a greater than college education, patients with a high school education had approximately three 
times the odds of inadequate weight gain and twice the odds of excessive weight gain. 
 In the second specific aim, we determined the proportion of pregnant women with SLE meeting 
the American Heart Association (AHA) guidelines for ideal cardiovascular health, and estimated the 
effects of pre-conceptional cardiovascular health on pregnancy outcomes. Body mass index (BMI), total 
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cholesterol and blood pressure in the most recent clinic visit in the one-year prior to conception or 1st 
trimester were used to classify cardiovascular health according to AHA criteria (ideal, intermediate or poor 
health). Pregnancy outcomes of interest included preterm birth (delivery prior to 37 completed weeks’ 
gestation), gestational age at birth, small for gestational age (SGA; less than the 10th percentile of weight 
for gestational age) and birth weight-for-gestational age z-score. Among 309 singleton live births to 261 
SLE patients, there were 95 preterm births (31%), and of the 293 pregnancies with birth weights, 18% 
were SGA. Ideal BMI (underweight/normal weight), ideal total cholesterol (<200 mg/dL), and ideal blood 
pressure (<120/<80 mm Hg) were observed in 56%, 86%, and 51% of pregnancies, respectively. Among 
SLE patients, overweight was associated with increased odds of preterm birth [Odds Ratio (OR): 1.38; 
95% CI: 0.70, 2.71] and decreased odds of SGA (OR: 0.26; 95% CI: 0.11, 0.63) compared to 
underweight/normal weight, adjusted for race and prednisone use. In models adjusted for race and anti-
malarial use, intermediate/poor total cholesterol was associated with increased odds of preterm birth (OR: 
1.91; 95% CI: 0.96, 3.79). Intermediate/poor blood pressure was associated with decreased gestational 
age at birth (β: -0.96; 95% CI: -1.62, -0.29).  
 The third specific aim estimated the effect of pregnancy and one-year postpartum period on flares 
in women SLE. Using data available on all women aged 15-45 in the Hopkins Lupus Cohort, we 
calculated disease flares during periods of pregnancy, a one-year postpartum period, and during 
unexposed periods when patients were neither pregnancy nor in a postpartum period. SLE disease flares 
were classified according to two indices: Physician Global Assessment of disease activity (PGA) and 
SELENA SLE Disease Activity Index (SLEDAI). A flare based on the PGA index was defined as a change 
in PGA ≥1 from previous visit, and a flare based on the SELENA SLEDAI index was defined as a change 
in SELENA SLEDAI ≥4 from the previous visit. The hazard ratios of flares during pregnancy compared to 
unexposed periods and postpartum compared to unexposed periods were estimated using two variations 
of Cox models. The first model was the standard counting process Cox proportional hazards model, 
which assumed that the order of the events of flares did not need to be taken into consideration. The 
second model was a stratified Cox model, a conditional model that did not assume independence of 
multiple events of flare, and instead included a stratum for the time interval number was included in the 
model so a patient was not at risk for a second flare without having experienced a previous flare. The 
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analysis included 1349 SLE patients, of which n=304 patients had n=398 pregnancies. In counting 
process Cox models, an increased rate of flares during pregnancy compared to unexposed periods was 
estimated in counting process Cox models for PGA (HR: 1.44; 95% CI: 1.14, 1.75) and SELENA SLEDAI 
flare (HR: 1.30; 95% CI: 1.04, 1.62). There was no evidence of increased rate of flares during postpartum 
compared to unexposed periods. In stratified Cox models, the increased rate of flare during pregnancy 
persisted for PGA (HR: 1.59; 95% CI: 1.27, 1.96) and SELENA SLEDAI flare (HR: 1.09; 95% CI: 0.89, 
1.32). Similar to counting process Cox models, there was no evidence of increased rate of flares during 
postpartum compared to unexposed periods. Hydroxychloroquine use was found to be an effect modifier 
in the association of pregnancy and flares. When flares were measured by PGA, counting process Cox 
models estimated the HR of flares in pregnancy compared to unexposed periods to be 1.74 (95% CI: 
1.27, 2.29) for patients with no hydroxychloroquine use and 1.15 (95% CI: 0.81, 1.54) for patients with 
hydroxychloroquine use (likelihood ratio p-value: 0.02). This modification by hydroxychloroquine use was 
also observed in stratified Cox models. When flares were measured by SELENA SLEDAI, counting 
process Cox models estimated the HR of flares in pregnancy compared to unexposed periods to be 1.50 
(95% CI: 1.11, 1.98) for patients with no hydroxychloroquine use and 1.14 (95% CI: 0.80, 1.52) for 
patients with hydroxychloroquine use (likelihood ratio p-value=0.12). There was no evidence in any 
models that hydroxychloroquine use modified the association of flares in the postpartum period compared 
to unexposed periods. We included two variations of Cox models in our analysis: the stratified Cox model 
and the counting process Cox model. Given that the stratified Cox model takes into consideration the 
order in which flares occur and allows different baseline hazards for the number of previous flares a 
patient had in the cohort (165), we concluded that the results of the stratified Cox model are more 
representative of the true association of pregnancy and postpartum periods with flares than results from 
the counting process Cox models.  
 
Study Limitations 
 Our study had several limitations. In Aims 1 and 2, our study suffered from small sample sizes. In 
Aim 1, we were unable to further explore the interaction of BMI with demographic and clinical features 
due to insufficient power. Previous research has found that factors associated with non-adherence, such 
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as race, education and certain co-morbidities vary by BMI group (141), but we were unable to further 
explore these interactions in our analysis. In Aim 2, the small sample size and low frequency of large for 
gestational age births did not allow us to explore the effect of cardiovascular health on this birth outcome. 
While the cohort is larger than other SLE pregnancy cohorts, the modest sample size did not provide 
sufficient power to detect small differences in outcomes. 
 Another limitation of our analysis, particularly in Aims 1 and 2, is the possibility of selection bias 
due to clinical and demographics differences in pregnancies that were excluded from analyses due to 
missing data. It is possible that our results in Aims 1 and 2 would differ if excluded patients had been 
retained in the analysis. In Aim 1, maternal weight at the beginning and end of pregnancy were not 
available for all live births in the cohort. Live births excluded from the analysis (210 of 421 singleton live 
births) were more frequently to mothers with a high school education and a pregnancy outcome date prior 
to 1999. Additionally, excluded pregnancies were to mothers with a lower frequency of anti-malarial use 
during pregnancy and shorter disease duration. In Aim 2, cardiovascular data were not available for all 
live births in the cohort. A greater proportion of live births excluded from the analysis due to missing 
cardiovascular health data (112 of 421 singleton live births) were to mothers who were black and had a 
pregnancy outcome data prior to 1999, compared to the final analysis population. Additionally, excluded 
births were to mothers who had shorter disease duration, lower frequency of anti-malarial use during 
pregnancy and lower frequency of low C3/C4. In Aim 3, we excluded 77 pregnancies in patients who did 
not have any unexposed follow-up time. While our sensitivity analysis that included these patients found 
no major differences in the estimated hazards ratios, it is unknown what disease activity these patients 
had when they were not pregnant and if the missingness of their data was due to their disease activity. In 
Aim 3, we also considered patients who had more than a one year gap between study visits to be 
considered lost to follow-up, although patients were allowed to re-enter the analytic cohort when study 
visits resumed. This was done to include patients who were under routine care and to allow for an 
appropriate comparator PGA or SELENA SLEDAI score for the calculation of disease flare. The disease 
activity of these patients during unobserved periods is unknown, and if a gap in visits was due to 
remission of the disease, it is possible we underestimated the person-time for low disease activity periods 
for these patients. 
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 Third, data were unavailable on the four remaining AHA cardiovascular metrics (glucose, physical 
activity, diet, and cigarette smoking); therefore, we were unable to assess the combined effects of 
cardiovascular risk factors in Aim 2. Additional data on physical activity and diet would have also 
benefited Aim 1 by allowing us to understand how physical activity and diet can help further explain 
differences in weight gain patterns in this patient population. 
 Fourth, the data were collected at a single academic center. While this is favorable with respects 
to consistency in the treatment of patients and data collection, the cohort described in this analysis may 
not be representative of all SLE patients and our results may not be generalizable to all SLE patients. 
 Finally, although we used prospectively collected data from a longitudinal cohort and were able to 
adjust for potential confounders in our analyses, there remains the possibility of unmeasured confounding 
that could affect our results. This concern is common in all observational studies, though, and is not 
limited to this study.  
 
Study Strengths 
 Although the sample sizes in Aims 1 and 2 were modest, this study reports one of the largest 
cohorts of pregnant women with SLE, and it is the first study to analyze gestational weight gain patterns 
in SLE, as well as the first to examine the AHA’s guidelines for cardiovascular health in patients with SLE 
prior to conception.  
 The Hopkins Lupus Cohort is a longitudinal cohort study, with data prospectively collected by a 
single rheumatologist since 1987. The prospective collection of data provided us with clinically recorded 
weights, rather than having to rely on self-report of pre-pregnancy weight of total gestational weight gain 
by the patient, which has been found to often be inaccurately remembered at the time of delivery (145). 
Additionally, the longitudinal nature of the cohort allowed for weights to be measured at multiple times 
during pregnancy, which allowed for weight gain trajectories to be constructed in Aim 1. 
 The analysis utilized various statistical methods to determine the incidence of flare during 
pregnancy and the postpartum period compared to unexposed periods. We demonstrated that results 
were similar in both counting process and stratified Cox models. Our results support the importance of 
continuing to monitor SLE patients for flares during pregnancy and suggest that there is no increased rate 
 86 
of flare during the one year postpartum period. Additionally, we were able to utilize two accepted and 
validated clinical indices of disease activity, PGA and SELENA SLEDAI, in our analysis, which allowed us 
to compare results across different indices. 
 
Public Health Implications 
 The appropriate amount of weight gained during pregnancy has great implications for the infant: 
gaining too much weight during pregnancy has been shown to be associated with delivering large for 
gestational age or macrosomic (>4000 g) infants (73-89), while insufficient weight gain is associated with 
the delivery of a small for gestational age infant (74, 75, 78-84, 90). The adverse effect of gaining too 
much weight during pregnancy continues throughout childhood, with excessive GWG being associated 
with childhood obesity (94, 139, 140). Gestational weight gain also has implications for preterm birth. 
There appears to be a U-shaped association of GWG with preterm birth, with modification by pre-
pregnancy BMI (10, 91-94). Among women who are underweight according to their pre-pregnancy BMI, 
less than ideal GWG is associated with an increased risk of preterm birth, and this association weakens 
as pre-pregnancy BMI increases. More than ideal GWG may be associated with preterm birth in women 
of all pre-pregnancy BMI categories (9, 10). Our analysis in Aim 1 found that only 24% of SLE patients 
gained an adequate amount of weight, which could have an effect on pregnancy outcomes in this 
population. Additionally, our findings in Aim 1 identified maternal education and pre-pregnancy BMI as 
correlates of adherence to GWG guidelines. This suggests interventions in this patient population may 
benefit from being targeted toward patients with increased BMI and lower maternal education.  
 The findings of Aim 2 have important implications for SLE patients during pregnancy. Of particular 
interest in our analysis was the apparent inverse association of obesity but the increased risk of preterm 
birth in overweight patients. This suggests that efforts to normalize maternal weight prior to pregnancy 
may improve pregnancy outcomes. Previous studies have found that among patients with SLE, 
pregnancy increases the risk of future major cardiovascular events and a poor pregnancy outcome 
increases the risk cardiovascular mortality (164). Interventions to improve the cardiovascular health of 
patients prior to pregnancy would improve pregnancy outcomes, as well as benefit the long-term health of 
SLE patients. 
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 The results from Aim 3 support previous findings that the incidence of flare is increased during 
pregnancy compared to unexposed periods. However, in our sensitivity analysis limited to time since the 
year 2000, we observed no evidence of increased flares defined by SELENA SLEDAI during pregnancy, 
which may indicate that previous recommendations of increased monitoring of pregnant SLE patients 
have been successful in reducing the rate of flare during pregnancy. We did not find evidence of an 
increased rate of flare during postpartum periods compared to unexposed periods, suggesting that 
patients may resume their standard rheumatologic care following pregnancy and do not need to be 
monitored as closely as they are during pregnancy. Additionally, our analysis supported previous 
research that hydroxychloroquine should be continued to be used during pregnancy, by finding the 
association of flare during pregnancy compared to unexposed periods to be modified by 
hydroxychloroquine use. Based on previous findings that high disease activity during pregnancy is 
associated with poor pregnancy outcomes (7), understanding how disease activity changes during 
pregnancy will be important to improve pregnancy outcomes in women with SLE. 
 
Direction of Future Research 
 As described previously, our study was limited by sample size, as well as the lack of several 
important cardiovascular health metrics. Further investigations of our research topic in a diverse and 
global SLE cohort would increase statistical power and improve generalizability of study results. 
Specifically, we believe the following areas are important for future research: 
 
1) Collect additional measures of cardiovascular health  
The American Heart Association 2020 Impact Goals included the development of the concept of 
“ideal cardiovascular health,” focuses on primary prevention and is composed of seven modifiable 
cardiovascular metrics: health factors (glucose, cholesterol, and blood pressure) and health behaviors 
(body mass index, physical activity, diet, and cigarette smoking) (95). Meeting these metrics for ideal 
cardiovascular health is associated with a lower risk of cardiovascular disease and lower 
cardiovascular and all-cause mortality rates. Data were unavailable in our study on glucose, physical 
activity, diet, and current cigarette smoking. Availability of these data would provide a more complete 
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picture of how pre-cardiovascular health impacts pregnancy outcomes by analyzing the combined 
effects of all seven cardiovascular risk factors. Additionally, having a further understanding of SLE 
patients who are able to maintain ideal cardiovascular health will be important in order to develop 
future targeted treatments. Data on physical activity and diet would also benefit our understanding of 
the patterns of physical activity and diet during pregnancy for SLE patients, and the implications of 
each on gestational weight gain patterns in SLE. 
 
2) Understand appropriateness of IOM guidelines for SLE patients 
The IOM formed a committee to update the recommendations for GWG. Guidelines were revised to 
reflect the recognized need for weight gain recommendations to be specific to a woman’s pre-
pregnancy BMI. Although the 2009 committee was not intended to develop GWG guidelines for 
specific diseases or conditions, a noticeable gap in the literature was the availability of data on the 
weight gain patterns in patients with SLE. It has yet to be determined if the IOM guidelines for weight 
gain in the general population are appropriate for women with SLE. Our study found that the majority 
of SLE patients do not meet IOM guidelines for GWG, and future studies are necessary to determine 
if pregnancy outcomes in women with SLE are improved when IOM guidelines for gestational weight 
gain are met.   
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APPENDIX 1. 1997 UPDATE OF THE 1982 AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) 
CRITERIA FOR CLASSIFICATION OF SLE (12, 13) 
 
Criteria Description 
1. Malar Rash Fixed erythema, flat or raised, over the malar eminences, tending to spare the 
nasolabial folds 
2. Discoid Rash Erythematous raised patches with adherent keratotic scaling and follicular 
plugging; atrophic scarring may occur in older lesions 
3. Photosensitivity Skin rash as a result of unusual reaction to sunlight, by patient history or 
physician observation 
4. Oral ulcers Oral or nasopharyngeal ulceration, usually painless, observed by physician 
5. Nonerosive 
Arthritis 
Involving 2 or more peripheral joints, characterized by tenderness, swelling, or 
effusion 
6. Pleuritis or 
Pericarditis 
a. Pleuritis (convincing history of pleuritic pain or rubbing heard by a 
physician or evidence of pleural effusion) 
OR 
b. Pericarditis (documented by electrocardigram or rub or evidence of 
pericardial effusion) 
7. Kidney Disorder a. Persistent proteinuria > 0.5 grams per day or > than 3+ if quantitation 
not performed 
OR 
b. Cellular casts (may be red cell, hemoglobin, granular, tubular, or 
mixed) 
8. Neurologic 
Disorder 
a. Seizures in the absence of offending drugs or known metabolic 
derangements (e.g., uremia, ketoacidosis, or electrolyte imbalance) 
OR 
b. Psychosis in the absence of offending drugs or known metabolic 
derangements (e.g., uremia, ketoacidosis, or electrolyte imbalance) 
9. Hematologic 
Disorder 
a. Hemolytic anemia with reticulocytosis 
OR 
b. Leukopenia (< 4,000/mm3 on ≥ 2 occasions) 
OR 
c. Lyphopenia (< 1,500/ mm3 on ≥ 2 occasions) 
OR 
d. Thrombocytopenia (<100,000/ mm3 in the absence of offending 
drugs) 
10. Immunologic 
Disorder 
a. Anti-DNA (antibody to native DNA in abnormal titer) 
OR 
b. Anti-Sm (presence of antibody to Sm nuclear antigen) 
OR 
c. Positive finding of antiphospholipid antibodies on: 
i. an abnormal serum level of IgG or IgM anticardiolipin 
antibodies, 
ii. a positive test result for lupus anticoagulant using a standard 
method, or 
iii. a false-positive test result for at least 6 months confirmed by 
Treponema pallidum immobilization or fluorescent treponemal 
antibody absorption test 
11. Positive 
Antinuclear 
Antibody 
An abnormal titer of antinuclear antibody by immunofluorescence or an 
equivalent assay at any point in time and in the absence of drugs 
Hochberg, M. C. (1997). "Updating the American college of rheumatology revised criteria for the 
classification of systemic lupus erythematosus." Arthritis & Rheumatism 40(9): 1725-1725.  
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APPENDIX 2. SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX (SLEDAI) SELENA 
MODIFICATION 
 
Check box: if descriptor is present at the time of visit or in the preceding 10 days. 
Weight 
Check if 
Present Descriptor Definition 
8 □ Seizure Recent onset (last 10 days). Exclude metabolic, infectious or 
drug cause. 
8 □ Psychosis Altered ability to function in normal activity due to severe 
disturbance in the perception of reality. Include 
hallucinations, incoherence, marked loose associations, 
impoverished thought content, marked illogical thinking, 
bizarre, disorganized, or catatonic behavior. Excluded 
uremia and drug causes. 
8 □ Organic brain 
syndrome 
Altered mental function with impaired orientation, memory or 
other intelligent function, with rapid onset fluctuating clinical 
features. Include clouding of consciousness with reduced 
capacity to focus, and inability to sustain attention to 
environment, plus at least two of the following: perceptual 
disturbance, incoherent speech, insomnia or daytime 
drowsiness, or increased or decreased psychomotor activity. 
Exclude metabolic, infectious or drug causes. 
8 □ Visual disturbance Retinal changes of SLE. Include cytoid bodies, retinal 
hemorrhages, serious exodate or hemorrhages in the 
choroids, or optic neuritis.  Exclude hypertension, infection, 
or drug causes. 
8 □ Cranial nerve 
disorder 
New onset of sensory or motor neuropathy involving cranial 
nerves.  
8 □ Lupus headache Severe persistent headache: may be migrainous, but must be 
nonresponsive to narcotic analgesia 
8 □ CVA New onset of cerebrovascular accident(s). Exclude 
arteriosclerosis. 
8 □ Vasculitis Ulceration, gangrene, tender finger nodules, periungual, 
infarction, splinter hemorrhages, or biopsy or angiogram proof 
of vasculitis 
4 □ Arthritis More than 2 joints with pain and signs of inflammation (i.e., 
tenderness, swelling or effusion). 
4 □ Myositis Proximal muscle aching/weakness, associated with elevated 
creatine phosphokinase/aldolase or electromyogram 
changes or a biopsy showing myositis. 
4 □ Urinary casts Heme-granular or red blood cell casts 
4 □ Hematuria >5 red blood cells/high power field. Exclude stone, infection 
or other cause. 
4 □ Proteinuria >0.5 gm/24 hours. New onset or recent increase of more than 
0.5 gm/24 hours. 
4 □ Pyuria >5 white blood cells/high power field. Exclude infection. 
2 □ New Rash New onset or recurrence of inflammatory type rash. 
2 □ Alopecia New onset or recurrence of abnormal, patchy or diffuse loss 
of hair. 
2 □ Mucosal ulcers  New onset or recurrence of oral or nasal ulcerations 
2 □ Pleurisy Pleuritic chest pain with pleural rub or effusion, or pleural 
thickening. 
2 □ Pericarditis Pericardial pain with at least 1 of the following: rub, effusion, 
or electrocardiogram confirmation. 
2 □ Low complement Decrease in CH50, C3 or C4 below the lower limit of normal 
for testing laboratory. 
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2 □ Increased DNA 
binding 
>25% binding by Farr assay or above normal range for testing 
laboratory. 
1 □ Fever >38○C. Exclude infectious cause. 
1 □ Thrombocytopenia <100,000 platelets/mm3. 
1 □ Leukopenia <3,000 white blood cells/mm3. Exclude drug causes. 
          __________ TOTAL SCORE (Sum of weights next to descriptors marked present) 
Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus 
erythematosus. N Engl J Med 2005;353:2550-8. (117) 
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APPENDIX 3. PHYSICIAN’S GLOBAL ASSESSMENT OF DISEASE ACTIVITY (PGA) 
 
 
How do you assess your patient’s current disease activity? 
 
               
            
0 
None 
1 
Mild 
2 
Moderate 
3 
Severe 
 
 
Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus 
erythematosus. N Engl J Med 2005;353:2550-8. (117) 
  
 93 
APPENDIX 4. SUPPLEMENTAL TABLES FOR CHAPTER IV: GESTATIONAL WEIGHT GAIN IN 
PREGNANT WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS 
 
APPENDIX 4.1. UNIVARIATE LOGISTIC REGRESSION MODELS FOR CLINICAL AND 
DEMOGRAPHICS FACTORS ASSOCIATED WITH GESTATIONAL WEIGHT GAIN IN WOMEN WITH 
SLE IN THE HOPKINS LUPUS PREGNANCY COHORT (N=211). 
  Inadequate Weight 
Gain 
 Excessive Weight 
Gain 
 n OR (95% CI)  OR (95% CI) 
Race    
Black 65 2.46 (1.12, 5.41)  1.08 (0.50, 2.37) 
White 146 1.0  1.0 
Age     
>30 110 1.16 (0.55, 2.45)  1.19 (0.60, 2.37) 
≤30 101 1.0  1.0 
Education     
HS Education (≤12 years) 57 3.85 (1.35, 10.99)  2.00 (0.73, 5.55) 
College (13-16 years) 100 1.96 (0.77, 4.97)  1.37 (0.61, 3.09) 
Greater than College (>16 years) 54 1.0  1.0 
Duration of SLE     
>5 years 110 0.97 (0.48, 1.96)  0.79 (0.40, 1.55) 
≤5 years 101 1.0  1.0 
Prednisone use during pregnancy     
Yes 102 1.39 (0.68, 2.86)  1.26 (0.61, 2.59) 
No 109 1.0  1.0 
Prednisone Use ≥15 mg/day  
During Pregnancy among  
Prednisone Users (n=102) 
    
Yes 48 1.35 (0.44, 4.18)  1.48 (0.51, 4.26) 
No 54 1.0  1.0 
Anti-malarial use during pregnancy     
Yes 152 0.86 (0.39, 1.91)  0.66 (0.30, 1.47) 
No 59 1.0  1.0 
Immunosuppressants use during pregnancy     
Yes 37 1.13 (0.41, 3.17)  1.73 (0.66, 4.55) 
No 174 1.0  1.0 
High PGA (≥2) during pregnancy     
Yes 36 1.13 (0.40, 3.18)  1.62 (0.64, 4.06) 
No 175 1.0  1.0 
SDI at Conception     
≥1 79 2.00 (0.93, 4.28)  1.66 (0.80, 3.46) 
0 132 1.0  1.0 
Renal involvement during pregnancy     
Yes 60 1.20 (0.53, 2.72)  1.23 (0.56, 2.67) 
No 151 1.0  1.0 
Low C3 during pregnancy     
Yes 51 0.61 (0.28, 1.32)  0.38 (0.17, 0.83) 
No 160 1.0  1.0 
Low C4 during pregnancy     
Yes 76 0.73 (0.36, 1.49)  0.51 (0.25, 1.06) 
No 135 1.0  1.0 
Anti-dsDNA during pregnancy     
Yes 83 1.47 (0.70, 3.07)  1.10 (0.53, 2.27) 
No 128 1.0  1.0 
Pre-pregnancy blood pressure     
Intermediate/poor 106 2.65 (1.28, 5.47)  2.40 (1.16, 4.95) 
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Ideal 105 1.0  1.0 
Pre-pregnancy cholesterol     
Ideal 178 1.0  1.0 
Intermediate/poor 22 1.24 (0.41, 3.74)  1.03 (0.32, 3.30) 
Pre-pregnancy BMI     
Under/normal weight (≤24.9) 121 1.0  1.0 
Overweight (25.0 - 29.9) 47 1.52 (0.58, 4.00)  2.48 (1.05, 5.82) 
Obese (≥30) 43 5.85 (1.56, 21.91)  6.81 (1.86, 25.00) 
     
Age at conception, years 211 0.99 (0.92, 1.07)  0.98 (0.91, 1.05) 
Disease duration, years 211 0.97 (0.92, 1.03)  0.96 (0.91, 1.02) 
Highest PGA during pregnancy 211 1.15 (0.67, 1.96)  1.40 (0.84, 2.32) 
SDI at conception 211 1.43 (1.00, 2.04)  1.35 (0.96, 1.89) 
Highest daily prednisone dose during pregnancy, 
mg 
211 1.02 (0.99, 1.05)  1.00 (0.98, 1.03) 
Highest daily prednisone dose during pregnancy 
among prednisone users, mg 
102 1.01 (0.98, 1.06)  0.99 (0.96, 1.03) 
Pre-pregnancy BMI, kg/m2 211 1.13 (1.04, 1.22)  1.12 (1.04, 1.21) 
Abbreviations: BMI, body mass index; C3, complement 3; C4, complement 4; HS, high school; LAI, Lupus 
Activity Index; OR, odds ratios; PGA: Physician Global Assessment of Disease Activity; SDI: SLICC/ACR 
Damage Index 
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APPENDIX 4.2. MEAN PREDICTED CHANGE IN WEIGHT DURING PREGNANCY FROM MIXED 
EFFECTS MODELS, STRATIFIED BY PRE-PREGNANCY BMI (EXCLUDING UNDERWEIGHT 
WOMEN). 
 
AMean weight change = 4.4778 + 0.3973(gestational age) + 0.0076(gestational age2) + 
0.6414(overweight) + 3.3288(obese) – 0.0268(gestational age x overweight) – 0.1647(gestational age x 
obese) – 0.0004 (gestational age2 x overweight) + 0.0006 (gestational age2 x obese) 
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APPENDIX 5. SUPPLEMENTAL TABLES FOR CHAPTER V: PRE-CONCEPTIONAL 
CARDIOVASCULAR HEALTH AND PREGNANCY OUTCOMES IN WOMEN WITH SYSTEMIC LUPUS 
ERYTHEMATOSUS 
 
APPENDIX 5.1. DEMOGRAPHICS STRATIFIED BY PRE-PREGNANCY OR 1ST TRIMESTER VISIT 
(N=309) 
 Pre-Pregnancy 
Visit 
(n=195) 
1st Trimester 
Visit 
(n=114) 
 
 n (%) n (%) Fisher p-
value 
Race    
White 108 (55%) 76 (67%) 0.1 
Black 64 (32%) 29 (25%)  
Other 23 (12%) 9 (8%)  
Education    
HS Education (≤12 years) 64 (33%) 37 (32%) 0.1 
College (13-16 years) 82 (42%) 59 (52%)  
Greater than College (>16 years) 49 (25%) 18 (16%)  
Infant birth date    
Prior to Jan 1999 51 (26%) 66 (58%) <0.0001 
Jan 1999 – February 2015 144 (74%) 48 (42%)  
Medication use during pregnancyA    
Anti-malarial 134 (69%) 50 (44%) <0.0001 
Immunosuppressant  38 (19%) 10 (9%) 0.01 
Prednisone  92 (47%) 68 (60%) 0.04 
Prednisone ≥7.5 mg/day 62 (32%) 54 (47%) 0.01 
Prednisone ≥7.5 mg/day among prednisone 
users (n=160) 
62 (67%) 54 (79%) 0.1 
Clinical characteristics during pregnancyA     
Renal involvement (LAI) 49 (25%) 30 (26%) 0.9 
Elevated serum creatinine (>1) 17 (9%) 7 (6%) 0.5 
High PGA during pregnancy (PGA ≥2) 26 (13%) 23 (20%) 0.1 
Low C3 during pregnancy 39 (20%) 35 (31%) 0.04 
Low C4 during pregnancy 64 (33%) 42 (37%) 0.5 
Anti-dsDNA 70 (36%) 45 (39%) 0.5 
    
 Mean (SD) Mean (SD) ANOVA p-
value 
Age at conception, years 30.2 (4.9) 29.4 (5.0) 0.2 
Disease duration, years 7.4 (5.2) 4.6 (5.0) <0.0001 
Highest PGA during pregnancy (scale: 0-3) 0.9 (0.7) 1.1 (0.7) 0.01 
Highest daily prednisone dose during 
pregnancy, mg 
7.9 (13.0) 11.4 (14.0) 0.03 
BMI, kg/m2 26.2 (6.1) 25.5 (6.1) 0.4 
Total cholesterol 168.8 (36.1) 157.0 (30.4) 0.01 
Systolic blood pressure 117.5 (15.2) 115.3 (14.5) 0.2 
Diastolic blood pressure 73.1 (10.9) 69.7 (8.7) 0.005 
Acategories not mutually exclusive; women can be in multiple categories, therefore, percentages add up 
to more than 100% 
Abbreviations: BMI, body mass index; C3, complement 3; C4, complement 4; HS, high school; LAI, Lupus 
Activity Index; OR, odds ratios; PGA: Physician Global Assessment of Disease Activity; SDI: SLICC/ACR 
Damage Index 
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APPENDIX 5.2. LIVE BIRTH OUTCOMES STRATIFIED BY PRE-PREGNANCY OR 1ST TRIMESTER 
VISIT (N=309) 
 Pre-Pregnancy Visit 
(n=195) 
1st Trimester Visit 
(n=114) 
 
 n (%) n (%) Fisher p-value 
Small for gestational age (n=293)  29 (16%) 24 (22%) 0.2 
Large for gestational age (n=293) 9 (5%) 3 (3%) 0.5 
Preterm birth 56 (29%) 39 (34%) 0.4 
    
 Mean (SD) Mean (SD) ANOVA p-value 
Gestational age at birth, weeks 36.9 (3.0) 36.9 (3.3) 1.0 
Birth weight percentile (n=293) 37.5 (27.0) 32.8 (24.8) 0.1 
Birth weight z-score (n=293) -0.42 (0.92) -0.62 (0.92) 0.07 
Birth weight (g) (n=293) 2859.0 (762.4) 2793.7 (750.2) 0.5 
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APPENDIX 5.3. PRE-CONCEPTIONAL CARDIOVASCULAR HEALTH ACCORDING TO AHA CRITERIA STRATIFIED BY PRE-PREGNANCY 
OR 1ST TRIMESTER VISIT 
  Poor Health Intermediate Health Ideal Health Fisher p-value 
Body mass indexA (n=291)      
Pre-Pregnancy Visit (n=193) n (%) 43 (22%) 44 (23%) 106 (55%) 0.5 
1st Trimester Visit (n=98) n (%) 16 (16%) 25 (26%) 57 (58%)  
Total cholesterolB (n=275)      
Pre-Pregnancy Visit (n=192) n (%) 8 (4%) 24 (13%) 160 (83%) 0.1 
1st Trimester Visit (n=83) n (%) 0 (0%) 8 (10%) 75 (90%)  
Blood pressureC (n=309)      
Pre-Pregnancy Visit (n=195) n (%) 25 (13%) 78 (40%) 92 (47%) 0.2 
1st Trimester Visit (n=114) n (%) 9 (8%) 39 (34%) 66 (58%)  
A Body mass index: (1) poor health: ≥30 kg/m2; (2) intermediate health: 25-29.9 kg/m2; (3) ideal health: <25 kg/m2 
B Total cholesterol: (1) poor health: ≥240 mg/dL; (2) intermediate health: 200–239 mg/dL or treated to goal; (3) ideal health: <200 mg/Dl 
C Blood pressure: (1) poor health: Systolic ≥140 or Diastolic ≥90 mm Hg; (2) intermediate health: Systolic 120–139 or Diastolic 80–89 mm Hg or 
treated to goal; (3) ideal health: <120/<80 mm Hg 
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APPENDIX 5.4. DISTRIBUTION OF PRETERM BIRTH, SGA AND LGA BY PRE-CONCEPTIONAL 
CARDIOVASCULAR HEALTH AMONG PATIENTS WITH PRE-PREGNANCY VISITS ONLY (N=195) 
 Preterm birth SGA LGA 
Body mass index    
Ideal health (under/normal weight; <25 kg/m2) 31 of 106 (29%) 19 of 100 (19%) 4 of 100 (5%) 
Intermediate health (overweight; 25-29.9 kg/m2) 17 of 44 (39%) 2 of 43 (5%) 3 of 43 (7%) 
Poor health (obese; ≥30 kg/m2) 8 of 43 (19%) 7 of 40 (18%) 2 of 40 (6%) 
ANOVA p-value 0.1 0.06 0.7 
Total cholesterol    
Ideal health (<200 mg/dL) 42 of 160 (26%) 26 of 151 (17%) 6 of 151 (4%) 
Intermediate health (200–239 mg/dL  or treated 
to goal) 
8 of 24 (33%) 2 of 23 (9%) 3 of 23 (13%) 
Poor health (≥240 mg/dL) 6 of 8 (75%) 1 of 8 (13%) 0 of 8 (0%) 
ANOVA p-value 0.01 0.8 0.1 
Blood pressure    
Ideal health (<120/<80 mm Hg) 23 of 92 (25%) 15 of 87 (17%) 7 of 87 (8%) 
Intermediate health (Systolic 120–139 or 
Diastolic 80–89 mm Hg or treated to goal) 
25 of 78 (32%) 13 of 75 (17%) 2 of 75 (3%) 
Poor health (Systolic ≥140 or Diastolic ≥90 mm 
Hg) 
8 of 25 (32%) 1 of 23 (4%) 0 of 23 (0%) 
ANOVA p-value 0.5 0.3 0.2 
LGA: large for gestational age; SGA: small for gestational age
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APPENDIX 5.5. MEAN GESTATIONAL AGE AND BIRTH WEIGHT Z-SCORES BY PRE-
CONCEPTIONAL CARDIOVASCULAR HEALTH, WITH ANOVA TESTS FOR DIFFERENCES IN 
MEANS, AMONG PATIENTS WITH PRE-PREGNANCY VISITS ONLY (N=195) 
 Gestational Age Birth Weight Z-Score 
 Mean Weeks (SD) Mean (SD) 
Body mass index   
Ideal health (under/normal weight; <25 kg/m2) 36.6 (3.3) -0.49 (0.90) 
Intermediate health (overweight; 25-29.9 kg/m2) 36.7 (2.7) -0.20 (0.81) 
Poor health (obese; ≥30 kg/m2) 37.6 (2.6) -0.42 (1.06) 
ANOVA p-value 0.2 0.2 
Total cholesterol   
Ideal health (<200 mg/dL) 36.9 (3.1) -0.42 (0.94) 
Intermediate health (200–239 mg/dL  or treated 
to goal) 
37.1 (2.3) -0.27 (0.96) 
Poor health (≥240 mg/dL) 34.9 (3.9) -0.53 (0.60) 
ANOVA p-value 0.2 0.7 
Blood pressure   
Ideal health (<120/<80 mm Hg) 37.4 (2.7) -0.39 (0.98) 
Intermediate health (Systolic 120–139 or 
Diastolic 80–89 mm Hg or treated to goal) 
36.4 (3.2) -0.43 (0.95) 
Poor health (Systolic ≥140 or Diastolic ≥90 mm 
Hg) 
36.4 (3.4) -0.49 (0.54) 
ANOVA p-value 0.08 0.9 
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APPENDIX 5.6. MULTIVARIABLE LOGISTIC REGRESSION MODELS FOR ASSOCIATION OF PRE-CONCEPTIONAL CARDIOVASCULAR 
HEALTH AND PREGNANCY OUTCOMES IN SLE, AMONG PATIENTS WITH PRE-PREGNANCY VISITS ONLY (N=195). 
 Preterm Birth SGA 
 OR (95% CI) AOR (95% CI) OR (95% CI) AOR (95% CI) 
Body Mass IndexA     
Ideal Health (under/normal weight) 1.0 1.0 1.0 1.0 
Intermediate Health (overweight) 1.52 (0.72, 3.17)  1.43 (0.62, 3.33)D  0.24 (0.06, 0.92)  0.21 (0.05, 0.82)D  
Poor Health (obese) 0.55 (0.24, 1.28)  0.52 (0.20, 1.38)D  0.81 (0.30, 2.23)  0.69 (0.23, 2.05)D 
Total CholesterolB     
Ideal Health 1.0 1.0 1.0 1.0 
Intermediate/Poor Health 2.20 (1.01, 4.79) 2.02 (0.87, 4.70)D 0.40 (0.10, 1.59) 0.21 (0.03, 1.46)D 
  1.83 (0.83, 4.04)E  0.46 (0.12, 1.81)E 
  1.76 (0.77, 4.01)F  0.28 (0.05, 1.68)F 
Blood PressureC     
Ideal Health 1.0 1.0 1.0 1.0 
Intermediate/Poor Health 1.40 (0.74, 2.62) 1.23 (0.65, 2.32)G 0.72 (0.34, 1.57) 0.72 (0.32, 1.59)G 
Continuous variables     
BMI, kg/m2 0.97 (0.92, 1.02) 0.96 (0.90, 1.02)D 0.99 (0.92, 1.06) 0.97 (0.89, 1.06)D 
Total cholesterol, per 10 mg/dL change  1.11 (1.02, 1.21) 1.10 (1.00, 1.21)D 0.87 (0.75, 1.02) 0.83 (0.70, 0.99)D 
  1.07 (0.99, 1.16)E  0.88 (0.75, 1.03)E 
  1.09 (0.99, 1.19)F  0.84 (0.70, 1.00)F 
Systolic blood pressure, per 10 mmHg change 1.15 (0.95, 1.40) 1.11 (0.91, 1.36)G 0.72 (0.52, 1.00) 0.72 (0.52, 0.99)G 
Diastolic blood pressure, per 10 mmHg change 1.33 (1.01, 1.75) 1.27 (0.95, 1.69)G 0.78 (0.54, 1.13) 0.78 (0.54, 1.13)G 
A Body mass index: (1) poor health: ≥30 kg/m2; (2) intermediate health: 25-29.9 kg/m2; (3) ideal health: <25 kg/m2 
B Total cholesterol: (1) poor health: ≥240 mg/dL; (2) intermediate health: 200–239 mg/dL or treated to goal; (3) ideal health: <200 mg/Dl 
C Blood pressure: (1) poor health: Systolic ≥140 or Diastolic ≥90 mm Hg; (2) intermediate health: Systolic 120–139 or Diastolic 80–89 mm Hg or 
treated to goal; (3) ideal health: <120/<80 mm Hg 
D Adjusted for race (black vs. non-black) and prednisone use ever during pregnancy 
E Adjusted for race (black vs. non-black) and anti-malarial use ever during pregnancy 
F Adjusted for race (black vs. non-black), prednisone use ever during pregnancy, and anti-malarial use ever during pregnancy 
G Adjusted for race (black vs. non-black) and renal involvement during pregnancy (Renal LAI ≥1) 
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APPENDIX 5.7. MULTIVARIABLE LINEAR REGRESSION MODELS FOR ASSOCIATION OF PRE-CONCEPTIONAL CARDIOVASCULAR 
HEALTH AND PREGNANCY OUTCOMES IN SLE, AMONG PATIENTS WITH PRE-PREGNANCY VISITS ONLY (N=195). 
 
Gestational Age 
 Birthweight for  
Gestational Age Z-Score 
 Β (95% CI) Adjusted β (95% CI)  Β (95% CI) Adjusted β (95% CI) 
Body Mass IndexA      
Ideal Health (under/normal weight) Ref Ref  Ref Ref 
Intermediate Health (overweight) 0.11 (-0.96, 1.18) 0.20 (-0.93, 1.23)D  0.29 (-0.04, 0.62) 0.35 (0.03, 0.68)D 
Poor Health (obese) 1.01 (-0.06, 2.09) 0.89 (-0.16, 1.94)D  0.07 (-0.27, 0.41) 0.11 (-0.22, 0.45)D 
Total CholesterolB      
Ideal Health Ref Ref  Ref Ref 
Intermediate/Poor Health -0.41 (-1.57, 0.76) -0.20 (-1.31, 0.92)D  0.08 (-0.28, 0.44) 0.10 (-0.25, 0.46)D 
  -0.18 (1.36, 0.99)E   0.01 (-0.35, 0.37)E 
  -0.07 (-1.20, 1.06))F   0.01 (-0.34, 0.37)F 
Blood PressureC      
Ideal Health Ref Ref  Ref Ref 
Intermediate/Poor Health -0.97 (-1.82, -0.13) -0.86 (-1.72, -0.003)G  -0.05 (-0.32, 0.22) 0.01 (-0.26, 0.28)G 
Continuous variables      
BMI, kg/m2 0.07 (-0.003, 0.14) 0.07 (-0.001, 0.14)D  0.01 (-0.01, 0.03) 0.01 (-0.01, 0.04)D 
Total cholesterol, mg/dL  -0.07 (-0.19, 0.05) -0.05 (-0.17, 0.06)D  0.01 (-0.03, 0.05) 0.02 (-0.02, 0.05)D 
  -0.05 (-0.17, 0.08)E   0.004 (-0.03, 0.04)E 
  -0.04 (-0.15, 0.08)F   0.01 (-0.03, 0.04)F 
Systolic BP, mm Hg -0.39 (-0.67, -0.12) -0.35 (-0.64, -0.07)G  0.03 (-0.06, 0.12) 0.05 (-0.04, 0.14)G 
Diastolic BP, mm Hg -0.57 (-0.95, -0.18) -0.51 (-0.91, -0.11)G  -0.03 (-0.15, 0.10) 0.01 (-0.12, 0.13)G 
A Body mass index: (1) poor health: ≥30 kg/m2; (2) intermediate health: 25-29.9 kg/m2; (3) ideal health: <25 kg/m2 
B Total cholesterol: (1) poor health: ≥240 mg/dL; (2) intermediate health: 200–239 mg/dL or treated to goal; (3) ideal health: <200 mg/Dl 
C Blood pressure: (1) poor health: Systolic ≥140 or Diastolic ≥90 mm Hg; (2) intermediate health: Systolic 120–139 or Diastolic 80–89 mm Hg or 
treated to goal; (3) ideal health: <120/<80 mm Hg 
D Adjusted for race (black vs. non-black) and prednisone use ever during pregnancy 
E Adjusted for race (black vs. non-black) and anti-malarial use ever during pregnancy 
F Adjusted for race (black vs. non-black), prednisone use ever during pregnancy, and anti-malarial use ever during pregnancy 
G Adjusted for race (black vs. non-black) and renal involvement during pregnancy (Renal LAI ≥1) 
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APPENDIX 5.8. PREVALENCE OF PRETERM BIRTH, SGA AND LGA AMONG LIVE BIRTHS BY 
PRE-CONCEPTIONAL CARDIOVASCULAR HEALTH IN THE HOPKINS LUPUS PREGNANCY 
COHORT (N=309) 
  
 
  
*Body mass index: (1) poor health: ≥30 kg/m2; (2) intermediate health: 25-29.9 kg/m2; (3) ideal health: 
<25 kg/m2; Total cholesterol: (1) poor health: ≥240 mg/dL; (2) intermediate health: 200–239 mg/dL or 
treated to goal; (3) ideal health: <200 mg/dL; Blood pressure: (1) poor health: Systolic ≥140 or Diastolic 
≥90 mm Hg; (2) intermediate health: Systolic 120–139 or Diastolic 80–89 mm Hg or treated to goal; (3) 
ideal health: <120/<80 mm Hg 
†Fisher’s exact p-value <0.05  
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APPENDIX 6. SUPPLEMENTAL TABLES FOR CHAPTER VI: EFFECT OF PREGNANCY ON 
DISEASE FLARES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS 
 
APPENDIX 6.1. MODIFICATION BY PREDNISONE OF HAZARD RATIOS OF FLARES BASED ON 
PGAA DURING PREGNANCY AND 1-YEAR POSTPARTUM PERIOD COMPARED TO UNEXPOSED 
PERIODS FOR WOMEN WITH SLE IN THE HOPKINS LUPUS COHORT, 1987-2015 (N=1349). 
 Counting Process CoxB Stratified CoxC 
 No Prednisone Use  Prednisone Use  No Prednisone Use  Prednisone Use  
 HR (95% CI)  HR (95% CI)  HR (95% CI)  HR (95% CI)  
All patients (n=1349)  
Unexposed  1.0 (ref)  1.0 (ref)  1.0 (ref)  1.0 (ref)  
Pregnancy  1.54 (1.09, 2.10) 1.48 (1.13, 1.93) 1.54 (1.09, 2.12) 1.51 (1.15, 1.97) 
Postpartum  0.96 (0.65, 1.32) 0.94 (0.73, 1.17) 0.97 (0.65, 1.36) 0.96 (0.75, 1.21) 
     
Patients with history of pregnancy or ≥1 observed pregnancy (n=999)  
Unexposed  1.0 (ref)  1.0 (ref)  1.0 (ref)  1.0 (ref)  
Pregnancy  1.63 (1.14, 2.18) 1.50 (1.11, 1.93) 1.69 (1.18, 2.29) 1.53 (1.14, 2.03) 
Postpartum  1.02 (0.69, 1.44) 0.95 (0.73, 1.21) 1.03 (0.69, 1.45) 0.98 (0.74, 1.25) 
     
Patients with ≥1 observed pregnancy in the cohort (n=304)  
Unexposed  1.0 (ref)  1.0 (ref)  1.0 (ref)  1.0 (ref)  
Pregnancy  1.76 (1.18, 2.57) 1.53 (1.09, 2.09) 1.82 (1.20, 2.72) 1.57 (1.11, 2.24) 
Postpartum  1.13 (0.72, 1.63) 0.98 (0.72, 1.30) 1.14 (0.71, 1.66) 1.02 (0.76, 1.41) 
Aflare defined as change in ≥1 from PGA score at previous visit  
BCounting process Cox proportional hazards model assumes the order of the events of flares did not 
need to be taken into consideration 
CStratified Cox model is a conditional model that does not assume independence of multiple events of 
flares and allows different baseline hazards based on the number of previous flares a patient experienced 
CI: confidence interval; HR: hazard ratio; PGA: Physician Global Assessment of disease activity; SLE: 
systemic lupus erythematosus 
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APPENDIX 6.2. MODIFICATION BY PREDNISONE OF HAZARD RATIOS OF FLARES BASED ON 
SELENA SLEDAIA DURING PREGNANCY AND 1-YEAR POSTPARTUM PERIOD COMPARED TO 
UNEXPOSED PERIODS FOR WOMEN WITH SLE IN THE HOPKINS LUPUS COHORT, 1987-2015 
(N=1349). 
 Counting Process CoxB Stratified CoxC 
 No Prednisone Use  Prednisone Use  No Prednisone Use  Prednisone Use  
 HR (95% CI)  HR (95% CI)  HR (95% CI)  HR (95% CI)  
All patients (n=1349)  
Unexposed  1.0 (ref)  1.0 (ref)  1.0 (ref)  1.0 (ref)  
Pregnancy  1.62 (1.09, 2.19) 1.30 (0.95, 1.66) 1.68 (1.15, 2.31) 1.41 (1.03, 1.81) 
Postpartum  0.95 (0.65, 1.33) 0.95 (0.74, 1.19) 1.00 (0.67, 1.38) 1.01 (0.78, 1.28) 
     
Patients with history of pregnancy or ≥1 observed pregnancy (n=999)  
Unexposed  1.0 (ref)  1.0 (ref)  1.0 (ref)  1.0 (ref)  
Pregnancy  1.69 (1.16, 2.37) 1.35 (0.98, 1.75) 1.74 (1.16, 2.43) 1.45 (1.03, 1.94) 
Postpartum  1.00 (0.67, 1.41) 0.99 (0.77, 1.25) 1.04 (0.69, 1.46) 1.06 (0.82, 1.36) 
     
Patients with ≥1 observed pregnancy in the cohort (n=304)  
Unexposed  1.0 (ref)  1.0 (ref)  1.0 (ref)  1.0 (ref)  
Pregnancy  1.84 (1.19, 2.65)  1.38 (0.99, 1.85)  1.91 (1.23, 2.81)  1.44 (0.98, 2.01)  
Postpartum  1.09 (0.70, 1.59)  1.02 (0.77, 1.31)  1.14  (0.75, 1.75)  1.09 (0.78, 1.46)  
Aflare defined as change in ≥4 from SELENA SLEDAI score at previous visit  
BCounting process Cox proportional hazards model assumes the order of the events of flares did not 
need to be taken into consideration 
CStratified Cox model is a conditional model that does not assume independence of multiple events of 
flares and allows different baseline hazards based on the number of previous flares a patient experienced 
CI: confidence interval; HR: hazard ratio; SLE: systemic lupus erythematosus; SLEDAI: SLE Disease 
Activity Index 
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APPENDIX 6.3. NUMBER AND CRUDE INCIDENCE OF FLARES DURING PREGNANCY, 1-YEAR 
POSTPARTUM PERIOD, AND UNEXPOSED PERIODS OF TIME FOR WOMEN WITH SLE IN THE 
HOPKINS LUPUS COHORT, 2000-2015 (N=1073). 
 
Flares PY 
Crude incidence  
per 100 PY Crude IRR (95% CI)  
PGAA    
All patients (n=1073) 
Unexposed 1373 4015.0 34.2 1.0 (ref) 
Pregnancy 61 136.7 44.6 1.31 (1.01, 1.69) 
Postpartum 70 219.5 31.9 0.93 (0.73, 1.19) 
     
Patients with history of pregnancy or ≥1 observed pregnancy (n=787) 
Unexposed 1036 3071.3 33.7 1.0 (ref) 
Pregnancy 61 136.7 44.6 1.32 (1.02, 1.71) 
Postpartum 70 219.5 31.9 0.95 (0.74, 1.20) 
     
Patients with ≥1 observed pregnancy in the cohort (n=268) 
Unexposed 395 1301.9 30.3 1.0 (ref) 
Pregnancy 61 136.7 44.6 1.47 (1.12, 1.93) 
Postpartum 70 219.5 31.9 1.05 (0.82, 1.36) 
     
SELENA SLEDAIB     
All patients (n=1073) 
Unexposed 1720 4015.0 42.8 1.0 (ref) 
Pregnancy 65 136.7 47.6 1.11 (0.87, 1.42) 
Postpartum 95 219.5 43.3 1.01 (0.82, 1.24) 
     
Patients with history of pregnancy or ≥1 observed pregnancy (n=787) 
Unexposed 1220 4015.0 39.7 1.0 (ref) 
Pregnancy 65 136.7 47.6 1.20 (0.93, 1.54) 
Postpartum 95 219.5 43.3 1.09 (0.88, 1.34) 
     
Patients with ≥1 observed pregnancy in the cohort (n=268) 
Unexposed 461 4015.0 34.8 1.0 (ref) 
Pregnancy 65 136.7 47.6 1.37 (1.05, 1.77) 
Postpartum 95 219.5 43.3 1.24 (1.00, 1.55) 
Aflare defined as change in ≥1 from PGA score at previous visit  
Bflare defined as change in ≥4 from SELENA SLEDAI score at previous visit  
CI: confidence interval; IRR: incidence rate ratio; PGA: Physician Global Assessment of disease activity; 
PY: person-years; SLE: systemic lupus erythematosus; SLEDAI: SLE Disease Activity Index 
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APPENDIX 6.4. NUMBER AND CRUDE INCIDENCE OF PGAA FLARES DURING PREGNANCY, 1-YEAR POSTPARTUM PERIOD, AND 
UNEXPOSED PERIODS OF TIME FOR WOMEN WITH SLE IN THE HOPKINS LUPUS COHORT STRATIFIED BY HYDROXYCHLOROQUINE 
USE, 1987-2015 (N=1349). 
 No HCQ Use  HCQ Use 
 
Flares PY 
Crude incidence  
per 100 PY Crude IRR (95% CI)  Flares PY 
Crude incidence  
per 100 PY Crude IRR (95% CI) 
Prior to 2000         
All patients (n=550) 
Unexposed 417 767.6 54.3 1.0 (ref)  456 800.1 57.0 1.0 (ref) 
Pregnancy 60 63.2 94.9 1.75 (1.33, 2.29)  13 20.9 62.1 1.09 (0.63, 1.89) 
Postpartum 52 104.8 49.6 0.91 (0.68, 1.22)  26 46.5 55.9 0.98 (0.66, 1.46) 
          
Patients with history of pregnancy or ≥1 observed pregnancy (n=439) 
Unexposed 292 594.2 49.1 1.0 (ref)  385 691.5 55.7 1.0 (ref) 
Pregnancy 60 63.2 94.9 1.93 (1.46, 2.55)  13 20.9 62.1 1.12 (0.64, 1.94) 
Postpartum 52 104.8 49.6 1.01 (0.75, 1.36)  26 46.5 55.9 1.00 (0.68, 1.49) 
          
Patients with ≥1 observed pregnancy in the cohort (n=161) 
Unexposed 111 232.0 47.9 1.0 (ref)  136 270.2 50.3 1.0 (ref) 
Pregnancy 60 63.2 94.9 1.98 (1.45, 2.72)  13 20.9 62.1 1.23 (0.70, 2.18) 
Postpartum 52 104.8 49.6 1.04 (0.75, 1.44)  26 46.5 55.9 1.11 (0.73, 1.69) 
          
2000 and after 
All patients (n=1073) 
Unexposed 371 973.5 38.1 1.0 (ref)  1002 3041.4 32.9 1.0 (ref) 
Pregnancy 22 34.1 64.5 1.69 (1.10, 2.60)  39 102.6 38.0 1.15 (0.84, 1.59) 
Postpartum 21 53.8 39.0 1.02 (0.66, 1.60)  49 165.7 29.6 0.90 (0.67, 1.20) 
          
Patients with history of pregnancy or ≥1 observed pregnancy (n=787) 
Unexposed 262 718.9 36.4 1.0 (ref)  774 2352.4 32.9 1.0 (ref) 
Pregnancy 22 34.1 64.5 1.77 (1.15, 2.74)  39 102.6 38.0 1.16 (0.84, 1.59) 
Postpartum 21 53.8 39.0 1.07 (0.69, 1.67)  49 165.7 29.6 0.90 (0.67, 1.20) 
          
Patients with ≥1 observed pregnancy in the cohort (n=268) 
Unexposed 83 300.9 27.6 1.0 (ref)  312 1023.6 30.5 1.0 (ref) 
Pregnancy 22 34.1 64.5 2.34 (1.46, 3.74)  39 102.6 38.0 1.25 (0.89, 1.74) 
Postpartum 21 53.8 39.0 1.41 (0.88, 2.28)  49 165.7 29.6 0.97 (0.72, 1.31) 
Aflare defined as change in ≥1 from PGA score at previous visit  
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APPENDIX 6.5. NUMBER AND CRUDE INCIDENCE OF SELENA-SLEDAIA FLARES DURING PREGNANCY, 1-YEAR POSTPARTUM 
PERIOD, AND UNEXPOSED PERIODS OF TIME FOR WOMEN WITH SLE IN THE HOPKINS LUPUS COHORT STRATIFIED BY 
HYDROXYCHLOROQUINE USE, 1987-2015 (N=1349). 
 No HCQ Use  HCQ Use 
 
Flares PY 
Crude incidence  
per 100 PY Crude IRR (95% CI)  Flares PY 
Crude incidence  
per 100 PY Crude IRR (95% CI) 
Prior to 2000         
All patients (n=550) 
Unexposed 449 767.6 58.5 1.0 (ref)  472 800.1 59.0 1.0 (ref) 
Pregnancy 64 63.2 101.2 1.73 (1.33, 2.25)  11 20.9 52.6 0.89 (0.49, 1.62) 
Postpartum 54 104.8 51.5 0.88 (0.66, 1.17)  21 46.5 45.2 0.77 (0.49, 1.19) 
          
Patients with history of pregnancy or ≥1 observed pregnancy (n=439) 
Unexposed 325 594.2 54.7 1.0 (ref)  400 691.5 57.8 1.0 (ref) 
Pregnancy 64 63.2 101.2 1.85 (1.42, 2.42)  11 20.9 52.6 0.91 (0.50, 1.65) 
Postpartum 54 104.8 51.5 0.94 (0.71, 1.26)  21 46.5 45.2 0.78 (0.50, 1.21) 
          
Patients with ≥1 observed pregnancy in the cohort (n=161) 
Unexposed 106 232.0 45.7 1.0 (ref)  141 270.2 52.2 1.0 (ref) 
Pregnancy 64 63.2 101.2 2.22 (1.62, 3.02)  11 20.9 52.6 1.01 (0.55, 1.86) 
Postpartum 54 104.8 51.5 1.13 (0.81, 1.57)  21 46.5 45.2 0.87 (0.55, 1.37) 
          
2000 and after          
All patients (n=1073) 
Unexposed 427 973.5 43.9 1.0 (ref)  1293 3041.4 42.5 1.0 (ref) 
Pregnancy 12 34.1 35.2 0.80 (0.45, 1.42)  53 102.6 51.7 1.22 (0.92, 1.60) 
Postpartum 16 53.8 29.7 0.68 (0.41, 1.12)  79 165.7 47.7 1.12 (0.89, 1.41) 
          
Patients with history of pregnancy or ≥1 observed pregnancy (n=787) 
Unexposed 263 718.9 36.6 1.0 (ref)  957 2352.4 40.7 1.0 (ref) 
Pregnancy 12 34.1 35.2 0.96 (0.54, 1.72)  53 102.6 51.7 1.27 (0.96, 1.67) 
Postpartum 16 53.8 29.7 0.81 (0.49, 1.35)  79 165.7 47.7 1.17 (0.93, 1.47) 
          
Patients with ≥1 observed pregnancy in the cohort (n=268) 
Unexposed 81 300.9 26.9 1.0 (ref)  380 1023.6 37.1 1.0 (ref) 
Pregnancy 12 34.1 35.2 1.31 (0.71, 2.40)  53 102.6 51.7 1.39 (1.04, 1.86) 
Postpartum 16 53.8 29.7 1.10 (0.65, 1.89)  79 165.7 47.7 1.28 (1.01, 1.63) 
Aflare defined as change in ≥4 from SELENA SLEDAI score at previous visit  
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APPENDIX 6.6. NUMBER AND CRUDE INCIDENCE OF FLARES DURING PREGNANCY, 1-YEAR 
POSTPARTUM PERIOD, AND UNEXPOSED PERIODS OF TIME FOR WOMEN WITH SLE IN THE 
HOPKINS LUPUS COHORT, 1987-2015 (N=1426). 
 
Flares PY 
Crude incidence  
per 100 PY Crude IRR (95% CI)  
PGAA    
All patients (n=1426) 
Unexposed 2246 5583.0 40.2 1.0 (ref) 
Pregnancy 150 252.6 59.4 1.48 (1.25, 1.74) 
Postpartum 160 431.6 37.1 0.92 (0.78, 1.08) 
     
Patients with history of pregnancy or ≥1 observed pregnancy (n=1076) 
Unexposed 1713 4357.2 39.3 1.0 (ref) 
Pregnancy 150 252.6 59.4 1.51 (1.28, 1.79) 
Postpartum 160 431.6 37.1 0.94 (0.80, 1.11) 
     
Patients with ≥1 observed pregnancy in the cohort (n=381) 
Unexposed 642 1791.8 35.8 1.0 (ref) 
Pregnancy 150 252.6 59.4 1.66 (1.39, 1.98) 
Postpartum 160 431.6 37.1 1.03 (0.87, 1.23) 
     
SELENA SLEDAIB     
All patients (n=1426) 
Unexposed 2641 5583.0 47.3 1.0 (ref) 
Pregnancy 166 252.6 65.7 1.39 (1.19, 1.63) 
Postpartum 181 431.6 41.9 0.89 (0.76, 1.03) 
     
Patients with history of pregnancy or ≥1 observed pregnancy (n=1076) 
Unexposed 1945 4357.2 44.6 1.0 (ref) 
Pregnancy 166 252.6 65.7 1.47 (1.26, 1.73) 
Postpartum 181 431.6 41.9 0.94 (0.81, 1.09) 
     
Patients with ≥1 observed pregnancy in the cohort (n=381) 
Unexposed 708 1791.8 39.5 1.0 (ref) 
Pregnancy 166 252.6 65.7 1.66 (1.40, 1.97) 
Postpartum 181 431.6 41.9 1.06 (0.90, 1.25) 
Aflare defined as change in ≥1 from PGA score at previous visit  
Bflare defined as change in ≥4 from SELENA SLEDAI score at previous visit  
CI: confidence interval; IRR: incidence rate ratio; PGA: Physician Global Assessment of disease activity; 
PY: person-years; SLE: systemic lupus erythematosus; SLEDAI: SLE Disease Activity Index 
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APPENDIX 6.7 HAZARD RATIOS OF FLARES BASED ON PGAA DURING PREGNANCY AND 1-
YEAR POSTPARTUM PERIOD COMPARED TO UNEXPOSED PERIODS FOR WOMEN WITH SLE IN 
THE HOPKINS LUPUS COHORT, 1987-2015 (N=1426). 
 Counting Process CoxB Stratified CoxC 
 HR (95% CI) HR (95% CI) 
All patients (n=1426) 
Unexposed 1.0 (ref) 1.0 (ref) 
Pregnancy 1.38 (1.13, 1.67) 1.52 (1.25, 1.83) 
Postpartum 0.86 (0.70, 1.03) 0.94 (0.76, 1.15) 
   
Patients with history of pregnancy or ≥1 observed pregnancy (n=1076) 
Unexposed 1.0 (ref) 1.0 (ref) 
Pregnancy 1.44 (1.15, 1.73) 1.62 (1.30, 1.98) 
Postpartum 0.90 (0.72, 1.09) 1.01 (0.80, 1.23) 
   
Patients with ≥1 observed pregnancy in the cohort (n=381) 
Unexposed 1.0 (ref) 1.0 (ref) 
Pregnancy 1.53 (1.20, 1.95) 1.82 (1.43, 2.33) 
Postpartum 0.96 (0.77, 1.22) 1.15 (0.94, 1.52) 
Aflare defined as change in ≥1 from PGA score at previous visit  
BCounting process Cox proportional hazards model assumes the order of the events of flares did not 
need to be taken into consideration 
CStratified Cox model is a conditional model that does not assume independence of multiple events of 
flares and allows different baseline hazards based on the number of previous flares a patient experienced 
CI: confidence interval; HR: hazard ratio; PGA: Physician Global Assessment of disease activity; SLE: 
systemic lupus erythematosus 
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APPENDIX 6.8. HAZARD RATIOS OF FLARES BASED ON SELENA SLEDAIA DURING PREGNANCY 
AND 1-YEAR POSTPARTUM PERIOD COMPARED TO UNEXPOSED PERIODS FOR WOMEN WITH 
SLE IN THE HOPKINS LUPUS COHORT, 1987-2015 (N=1426). 
 Counting Process CoxB Stratified CoxC 
 HR (95% CI) HR (95% CI) 
All patients (n=1426) 
Unexposed 1.0 (ref) 1.0 (ref) 
Pregnancy 1.34 (1.08, 1.63) 1.60 (1.30, 1.96) 
Postpartum 0.85 (0.68, 1.01) 1.02 (0.81, 1.24) 
   
Patients with history of pregnancy or ≥1 observed pregnancy (n=1076) 
Unexposed 1.0 (ref) 1.0 (ref) 
Pregnancy 1.42 (1.12, 1.71) 1.67 (1.33, 2.07) 
Postpartum 0.90 (0.74, 1.09) 1.07 (0.88, 1.30) 
   
Patients with ≥1 observed pregnancy in the cohort (n=381) 
Unexposed 1.0 (ref) 1.0 (ref) 
Pregnancy 1.54 (1.22, 1.90) 1.85 (1.43, 2.35) 
Postpartum 0.99 (0.79, 1.23) 1.21 (0.96, 1.53) 
Aflare defined as change in ≥4 from SELENA SLEDAI score at previous visit  
BCounting process Cox proportional hazards model assumes the order of the events of flares did not 
need to be taken into consideration 
CStratified Cox model is a conditional model that does not assume independence of multiple events of 
flares and allows different baseline hazards based on the number of previous flares a patient experienced 
CI: confidence interval; HR: hazard ratio; SLE: systemic lupus erythematosus; SLEDAI: SLE Disease 
Activity Index 
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